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Abstract
This thesis seeks to resolve difficulties in the development of a parenteral needle-free drug delivery
system. Analysis of the penetration performance of Glide Pharma’s Solid Dose Injector in two
clinical trials on man has shown that skin, and likely its inherent variation, was the cause
of incomplete deliveries. As indicated by the literature and issues with previous needle-free
technologies, a more complete understanding of skin penetration is required before such systems
are capable of ensuring delivery across a patient population.
Exploratory skin experiments led to the justification, design and build of a novel skin penetration
test rig capable of simulating the delivery of a solid dose implant. This test rig, the Penetrometer,
required significant software development to both stabilise and validate its performance before
use on the in vivo porcine model, an established non-clinical model for drug delivery through
human skin.
Two non-clinical studies have been performed using the Penetrometer to capture force displace-
ment profiles, using a metal probe equivalent to an implant, for penetration events on multiple
test sites on multiple models. Significant levels of variation in key parameters were shown to
be present intra- and inter-test site, as well as intra- and inter-model. It is likely that this
variation, as detected in the porcine model, was the cause of problematic system performance
during human clinical trials. Penetration experiments have also been performed to establish the
validity of using in vitro skin or silicone rubber as an alternative test bed to in vivo models.
The key parameters measured are the peak force during penetration, the displacement of the
skin at penetration and the work required to penetrate the skin, with variations observed of the
order of 30%, 100% and 140%, respectively. The results indicate how challenging it will be to
reliably administer drugs using needle-free injection. This information should be used to better
specify the device design and implant formulation to ensure delivery success.
Prior to this thesis there was no quantitative data available, either published or within the
collaborator, describing the magnitude and variation of the key parameters affecting needle-free
skin penetration. This thesis has used the porcine model, further work must determine the
parameters for the breadth of a human patient population.
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Nomenclature
Symbols used throughout this thesis:
σp - Stress to penetrate
d - Displacement
dp - Deflection to penetrate
Fa - Actuation force
Fd - Force to displace in vivo skin with a blunt probe by 1mm
Fm - Motor force
Fn - Net delivery force
Fp - Force to penetrate
Fsc - Average force of sub cut after penetration
m - Mass
k - Skin stiffness
t - Time
v - Velocity
Wp - Work done to penetration
Wi - Work done to a 5.5mm injection depth
Abbreviations used throughout this thesis:
API - Active Pharmaceutical Ingredient
AUC - Area Under the Curve
BCS - Best Case Scenario
BMI - Body Mass Index
Cmax - Peak Concentration
Nomenclature xvi
CRO - Contract Research Organisation
CV - Coefficient of Variation
ED - Epidermis
EOP - Equipment Operating Procedure
FDA - Food and Drug Administration
FEM - Finite Element Model
Ga - Needle Gauge
Glide or Glide Pharma - Glide Pharmaceutical Technologies Ltd.
HSC - High-Speed Camera
GUI - Graphical User Interface
ID - Intradermal
IM - Intramuscular
LHS - Left Hand Side
LAC-1 - SMAC Control Unit within the Penetrometer
Lloyd LFPlus - Lloyd LFPlus Materials Testing Machine
PK - Pharmacokinetics
RHS - Right Hand Side
SC - Stratum Corneum
SC - Subcutaneous Fat
SD - Standard Deviation
SDI - Solid Dose Injector
SEM - Scanning Electron Microscopy
US - Ultrasound
UV - Ultraviolet
VBA - Visual Basic Application
WCS - Worst Case Scenario
Glossary of specific terms used during this thesis:
Actuation Force (Fa) - Force on the skin required to trigger the SDI device
Penetrator - The item performing the penetrating, usually an implant or metal probe
Penetrometer - A test rig capable of dynamically measuring forces during penetration force
“I never guess. It is a capital mistake to theorise before one has data.
Insensibly one begins to twist facts to suit theories, instead of theories to suit facts.”
- Sir Arthur Conan Doyle
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Introduction
Drug delivery is the process of administering an active pharmaceutical ingredient (API) to
achieve a therapeutic effect in humans or animals. The term drug delivery system encompasses
all of the integral components that make up this process, including the delivery device, the drug
and the target site.
The easiest way to take a drug is orally in liquid or tablet form. This is not always possible as
some drugs are susceptible to enzymatic degradation in the gut. Oral and other transmucosal
(nasal, pulmonary, rectal) routes are also unsuitable for drugs too large to be absorbed across a
membrane into the systemic circulation. These drugs can often only be delivered parenterally,
i.e. injected through the skin. The use of a hypodermic needle and syringe is the conventional
method of administering an injection.
Needles, although reliable, are not without their faults. The most common problems being
needle-stick injuries, belonephobia (fear of needles) and safe disposal. Auto-injectors are one
way of dealing with these issues. They work by simplifying the injection process and retracting
the needle safely. For many years companies and research institutions have been attempting to
entirely remove the needle from the drug delivery system.
Liquid-jet injectors [1,2] and powder injectors [3,4] are two technologies that have been developed
and tested extensively. Both have struggled to convert the bench-top science into a marketable
drug delivery system as the device designs have been hindered by limited knowledge of the
mechanics of the novel injection processes. This has led to uncertainty that either technology
can be used to reliably inject a large proportion of a diverse patient population.
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It could be assumed that removing the needle from the injection process will remove the pain.
However, this thinking is naive. There may be a benefit of the injection being quicker, typically
fractions of a second as opposed to a few seconds, yet some component of the system must pierce
the skin. Both examples mentioned do so by firing the drug at high speeds (>100m.s−1).
Less traumatic methods for overcoming the barrier function of the skin are transdermal patches
[5, 6], which are suitable for small molecule drugs capable of permeating the stratum corneum
and micro-needle arrays [7, 8], which physically penetrate the outermost layers of skin (≤1mm)
making it possible to deliver larger molecules. Both approaches cause little or no pain sensation
but are limited in dose effectiveness and efficiency which restricts their clinical applications.
1.1 Solid Dose Injection
Instead of firing drugs at high speed or pressing them onto the surface of the skin another delivery
method is to formulate the API into an implant that is pushed through the skin without a needle.
The first example of a drug delivery system like this can be seen in a patent for a ‘Pellet Injector’
in 1963 [9].
As well as the benefits of removing the needle, containing the drug within an implant can increase
stability (extending the shelf life) and control the release rate of the API from an implant for the
desired therapeutic effect. There are several companies that have patented solid dose formats
and accompanying devices. The most active of these being Novo Nordisk [10,11] and Bioneedle
Technologies Group [12,13]. To date no needle-free solid dose delivery device has received market
authorisation.
Figure 1.1: Glide SDI device.
Glide Pharmaceutical Technologies Ltd. is a biotech start-up based near Abingdon, Oxford-
shire, UK. Founded in 2001 under the original name Caretek Medical Ltd., Glide Pharma has
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developed and patented a needle-free device called the Glide SDI (Solid Dose Injector), as shown
in Figure 1.1. The SDI is a spring-powered device that, when actuated, pushes a wedge-tipped
implant (measuring 4mm × 0.85mm) through the skin and into the subcutaneous tissue [14,15].
In the current Glide SDI prototype the implant is held within a disposable cassette component
which is inserted into a reusable actuator prior to use. Glide Pharma, to date, has performed
two Phase I clinical trials to generate bioequivalence data against an injection delivered with a
needle and syringe.
There are two current limitations to Glide Pharma’s technology;
The payload of the implant which is currently a maximum of 4mg. Within an implant, as well
as API, it is necessary to include excipients to enable the implant to be both manufactured and
mechanically strong enough to survive the injection.
The second, more fundamental issue, is that of skin penetration. In order to supplant a hypo-
dermic any needle-free alternative must deliver 100% of the time. The combined results from
Glide’s two clinical trials show a penetration success rate, classified as at least 90% of the im-
plant being delivered, to be 50% (n = 36). Therefore the current SDI prototype has been shown
to be affected by issues that have historically affected liquid-jet and powder injection devices. In
order to reliably inject a large proportion of the patient population further research was required
into the drug delivery system and the factors that govern penetration success.
1.2 Aims and Objectives
To fully investigate all aspects of solid dose drug delivery requires a multidisciplinary approach
encompassing the fields of mechanical engineering, software engineering, materials science, skin
biology, pharmacology and others. To explore and improve all aspects of the drug delivery
system would be beyond the scope of a single thesis.
The primary aim of this research is to develop a fundamental understanding of the key paramet-
ers which affect needle-free skin penetration, and in particular how the target itself will affect
delivery. Although there has been extensive study into skin penetration, most of this has been
in the context of more conventional parenteral systems. There is less research into needle-free
injection systems and none available the field of solid dose injection.
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In order to achieve this research aim there are several intermediate objectives that are to be
achieved. In the Glide SDI system there are three components; the SDI device, the implant
and the skin, as shown in the system model in Figure 1.2. The design or performance of
one component is likely to affect that of another. The components of the system that can be
controlled, the device and the implant, will need to adapt for the one that cannot; the skin,
which can only be understood and accounted for, not altered.
Figure 1.2: Glide SDI drug delivery system model.
This aim and research objectives can best be met through an engineering design led approach.
The first step, beyond the literature review, is to investigate what is currently known and
understood of the drug delivery system performance. To achieve this an extensive analysis of
results from previous clinical and non-clinical trials is to be undertaken.
To generate first-hand data and dynamically measure the forces, energies and deflections during
penetration requires a series of novel test rigs to be built. To justify the development of a
complex electromechanical test rig, smaller investigations with simpler test rigs are to be carried
out first. A novel skin penetration test rig is then to be used extensively with in vivo pig skin
to establish the response caused by penetration by a wedge-tipped probe; used to simulate the
delivery of a Glide implant. The skin is to be measured and its behaviour parameterised to
determine what may be responsible for any variation observed.
The results of the experimental work will lead to the design of an in vitro synthetic test bed. A
platform that can reliably challenge the device and implant removing the effect of skin’s inherent
variation.
The research performed within this thesis will be covered by Glide Pharma’s quality system and
internal procedures. The work will include, where necessary, appropriate approvals and licences
from the Home Office, local ethics committees and/or regulatory authorities.
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1.3 Thesis Outline
Chapter 2 - A literature review was undertaken to prove novelty of the research and identify the
freedom to operate within the field. Research into drug delivery systems, particularly parenteral
systems, has led to more focused investigation into skin properties and skin penetration mech-
anisms. During this review process it became apparent that although literature has investigated
similar areas of skin mechanics, there is little existing literature that directly overlaps with the
drug delivery aspects of this research project.
Chapter 3 - A detailed analysis and evaluation of current prototype device performance in the
two clinical trials has shown that the failures to deliver implants into man are probably due to
the current system design. The implant is failing by a buckling event, a the large unsupported
deflection, that occurs when the implant’s tip fails to initiate penetration. The exact reason
why this is the case for some administrations and not others, despite the same configuration,
has been investigated further.
The prototype devices, equivalent to those used within the trials, have been tested to ensure
that they were within specification and performed capably. This analysis has highlighted the
lack of knowledge of the mechanics of the penetration of skin before the SDI prototypes were
designed. There are likely to be a combination of skin factors that aid or reduce the likelihood
of successful skin penetration. At this stage the parameters of this performance window are
undefined.
Chapter 4 - With the fundamental problem established, initial skin investigations using a simple
hand-held test rig has identified some of the variables that are likely to affect skin penetration.
A parallel work package discusses the validity of imaging methods to try and understand skin
penetration after delivery and how the implant can be seen under the skin. After experimentation
all common non-invasive methods to help penetration understanding have been ruled out. Only
histology performed on biopsy samples was demonstrated to be useful.
Chapter 5 - This chapter details the design and validation of a novel skin penetration test rig;
including the justification, specification, delivery, software development and general operation.
The findings from Chapter 4 identified the need for a more accurate electromechanically con-
trolled ‘Penetrometer’ test rig capable of measuring the velocity, displacement and forces during
a skin penetration test. The methods in which the device has been calibrated, how its results
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can be interpreted and initial investigations into penetration using silicone rubber are detailed.
Chapter 6 - With the Penetrometer having proven capable of capturing force profiles of penetra-
tion experiments into synthetic materials it was possible to conduct a full investigation into skin
penetration and examine the level of variation. Two non-clinical studies have been conducted
using the in vivo porcine model as the best available substitute for human skin. The methodo-
logy justifies a comprehensive set of experiments to detect the amount of target variation seen in
the non-clinical model and correlate this to the target’s composition. The skin’s deflection until
penetration, peak force and stress, work done and average force encountered post-penetration
have all been measured.
All of these parameters and how they are affected by the different strata within the skin and
their variation due to site and size of the model have been captured. The studies have shown
the implications of using the neck site and in vitro tissue as a test bed. In their place the rump
site and an in vitro test bed, that has more uniform mechanical properties, have been proposed
as alternatives.
Chapter 7 - An analysis of skin penetration data generated in the previous chapter has been
performed to establish the causes of the inter- and intra-model variation detected. Sectioning
of the skin samples tested has shown that skin and subcutaneous tissue thickness may affect
the penetration parameters. This same method has also shown that the location may have an
effect. The amount of energy required to inject into the skin and the levels of variation seen in
the model are shown to have implications for the current drug delivery system design.
Chapter 8 - Finally, conclusions have drawn on what is now known of in vivo skin penetration,
including the variation detected, and the implications for the Glide SDI needle-free technology.
The only component of the system that Glide cannot truly control is the skin. Skin can only be
understood and characterised and the device and implant design must account for these findings.
System design recommendations on how to minimise the effect of skin variation, thus increas-
ing the likelihood of 100% delivery, are outlined. The understanding captured in the thesis
is summarised into a simple table to show the contributions and the gaps in the knowledge.
The suggestions of the further work necessary to bridge these gaps, including using a second
Penetrometer test rig capable of measuring forces at speeds up to 6m.s−1, have been put forward.
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1.4 Contribution
The work presented in this thesis has shown first-hand the difficulties in developing and testing
a parenteral needle-free drug delivery device.
This knowledge has been established through thorough research into the literature of needle-free
delivery technologies and the mechanisms each utilise to overcome the skin. An analysis has
been performed on the penetration data from two clinical trials in man. This has shown that
skin and its inherent variation, as with previous needle-free technologies, needs a more complete
understanding before the system can be optimised.
Initial experiments on skin led to the justification, design and build of a novel adaptable test
rig capable of simulating and measuring a solid dose injection in in vivo skin. This device,
the Penetrometer, required significant software development to both stabilise and validate its
performance before its use on the porcine model; the most widely established substitute for
human skin.
Two non-clinical studies have been performed using the Penetrometer. Through experimental
design it was possible to isolate the forces required to penetrate skin and provide evidence of
significant levels of variation present both intra- and inter-model (n = 3). It is likely that
the variation detected in the porcine model, that was undetected at the time, is to blame for
erroneous SDI development prior to the clinical trials. Experiments have also been performed to
establish the validity of using in vitro skin and suitable synthetic materials to use as a penetration
test bed.
The results also indicate how challenging it will be to reliably administer drugs through a
solid dose injection across a human patient population. Prior to this thesis there was no data
available, either published or at Glide, describing the magnitude or variation of the forces and
energies required to penetrate skin with a solid dose. Injections were only assessed subjectively
to determine whether the skin had been penetrated successfully or not.
The research concludes by summarising the implications these findings have on the current drug
delivery system and recommendations of how they can be overcome.
Chapter 2
Literature Review
The literature review has been undertaken to prove novelty of the research and identify the free-
dom to operate within the field. Research around drug delivery systems, particularly parenteral
systems has led to more focused research on skin properties and skin penetration mechanisms.
During this review it became apparent that, although there are areas in literature that have
tackled similar areas of skin mechanics, there was little literature that directly overlapped with
the drug delivery aspects of this research project.
2.1 Drug Delivery
Most drugs are delivered orally, however, to minimize drug degradation, prevent harmful side-
effects and to increase drug bioavailability many other alternative drug delivery and drug tar-
geting systems have been developed [16]. The pathway that the drug enters the body to achieve
the required pharmacological effect is known as the route of administration.
There are three main routes of administration these being topical, enteral and parenteral delivery,
describing whether a drug is applied onto, into or through into the body respectively. Within
each of these routes there are various pathways and each has a range of delivery devices and
methods available, as shown in Figure 2.1. The route of administration and choice of drug
delivery device are dependent on a wide-ranging number of factors such as the chemical state
of drug [17], the volume required to be delivered, the target site used for delivery (whether for
systemic or local effect) and patient comfort or preference, amongst others.
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Figure 2.1: Routes of administration and types and methods of drug delivery.
Enteral
Enteral delivery encompasses methods where the drug has to enter the body by passing through
an orifice and across a mucosal membrane where it is then absorbed into the blood stream.
Transmucosal drug delivery is classified as any drug delivery method where the drug passes
through a mucous membrane. Transmucosal delivery benefits from a much higher absorption
rate than transdermal delivery, due to favourable environmental conditions within the body,
rather than the resistance and barrier function of the skin on the outside.
Oral drug delivery is the most common type of enteral delivery where the drug is swallowed
and the dose is then delivered across the large mucosal surface of the gastrointestinal tract
during digestion. Dosage usually takes the form of pills, capsules or a suspension. This is a
convenient method of drug delivery as the patient can administer the dose themselves without
a specific device or expertise. The length of the gastrointestinal tract maximises successful
dosage, though accuracy of the release of the dose is limited due to the varying internal conditions
between patients. The challenging environment within the digestive system limits bioavailability,
especially for large molecules [18]. Orally disintegrating tablets (ODT) are highly porous tablets
allow for rapid water or saliva penetration and disintegration [19] and are designed for fast
delivery through the buccal or sublingual membrane, avoiding first-pass effect as the drug diffuses
into the capillary network and enters the system circulation directly without being metabolized
by the liver [20].
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Other examples of enteral delivery routes are; ocular medications in the form of eye drops which
can be delivered to the conjunctiva, the moist covering over the eye. Nasal delivery is targeted at
the nasal associated lymphoid tissue in the nose [21]. Nasal administration has been associated
with a high variability in the amount of drug absorbed. Like pulmonary delivery, this is due to
the difficulties in ensuring that the spray actuation method retains the drug in the nasal cavity
when self-administered [22]. Suppositories can be inserted into the rectum or vagina where they
dissolve and crosses mucosa into the bloodstream. Rectal suppositories are particularly suited
to treatments where a recipient may vomit oral medication out.
Topical
Topical drug delivery encompasses all drugs that are placed onto the surface of the skin or
directly onto a tissue. These methods are often employed for local effect where systemic delivery
is possible.
Transdermal delivery is the least invasive method of overcoming the skin, it is achieved by
permeation or diffusion via a poultice, gel, ointment or transdermal patch applied to the skin.
This method is best suited to smaller molecules as they must overcome the low permeability of
the stratum corneum [23]. The barrier function of the skin leads to inaccurate and inefficient
dosing with the number of drugs suitable limited by molecule weight (<500 Daltons [24]). The
first transdermal patch was approved by the FDA in 1979 [25]. To date approximately 20 drugs
have been approved by the FDA as transdermal patches [4]. Often transdermal methods require
several applications per day or patches can be used that apply continuous doses over several
days. Some patients can develop skin irritation from this form of drug delivery method.
There are ways in which, if the skin is damaged first, drugs can permeate better [25]. This
can be achieved through tape stripping or abrasion to remove the stratum corneum. Other
methods of improving diffusion of transdermal application are electrically assisted transdermal
drug delivery, e.g. iontophoresis, electrosmosis and electroporation and ultrasound to increase
the permeability of the skin during transdermal delivery [4, 26,27].
Many medications can be inhaled and given directly to the lungs. The large surface area of
the lungs and extensive network of blood vessels surrounding the bronchi and alveoli allow for
quick drug delivery and rapid absorption into the bloodstream. Pulmonary dosed medications
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are frequently used to treat lung conditions. Small molecules and proteins can be delivered by
aerosols with pressurised metered dose inhalers (pMDIs), powders using dry powder inhalers
(DPIs) or solutions via nebulisers [28].
Some patients can have difficulty in correctly coordinating the actuation of the device and
inhalation of the drug leaving drug at the back of the throat. Consequently patients may not
receive consistent dose delivery [21] and bioavailabilty of pulmonary delivery can be as low as
<15% of what is possible with parenteral methods [29]. For drugs with very large molecular
weights, such as monoclonal antibodies, penetration through the lung for systemic delivery may
require some type of transport enhancement mechanism, of which there are several still at the
stages of initial research. There are also potential safety issues with delivering large molecules
and protein to the lungs as the effects long term of inhalation of microparticles are unknown [18].
Parenteral
The choice of enteral and topical routes of administration are limited by the drug dosage form, its
molecular size and ability to permeate the target membrane. This is not the case for parenteral
methods. Parenteral delivery encompasses all types where the drug is injected through the skin
by mechanical means, unlike transdermal via diffusion methods. For this percutaneous delivery
it is important the surface of the skin is sterilised first to ensure microbes or contaminants
present do not get transported underneath the skin.
Parenteral delivery conquers the barrier mechanism of the skin offering a broad effectiveness
of drug delivery using a sharp needle [30]. Parenteral delivery is the most effective route for
drugs with narrow therapeutic index or poor bioavailabilty and avoids first pass metabolism.
It is the predominant method for delivering molecules that are either susceptible to enzymatic
degradation or cannot be absorbed efficiently, due to size, to be therapeutically effective [18].
There are several methods of injection targeting different substructures in or under the skin.
Each permit different opportunities for local and systemic effect, as discussed in § 2.2.2. Typically
an injection is performed using a sharp hypodermic needle and a syringe to deliver a liquid doses
under the skin. However, there are needle-free alternatives in development. A more detailed
review of parenteral devices is discussed in § 2.2.3.
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2.2 Parenteral Drug Delivery
The field of parenteral delivery encompasses all methods whereby a drug is mechanically injected
through the skin. To understand parenteral injection and the various applications of the different
delivery technologies available it is first necessary to understand the composition of the skin and
how the different layers can be targeted by altering the injection depth.
2.2.1 Skin Introduction
The skin is the largest organ of the human body, making up around 16% of the average person’s
body mass [31] and covers an area up to 2m2 [32, 33] and is constructed of three main layers;
the outer epidermis, the inner dermis and the subcutaneous tissue (which is not strictly part of
the skin but is involved with skin functions).
Skin permits terrestrial life by providing a structural mechanism for resisting fracture and pre-
venting the ingress of noxious chemicals and microorganisms thus allowing a life form to with-
stand its environment [34]. There are numerous secondary functions the skin performs. These
include temperature regulation, excretory functions and also has sensory roles responding to
tactile, painful and thermal stimuli. Figure 2.2 illustrates the complex structure of human skin
and the many different sub-layers and appendages it contains. As this organ is so large and
accessible it is ideal to administer drugs and therapeutic agents for both local and systemic
treatment [35].
Figure 2.2: Schematic of the skin showing the various layers and appendages [36].
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Epidermis The outermost layer of the skin is the epidermal layer. It is comprised of five
sub-layers; the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and
stratum basale [37]. During their lifespan skin cells travel upward due to the continual cell
division that occurs in the lower layers, eventually becoming the flat dead cells of the corneum,
the walls of which are comprised of the horny substance keratin which provides a physical barrier
to protect the live cells below [23].
The underlying viable epidermis contains immunological sensitive Langerhans cells, keratino-
cytes, stem cells and melanocytes. Unlike the dermis, the viable epidermis has no blood flow or
sensory nerve cells making it possible for painless drug delivery if shallow enough [38].
Dermis Despite its greater volume, the dermis contains far fewer cells than the epidermis.
Instead much of its bulk consists of a fibrous and amorphous extracellular matrix [39], a net-
work or gel structure of the cells as they are embedded in a mucopolysaccharide gel [40]. The
rest of the dermis is comprised of structural protein fibres (collagen, reticulum and elastin).
These are responsible for much of the mechanical structure of the skin and run parallel to the
surface. Elastin is a protein tightly coiled that stretches a lot and is responsible for the skin’s
compliance [41].
Interspersed between the skin’s appendages and nerves are dendritic cells, macrophages, lymph-
ocytes and a dense network of blood capillaries and lymphatic vessels [42]. Beneath the dermis
the fibrous tissue opens out and merges with subcutaneous tissue.
Subcutaneous Tissue Also known as adipose tissue, the subcutaneous tissue consists of
connective tissue comprising of lipid-filled cells called adipocytes, that attach the dermis to
the underlying structure [35]. The adipocytes are supported by two collagen-based structures:
collagen mesh, containing primarily type I and IV collagen, surrounding each cell, and a type I
collagen fibre network termed the interlobular septa [43]. Subcutaneous tissue or fat, by weight,
is comprised of 60–80% lipid, 5–30% water and the remaining 2–3% is protein and ground
substance [44]. Other structures such as blood vessels exist within the tissue and the intervening
space is filled with ground substance the non-cellular components of extracellular matrix which
contain the fibres. The adipose tissue serves to insulate the body, store nutrients and provides
mechanical protection against physical shock [35].
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2.2.2 Injection Depth
The type of tissue that a drug is delivered to will affect its uptake within the body and the
therapeutic response of the patient. It is possible to target different types of tissue through
varying the injection depth. The most common injection depths are;
Intradermal (ID) It has been widely reported that ID is the preferred route of adminis-
tration to elicit an immunological response from the body [6, 40, 45]. ID delivery targets the
immunocompetent cells in the skin (e.g., dermal dendritic cells, keratinocytes, macrophages,
and T lymphocytes) that trigger the skin’s immune responses. To perform an ID injection with
a hypodermic needle requires the Mantoux technique whereby the skin is stretched and a needle
inserted parallel to the surface [46]. Microneedles (<2mm) and microneedle patches are being
developed that make it easier to perform shallow perpendicular self-injections.
Subcutaneous (SC) Delivering drugs under the skin and into the subcutaneous tissue is
suitable for applications which require the drug to be absorbed more slowly into the body through
the subcutaneous tissue [47]. The difficulty of performing a regular subcutaneous injection is
associated with having to inject below the surface of the skin whilst avoiding delivering to blood
vessels, muscle or the skin itself. To achieve this a needle is usually inserted into a lifted or
pinched skin fold [48,49].
Intramuscular (IM) The most common medications delivered through IM route are for pain,
nausea and vaccinations [50]. IM injections are useful as the chances of successful delivery are
high when targeting large muscles such as the thigh or upper arm. The blood supply to the
muscles make systemic uptake quicker than subcutaneous [51, 52]. Although it is widely used,
IM is not necessarily optimal for immunisation as few antigen presenting cells infiltrate striated
muscle [46].
Other Types of Injection There are other types of parenteral delivery routes such as intra-
venous (IV) injection (into a vein), intraperitoneal (into a body cavity) and intraosseous (into
bone marrow), however these methods are outside the remit of this review that is focused on
delivery to and through the skin.
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2.2.3 Parenteral Drug Delivery Devices
Parenteral drug delivery devices are all required to penetrate the skin and deliver a set volume
of drug at a set depth within the skin. Mammalian skin has evolved to withstand mechanical
trauma from impact, pressure, frictional and shear forces, yet it still allows freedom of move-
ment [32]. These barrier mechanisms of the skin are particularly well suited at preventing ingress
or penetration into the body from the outside world.
Typical methods of overcoming the skin, and its variance across a population, have been to
deliver drugs with a hypodermic needle. Needle-based devices have been in development since
the 19th Century [53] and provide a sharp, effective, manual way to provide a liquid dose into
or through the skin. The hypodermic needle is not without problems, these often being cited as
their potential for needle-stick injuries, reuse, safe disposal and belonephobia (a fear of needles).
For these reasons the World Health Organisation’s (WHO) aim to remove needles in developing
countries and replace them with safer injection alternatives [54].
Advances in needle protection devices whereby simple passive needle guards that protect from
the needle-stick injuries and are more easily disposed of have gone someway to solving some of
the issues highlighted by the WHO [55]. Many derivatives of needle-based injection devices now
exist to deliver the wide ranges of drugs available more easily, safely and conveniently, allowing
patients to administer injections to themselves. Meanwhile other needle-free technologies have
been developed capable of administering drugs without the needle altogether. Some examples
of these devices are shown in Figure 2.3.
Figure 2.3: The parenteral drug delivery devices available or in development according to delivery
method. *Indicates devices not yet reached market.
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Needle-Based Injection Technologies
Prefilled Syringe The introduction of prefilled syringes (PFS) reduced the number of steps
required before a drug could be administered. This minimised cross-contamination, eliminated
the secondary container preparation, reduced medication errors due to fixed dosing and meant
less wasted drug product from the over filling of traditional syringes [56]. Not every drug can be
delivered with a PFS. Some drugs are formulated as lypholised powders (such as proteins) and
require a reconstitution step to take place prior to injection [57]. Delivery with a PFS is still
manual and this may be difficult for a patient to administer correctly themselves depending on
the injection site, depth and their physical condition.
Autoinjector and Pen Injectors An autoinjector (AI) serves to automate or semi-automate
the injection process. These devices are typically mechanically driven, single use, disposable and
suited for the emergency delivery of epinephrine to a person suffering anaphylaxis, whereas pen
injectors contain multiple doses of the same drug and the amount required is dialled in and
delivered manually down a thin needle. The pen injector format is ideal for insulin delivery and
diabetes management. There is some crossover, devices such as the Easypod [58] and Rebismart
[59] from Merck Serono Ltd. (Feltham, Middlesex) that are high value reusable AIs with a
reservoir of drug and capable of dialling in and performing an automated electromechanical
delivery.
Single use AIs can suffer from performance issues and authors have highlighted issues associated
with needle length adequacy to deliver IM injections across a population and the ease of use of
the devices [60–63]. Another issue arises from the glass primary container used to store the liquid
dose. Glass has superior containment properties as it is inert and has minimum interaction with
the drug however it is also brittle and can fail during the high forces exerted on it during an
injection. Polymer-based alternatives to glass are under development, such as Crystal Zenith [64]
a material from Daikyo Seiko Ltd. (Tokyo, Japan). Polymer-based primary containers in the
future may also improve or alter the form factor of AIs which up to now have been dependent
on the traditional syringe.
Trocar-Based Device Some drugs cannot be formulated or reconstituted into a liquid and
are instead best delivered as a depot or solid dose. Examples of these are Zoladex [65] from
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AstraZeneca PLC. (London) used for the treatment of prostate cancer and Nexplanon [66] from
MSD Ltd. (London), a female contraceptive. Both are combination products that deliver a solid
dose to the subcutaneous fat where the API release is sustained, typically, over 1–3 months.
There are many other patented devices based on the principles of a hypodermic needle techno-
logy [67] and needle and trocar-based technologies [68–73]. The implants delivered are comprised
of dry mouldable drug formulation which is cut into rods between 2–30mm long with a 0.3-2.5m
diameter depending on the patent. The implants do not need to be mechanically strong a needle
is used to penetrate the skin. More recently Forteq AG (Nidau, Switzerland) have developed a
method of delivering solid dose under the skin with semi-automated delivery steps [74,75].
Patch Pump A patch pump is a device that uses a cannula or microneedle to pierce and reside
within the skin which is then connected to a electromechanical pump, such as the PatchPump [76]
by SteadyMed Therapeutics Inc. (San Francisco, CA) suitable to deliver viscous drugs. Insulin
pumps have been available for some time [77]. Where patch pumps differ is that the whole
device is adhered to the skin. The drug can be administered over hours or days. Applications
for this technology are for chronic conditions diabetes management such as the OmniPump [77]
by Insulet Corporation (Bedford, MA) as well as viscous potent biologic drugs that for patient
comfort must be administered over time.
Needle-Free Injection Technologies
Microneedle Patch Although technically these patches use needles to penetrate the skin,
they are on a much smaller scale than a traditional hypodermic. A microneedle patch or array
is covered in micron-scale projections, typically 100–500µm, that can be fabricated from silicon,
metal, polycarbonate, ceramic and even the drug itself [78]. These projections can give access
for DNA-based drugs and vaccines that could not otherwise permeate the skin [7, 30]. When
applied to the skin surface the projections penetrate the stratum corneum allowing the drug
to reach the immune antigen presenting cells in the viable epidermis making them ideal for
delivery of immunotherapeutics [5, 6]. The patches are considered ‘pain-free’ as the projections
only breach the epidermis which is void of any sensory nerves.
Microneedle patches have been in development since the late 1990’s and, although there is an
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active community of academic researchers in the field, currently there are no products avail-
able [79]. The closest to market are the Nanopatch [8, 24, 80] developed by Vaxxas (Sydney,
Australia) and the ZP Patch Technology [81] from Zosano (Fremont, CA) that is currently in
Phase II clinical trials. Other technologies are in development that use microneedles in combin-
ation with syringe or pump or microinfuser [30], such as the AdminPen [24] by NanoBioSciences
LLC (Alameda, CA) where a liquid dose is forced through a microneedle array.
Liquid Jet Injector The working principle of jet injection is that a liquid dose is forced at
high speed, using a gas or spring power source, through a small orifice creating a jet stream
capable of penetrating the skin and delivering the drug. Liquid jet injection allows for rapid
drug delivery and quicker release to the systemic circulation than a needle and syringe possibly
due to the dispersion in the tissues [82].
Jet injectors can be broadly classified into multi-use nozzle-jet injectors (MUNJIs) and disposable
cartridge injectors (DCJIs) depending on the number of injections within a single device [83].
MUNJIs were once popular for mass administration of humans such as the vaccination of US Sol-
diers during World War II, although today MUNJIs are only used for veterinary applications [84].
There are many examples of DCJI liquid jet injectors that are available from companies such as
Zogenix Inc. (San Diego, CA), Roche AG (Basel, Switzerland) and Bioject Medical Technolo-
gies Inc. (Tualatin, OR). There are also combination devices such as the AJ1 Vibex by Antares
Pharma Inc. (Ewing, NJ) that uses a 2.5mm long needle to pierce the skin before a liquid dose
is delivered with a low-pressure jet injection. Combination devices such as this are capable of
delivering more viscous formulations susceptible to shear forces and also can better target the
subcutaneous tissue [85].
Despite there being marketed needle-free devices available the technology is yet to be widely
adopted. Reasons cited for this are often attributed to; cost per dose, patient perception, regula-
tion and fundamental penetration issues. Controlling the injection depth is difficult. Liquid jet
injectors can suffer from ‘wet injections’, where not all of the injectate is delivered successfully.
This occurs when an insufficient liquid static pressure head to keep open the surfaces of the
skin crack resulting in injectate being left on the surface of the skin [86]. Liquid jet injectors
are often limited to one speed, typically >100m.s−1, meaning, like the set needle depth on an
autoinjector, it is difficult to specify a single parameter suitable for all.
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Solid Dose Injectors There are advantages of delivering a solid dose rather than a liquid.
Some drugs are not very soluble and keeping the drug in a solid form can ensure greater stability
and control of over drug delivery [87]. There are two different technologies that are capable of
delivering solid dose into or through the skin without the use of a needle.
A gene gun uses a method whereby microparticles coated with drug are delivered by ballistic
principles at speeds in excess of 600m.s−1 using compressed helium gas. This technology was
originally used to impregnate plant seeds with DNA and was almost exclusively developed by
PowderMed Ltd. (now owned by Pfizer Inc., New York, NY). It is reported that microparticles
delivered intradermally and over a greater surface area can lead to improved immunological
performance in vaccine delivery compared to a needle and syringe [3,40]. The science of delivering
dry microparticles to the skin at subsonic speeds is recognised as ‘biolistics’ by Kendall [4].
Alternatively, to inject a solid dose deeper requires the drug to be packed into an implant with
more substantial mass that is robust enough to survive penetration. The detail behind solid
dose needle-free injection and Glide Pharma’s technology is discussed in § 2.2.4.
Summary of Parenteral Drug Delivery Devices
Table 2.1 summarises examples of different parenteral drug delivery devices that have been
discussed within this section. Each technology uses a different combination of power source and
dosage form to suit the intended application.
Company Device Format Power Dose Depth Application
Needle-Based
HumaPen Lilly Pen Injector Manual Liquid Subcut. HGH
EpiPen Meridian Autoinjector High Liquid IM Anaphylaxis
Hypak BD Prefilled Syringe Manual Liquid Various Various
Zoladex AZ Trocar-Based Manual Implant Subcut. Cancer
OmniPod Insulet Patch Pump Low Liquid Subcut. Insulin
Needle-Free
Nanopatch* Vaxxas Microneedle Patch Manual Solid ID Vaccine
DosePro Zogenix Liquid Jet High Liquid IM Pain Relief
PowderJect* Pfizer Powder Injector High Powder ID Vaccine
SDI* Glide Implant Injector Low Implant Subcut. Various
Table 2.1: Examples of parenteral drug delivery devices. *Indicates devices not yet reached
market.
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2.2.4 Needle-Free Solid Dose Injection
Realising the advantages of the solid dose format, the first needle-based solid dose injector was
patented in 1920 by Deininger [88] and resembled a gun. The first truly needle-free ‘pellet’
injector was patented in 1963 by Feldmann [9]. Drake and Rambosek [89] patented a solid dose
ballistic projectile with a conical tip formulated with drug, recognising the implant must be
capable of withstanding stresses imparted thereon when the projectile is ballistically propelled
at a velocity of 475m.s−1 and implanted through the hide of cattle [89]. There are other more
recent patents based on these principles for human therapeutic applications [10,11].
Unlike liquid jet injectors, no needle-free solid dose injection technologies have reached the
market. Aside from Glide Pharma the most active company in the field is Bioneedle Technologies
Group (Eindhoven, Netherlands) who have a patented a biodegradable hollow, implantable
needle (16mm × 0.2mm OD) that is intended to deliver vaccines [12, 13, 90]. The ‘Bioneedles’
have a tensile strength of 20–70MPa and are delivered with an air compressor at velocities in
excess of 340m.s−1, patents cite that energies between 0.1–5J are required to penetrate the
skin [13]. The technology has so far been demonstrated into a maurine model according to two
papers published by Hirschberg et al. [91,92]. To date, these are the only examples of literature
published in this field of drug delivery.
The Glide SDI device is needle-free and designed to deliver an implant (3.5–4mm × 0.85mm)
subcutaneously. To do this the implant must pierce the skin. The implant diameter is equivalent
to the outer diameter of a 20–21Ga needle [93]. The SDI device design is based on the principles
of an automatic centre punch [94]. Lyness [95] has shown using hi-speed photography that
the velocity that the current prototype Glide SDI device delivers an implant at ≈6m.s−1. The
actuator is reusable and powered by a 25N spring that resets between actuations, unlike gas-
powered delivery systems that rely on an exhaustible energy source that cannot be reused.
As the drug delivery system is needle-free the implant it delivers has dual roles; it must be mech-
anically strong and suitably sharp enough to penetrate the skin, yet also disperse as intended
within the subcutaneous tissue over time. Despite the necessary delivery dynamics required to
penetrate the skin, it is important the stresses on the implant during actuation are as low as
possible and the implant is robust. The device itself is reusable and the cassette that contains
the drug can enter municipal waste channels after delivery as it contains no sharps [96].
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2.3 Characterising Human Skin
Despite it being present all around, skin is often not considered in engineering and material
sciences. Skin has very unusual properties and its behaviour has been shown to be affected by
age, weight, gender, body mass index (a measure of mass in kilograms divided by the square of
height in meters), water content and other factors.
The thickness of the skin and subcutaneous fat will affect the delivery of a drug and can affect
its pharmacokinetics, the needle length required or method of injection. This composition of the
skin, and its mechanical properties, will determine the specification of a drug delivery system
that is required to initiate penetration and overcome the skin during injection. The following
section reports the findings of authors in this field.
2.3.1 Thickness
There are many quantitative techniques commonly used in measurement of skin layer thick-
ness [97]. Many measurements performed in vivo often use minimally invasive techniques.
Comparing measurements of skin layers thickness between individuals, and between studies,
is particularly challenging due to the presence of variation. This has been shown to be inherent
between skin sites within each individual and between individuals. Variation between studies is
also dependent on the sample population, the author’s method or the equipment used.
Confocal laser scanning microscopy allows a direct measurement without any restriction con-
cerning site and disadvantages for the patient. It is considered to be a gold standard for meas-
urement of stratum corneum and epidermal thickness. Various radiographic methods are also
commonly used. Light and electron microscopic studies have provided important evidence for
morphological changes in skin strata with age [98].
Pulsed ultrasound has been widely used in dermatology [99]. Ultrasound can be used for the
determination of whole skin thickness. Incidental ultrasonic energy is transmitted and partially
reflected at the boundary between adjacent structures. This generates echoes whose amplitudes
are characteristics can be measured. Although differences in frequencies used by different re-
searchers contribute to considerable variation in results measured [100].
Histological methods are used but the findings questioned due to possible artefacts caused by
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tissue preparation. The skin is also required to be excised making access to human skin testing
difficult. A traditional in vivo method of using the skin callipers can also be used but this
technique has lost popularity as it cannot fully eliminate the influence of the hypodermis and
does not give the most accurate measurements of skin thickness [101].
Stratum Corneum Measurements
There has been a lot of attention paid to the outermost layers of the skin as these are the most
important to understanding transdermal drug permeability [102] and also cosmetics [103] and
suntanning [104]. For these reasons, methods of identifying the thickness of the stratum corneum
(SC) are well established and often performed in vitro, using frozen skin samples recovered from
biopsy work. Using similar procedures and microscopy Panchagnula et al. [105] and Holbrook
and Odland [106] found the average stratum corneum thickness at the abdomen to be 18.4µm
and 8.2µm, respectively [52]. These findings are in agreement with a review by Nakatani et al.
that reported values between 10–30µm across multiple studies [103].
Maibach [97] states that ultrasound and microscopy studies focusing specifically on changes in
SC thickness with age show little or no appreciable change, even up to 97 years old. These
studies involved large numbers of individuals and generally accepted conclusions. However,
Maibach [97] also states that there is significant variation in SC thickness between individuals
and between sites within each individual. The thickness of the epidermis can vary from 0.06mm
on eyelids to 0.80mm on areas that encounter abrasion such as the soles of the feet [25]. The
thickness of the SC has also been shown to be dependent on its state of hydration [107].
Epidermis and Dermis Measurements
The inner layers of skin are subject to less attention from the cosmetics and drug industries.
Epidermis-dermis skin thickness tests are often performed in vivo. The most common non-
invasive methods are light tomography, echography and calliper testing, which is still used.
Sauermann et al. [98] used cofocal laser scanning microscopy, to take in vivo histometric meas-
urements of the skin and showed that epidermal thickness is affected by age and changes to the
cells. The thickness of the epidermis measurements taken at the forearm site were 40 ± 5.6µm
(mean 23.1 years, n = 13), 35.5 ±4.16µm (mean 72.5 years, n = 13).
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The most comprehensive study into mean epidermis-dermis skin thickness has been performed by
Laurent et al. [108] using echography. Human skin thicknesses were measured in areas used for
intradermal vaccination (deltoid, suprascapular, upper abdomen and thigh) across 205 women
and 137 men, aged 18–70 years old. The results for mean skin thickness were; arm 2.2mm, thigh
1.9mm, abdomen 2.2mm and buttocks 2.4mm. Thigh skin thickness was <0.6 mm thinner than
the buttocks. Differences in BMI of 10kg.m2 account for 0.2mm skin thickness variation, i.e. the
skin thickness difference between patients with BMI of 25kg.m2 vs. 35kg.m2 was only 0.2mm.
Additional analysis showed body site, gender, BMI and ethnicity were statistically significant
factors for skin thickness but the effects were small. These findings are in agreement with
research by Gniadecka and Jemec [104] who state skin thickness varies less between people of
different BMI, age, gender and ethnic origin than it did between different body sites in people
with very similar demographic characteristics.
Other findings from the study by Laurent et al. [108] showed that epidermis-dermis thickness
on the waist varies between 1.78mm and 2.20mm depending whether the subject is underweight
or obese. It is known that skin thickening in the obese subjects might reflect changes in skin
structure and fluid content. Skin is considered to be generally thinner in women than in men
by 0.06–0.20mm depending on the body site, but minimum skin thickness in women is >1.5mm
in all cases. This was in agreement with other authors [109, 110]. Laurent et al. [108] used this
research to conclude that a microneedle, of length 1.5mm, inserted perpendicular to the skin
surface would deliver an intradermal injection to nearly all subjects.
The decrease in epidermal-dermis skin thickness in later life is due to the synthesis of collagen
declining, leading to a reduction in the skin’s elasticity [37,111]. Maibach [97] states in a review
that several other studies find an increase in skin thickness over the first 20 years of life, then
a period of either constant skin thickness or progressive thinning. The epidermal thinning is
primarily due to a retraction of the epidermal projections into the dermis, resulting in a flattened
interface between the epidermis and dermis. A statistical analysis across the entire age range
of men tested across all ranges had 16% thicker epidermis than females, although these results
only represent skin at the forearm.
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Subcutaneous Tissue Measurements
Authors conflict when it comes to describing the compressibility of the subcutaneous tissue.
Samani et al. [112] states that subcutaneous tissue is believed to be isotropic in structure and
is thereby isotropic in mechanical properties and the large liquid content enforces material
incompressibility. Smith et al. [113] measured skin to muscle fascia distance at various sites in
diabetic children using high resolution real-time ultrasonography and additional measurements
were taken over the anterior thigh while pressing the ultrasound transducer with sufficient force
to cause maximum compression or displacement of underlying tissues. A comparison of this
data with measurements of uncompressed tissue at the same site showed that distances from
skin to muscle fascia were reduced by 33% (range 17–45%) as a result of the compression. The
ultrasound measurements varied due to the amount of force applied, although this does not
necessarily mean the subcutaneous tissue was compressed, it could have just been displaced for
the time period where the load was applied.
Fanelli et al. [99] performed a study comparing different non-invasive measuring methods. The
results showed mean subcutaneous fat thicknesses measured by callipers were greater than one-
half of the mean ultrasound values. An example at the waist is 16.0 ± 7.0µm using callipers
and 10.6 ± 3.8µm with ultrasound (mean 24.3 years, n = 124), indicating calliper testing is
inherently unreliable as there is some degree of compression of the subcutaneous tissue. The
study concluded thickness can be measured using skinfold compression, however, more research
is needed to determine how accurate this may be for non-lean individuals. A study by Clarys et
al. [114] showed even two identical thicknesses of adipose tissue may contain significantly different
concentrations of fat and therefore may result in very different responses to mechanical stress,
such as that brought about by calliper testing.
Kanehisa et al. [115] performed experiments on 194 young (20–29 years) and elderly (70–79
years) Japanese persons of both genders, investigating the influences of age and gender on the
muscle and subcutaneous fat on the abdomen (2–3cm from the umbilicus) using ultrasound.
The elderly groups showed significantly thinner muscle and thicker fat than the younger groups.
The percentage of the mean value of subcutaneous fat thickness in the elderly group compared
to that in the younger group was higher in women (176%) than in men (128%), despite the
corresponding muscle thickness being women (65%) and men (68%). In both generations the
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women had significantly thinner muscle and thicker fat than men. The percentage difference
between the genders was shown to be higher in the elderly (169%) than in the young (123%)
but the corresponding muscle thickness was similar for young (80%) as it was for the elderly
(77%) groups.
Song et al. [62] has shown the distance from skin to muscle in the anterolateral aspect of the
thigh was measured in 50 men and 50 women who had undergone a CT scan of the thighs for
other medical reasons. In the study the participants mean skin to muscle was 6.6 ± 4.7mm for
men and 14.8 ± 7.2mm for women (P < 0.001). One obese man and 21 women in the study
were shown to have a greater distance from skin to muscle than the 14.3mm long needle length
used in the marketed design of an epinephrine autoinjector.
Frid and Linden [116] showed in 14 non-obese adults (3 females) that subcutaneous fat in the
thigh and abdomen was often <10mm thick. In contrast, a second study showed that the
majority of 10 non-obese patients (6 females) had subcutaneous fat layers >12mm thick over
the upper medial thigh and abdomen. Both studies measured the depth of subcutaneous fat
with computed tomography. Other investigators such as Vaag et al., have used ultrasound to
find that the overall mean thickness of the subcutaneous fat layer in the anterolateral aspect of
the thigh was 4mm (range 2–10mm) in lean men, and 7mm (range 2–13mm) in lean women [117].
Hirsch and Gibney et al. [48, 118] proved that waist circumference is a good indicator of sub-
cutaneous fat amount. Different areas of the body sample sizes and imaging methods report
different results. Mean subcutaneous thicknesses measured were: arm 10.8mm, thigh 10.4mm,
abdomen 13.9mm and buttocks 15.4mm. Subcutaneous thickness in females was 5.1mm greater
than in males and differences in BMI of 10.0 accounted for a difference of 4mm subcutaneous
thickness. Hirsch and Gibney et al. found that a 4mm length needle, inserted perpendicularly
without a raised skin fold, will consistently provide subcutaneous medication, such as those
used in pen injectors. Delivery at injection depth of ≥8mm was shown to be required to achieve
intramuscular delivery which is in agreement with a review by Nakatani et al. [103] reported
that subcutaneous fat at the abdomen is between 8–15mm.
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2.3.2 Mechanical Properties In Vivo
Skin has been described as being many different things, such as; nonlinear, anisotropic, vis-
coelastic, incompressible and highly dependent on the environment [119]. Clancy et al. [41]
states that this unique behaviour is caused by the composite structure of skin with contribu-
tions from elastic collagen, elastin fibres, viscous tissue water and the ground substance. The
morphology of the skin, where it is on the body and its intended function also define the mech-
anical properties and their variation making skin very difficult to test and analyse.
Skin was first characterised by Langer in 1861. Langer was the first to notice that punctures
made with objects with a cylindrical cross section result in elliptical wounds. This is due to
anisotropic natural stresses and strain fields on the skin. Langer described the latent in vivo
skin tension fields. The term ‘Langer’s lines’ correspond to the alignment of collagen fibres
along the ‘grain’ is where the skin has the least flexibility [31]. Alexander et al. [120] reported
the latent axial tension skin, perpendicular and parallel to Langer’s lines, to be 5N.m−1 and
24N.m−1 respectively.
There are several non-invasive methods used to investigate the mechanical properties of human
skin in vivo, some are shown in Table 2.2. Many experimental methods are not useful for routine
testing as they are too sophisticated or require complex equipment or expertise. Some methods
have been adapted from other medical applications (ultrasound, tomography), while others
(indentation, ballistometry) were originally used in the field of metallurgy but have since been
used to establish fracture toughness of hard and soft tissues [21, 126]. Some authors have used
bespoke equipment that utilises suction, torsion or traction to understand the skin behaviour.
The main issue with all of these methods is that the natural state of the skin has to be modified
for it to comply with the test [119].
Technique Parameters Sampling Depth References
Cutometer Elasticity, Water content Full thickness/Superficial [37, 120]
Extensometer Elasticity Superficial [121,122]
Ultrasound Structure, Water distribution Full thickness [99,101,108,123]
Tomography Structure Full thickness/Superficial [116]
Skin Indentor Elasticity, Water content Full thickness/Superficial [21, 119,124]
Ballistometer Elasticity, Water content Full thickness [89,125]
Table 2.2: Devices and test rigs used for measuring the mechanical properties of skin in vivo.
Table adapted from Clancy et al. [41].
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Elasticity and Viscoelasticity
Skin turgor is the skin’s ability to change shape and return to its normal position. The skin
can undergo small extensions as the coiled collagen fibres are straightened and aligned rather
than stretched. It is generally acknowledged that the stress-strain response of biological soft
tissues is nonlinear resulting in a characteristic J-curve, where stiffening occurs above 40%.
Due to its composite structure, skin is capable of large deformations before yield due to the
presence of elastin, whilst the tensile strength remains high due to collagen. Lee et al. [127]
states that collagen, in vitro, has an elastic modulus of E ≈1GPa and a strain limit of only
0.2. In comparison, elastin has a much lower modulus but is capable of high elongations, up to
150%, and has a higher strain limit of 2.0.
Lee et al. also states that over a large low stress range (E = 5–100kPa) skin is linearly elastic
allowing it to retain its shape. Additionally the stress levels are thought to increase with applied
strain rate, showing strain hardening [128].
Grytz et al. [129] has shown, using an atomic force microscope (AFM), evidence of viscoelastic
behaviour at the single collagen fibril level comparing the fibril to an extensible helical spring.
The collagen fibrils present in the dermis are randomly arranged in layers or lamellae. At
a slightly larger scale, nanoindention experiments performed by Crichton et al. [130] showed
that across a scale of indenter probe sizes (1.90–6.62µm) the skin is nonlinear and viscoelastic.
Another static way of measuring skin elasticity is to use a Cutometer that measures using a
suction method. A vacuum is created over the skin and its resistance, and curvature in response
to this, is used to describe the skin’s elasticity. If suction is applied to one skin site with
repetition, the fatigue of the skin can be determined. When skin is stretched the modulus of
elasticity approaches that of a tendon according to Svensson et al. [131].
Drake et al. [89] used a ballistometer to measure the decay in restitution of elasticity of skin. The
highest skin elasticity was recorded in young patients and lowest in skin from the oldest subjects,
proving elasticity is reduced with age. These findings were more apparent in sun exposed areas
of the skin. Although, Tosti et al. [125] warns that results from a ballistometer can be affected
by the depth or volume of tissue and structures involved.
Gunner et al. [121] devised a method of measuring the recoils of patients skin. Measuring
these properties is critical for estimating dimensional behaviour of skin flap or graft. Mah-
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mud et al. [122] used dynamic motion capture technology as an improvement over traditional
extensometer-based approach. Using a grid of fiducial markings that were placed on the sur-
face of forearm arm skin and tracked during deformation. The deformation to the skin from
stretching was graphed in 3 dimensions to establish skin mobility. Moerman et al. [132] refined
this technique using digital image correlation at a higher resolution to measure shallow skin
indentation in 3D.
Christensen et al. [107] tested rate effects noninvasively on the surface of skin in vivo using a
novel test rig with a 0.38mm probe at ≤4mm displacement. The test rig utilised an elec-
trodynamometer and a linear variable differential transformer (LVDT), to output force and
displacement, respectively. The viscoelastic properties of skin have been reported to be in-
fluenced by anatomical site, gender, hydration, internal swelling (from injury), scarring, sun
exposure and aging [37, 107]. Hydration of the stratum corneum is known to greatly decrease
the stiffness of the stratum corneum, however, the underlying mechanisms that cause this are
not [31,107]. The primary driver for research in the area of skin elasticity and the effect of aging
is the cosmetic industry [133]. Consequently a disproportionate amount of research has focused
on female skin on and around the face. These sites are not of particular interest to the field of
parenteral drug delivery.
Young’s Modulus (E)
The Young’s modulus is a measure of the stiffness of an elastic material. Pailler-Mattei et
al. [119] used a skin indenter on forearm skin in vivo to measure the average value of the
skin of the Young’s modulus between 4.5–8.0kPa. Boyer et al. [134] used a micro-indenter and
established skin stiffness values of 47.3–128N.m−1. Other authors have used mechanical models
predicting the value of the Young’s modulus of the skin in vivo either by torsion systems or
using suction devices [37]. Nakatani et al. [103] has compared Cutometer measurements with a
novel pzieoelectric tactile sensor to isolate the Young’s modulus of the superficial layers and the
whole skin. The research proved that the softness of skin is greater deeper into the skin than
on the surface.
A review performed by Diridollou et al. [135] that encompassed several studies into the Young’s
modulus of skin, showed the results between authors can vary by a factor of 3000 depending on
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the model proposed or the stresses applied, which varied from 20kPa to 57MPa. Roderiges [136]
states that the range of E could be greater and vary by up to four orders of magnitude. This large
variation is most likely a combination of the skin thickness and composition differing between
subjects and test sites affecting the behaviour and results under applied stress. Also the results
may inevitably differ due to dissimilar methods of load application, force measurement and the
portion of the graph that was being measured. It is of interest that none of the literature on
skin extensibility reports any high strain rates indicative of an impact situation.
Toughness (JIc)
The resistance to propagation of cracks is regarded as fracture toughness, the energy required
per unit area of crack (JIc) as defined by Ashby and Jones [137]. Table 2.3 shows the JIc values
for a range of materials. JIc is an important mechanical property for any material, but to date
there have been few investigations of this in soft mammalian tissues [138]. Toughness testing can
be performed using two methods, the trouser tear test as described by Rivlin and Thomas [139]
or the scissors cutting test used by Pereira et al. [34]. Pereira et al. state that virtually all
fracture tests are not capable of measuring material toughness directly. Instead they impart
strain energy to a sharp notched specimen and measure the loss of energy when the crack grows
from the notch in a controlled way. Neither of these tests can be performed in vivo.
Toughness should be a tensile test of a standard geometry that includes a notch to measure the
energy needed to grow a crack, although this is very difficult to achieve with skin. Skin does not
tear as any crack that is formed is prone to blunting. Mammalian tissues are usually subject
to biaxial stress while in vivo. When tested in uniaxial tension the nonlinear ‘J-shaped’ stress-
strain curve has been contributed to the very low shear modulus of the extracellular matrix
(ECM) of connective tissues between the collagen fibres, which take the bulk of the tensile load.
Different skin layers absorb different amounts of energy when stressed and it is this design that
enhances skin’s tear resistance [140].
Goh et al. [141] suggests that skin is a biological example of a fibre-reinforced composite material
comprised of collagen fibrils embedded in and reinforcing a hydrated proteoglycan-rich gel.
Pereira et al. [34] states that the resistance is likely due to the viscoelastic behaviour of the
ground substance blunting the cracks and not allowing them to propagate.
Chapter 2. Literature Review 30
Material JIc (kJ.m
−2)
High-strength steels (HSS) 15–118
Mild steel 100
Rat skin [142] 13.2–26.9
Medium-carbon steel 13
Polypropelene (PP) 8
High density polyethylene (HDPE) 6–7
Human skin (Palm) [34] 2.6
Bone 2
Polystyrene 2
Rat skin [34] 0.6
Silicon carbide 0.05
Table 2.3: Experimental data for fracture toughness (JIc) for a range of materials. Adapted
from Ashby and Jones [137] to include data from Purslow [142] and Pereira et al. [34].
The difference in rat skin data produced by Purslow [142] and Pereira et al. [34], shown in
Table 2.3, is out by two orders of magnitude. This is likely to be caused by the presence of a
blade in the scissors cutting keeping the crack sharp compared to the trouser tear test. This
data indicates that the human palm skin data (2.6kJ.m−2), if tested with a trouser tear test,
could be significantly tougher. Skin toughness has been shown to be affected by extension rate,
temperature and also by Langer’s lines [34,142].
Finite Element Modelling
The mechanical properties of skin are dependent on the its composition. Specifically, the nature
and arrangement of the dermal collagen and elastic fibre network, presence of water, proteins
and the macromolecules embedded in extracellular matrix (ECM) are all reported to have an
effect [143]. The nonlinear stress-strain behaviour of skin in vivo is widely reported as being
due to the properties of elastic solids and various liquids that result in the viscoelastic beha-
viour [37, 120]. Buehler [144] coined the phrase ‘biomateriomics’ as the approach required to
understand the multiscale aspects of mechanical properties of biological materials and the in-
teraction of structure and function. This summarises the complex approach of empirical testing
and analytical modelling that is required to study biological materials and systems.
To solve the complex behaviour of soft-solid biomaterials mechanical engineers often use finite
element modelling (FEM) software. Most authors discussed have supplemented the development
of inverse FE models using empirical data gained from rudimentary mechanical testing of various
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materials [122,130,132,145–148]. The model can thus serve as a tool for evaluating the effect of
changes [133]. Modelling is particularly suited to understanding the problem of the mechanical
properties of skin as extensive testing of in vivo human skin is difficult to perform. Ethically it
is hard to justify and the number of subjects required, to generate statistically significant data
set, is foreboding.
FE models often consider in vivo skin as an incompressible solid-fluid mixture. Many rubber-
like solids can be treated as isotropic and incompressible elastic materials to a high degree of
approximation. The results from testing elongation response to suction, elastic response to
ballistic impact and rheological response to torsional stress all assume that skin is linear and
isotropic, which is acceptable for small strains across uniform material [149].
Many of the FE models that exist in literature are only valid at low strain rates <0.5s−1 [150].
There is a consensus that the Ogden strain energy density function provides a good description
of the uniaxial compressive and tensile stress versus strain behaviour of skin and silicone rubber
over a wide range of strain rates [43, 128, 150]. The Ogden model [151] works well for many
materials as it can be much more nonlinear than Neo-Hookean or Mooney-Rivlin models.
The one-term Ogden strain energy density function is given as:
φ =
2µ
α2
(λα1 + λ
α
2 + λ
α
3 − 3) (2.1)
Where φ is the strain energy density per undeformed unit volume, λ is the stretch ratio, α is
the strain hardening exponent and µ is the shear modulus.
Shergold and Fleck [128] applied the Ogden model for compression testing of pig skin and
provided a practical estimate to the tensile behaviour of skin first measured by Ankerson et
al. [152]. A single Ogden model will not fit all loads perfectly due to the multiple layers in
the skin and their different mechanical properties. To truly understand skin response to an
event such as penetration, a multi layered model would be required [153]. Scale aspects have
been tackled by Chrichton et al. [130] while modelling mouse skin. Although a multilayered
model for human skin with interaction between the scales, from collagen to ECM, has not yet
been established. Delalleau et al. [154] describes the task to account for the high number of
parameters and reduce the solutions to a single FE model as “daunting”.
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2.3.3 Skin Properties Summary
The biomechanical behaviour of skin has been described as inhomogeneous, nonlinear (depending
on stress rate) and anisotropic. The differences between the reported values for biomechanical
properties of human skin are large, although there is a consensus on the general behaviour
of the skin layers. The stratum corneum has a high tensile strength, but is very thin, whilst
the epidermis and dermis exhibits viscous and elastic behaviour. The subcutaneous tissue is
structureless, incompressible and highly mobile. Skin’s resistance to an applied vertical stress is
reported to be due to the combined epidermis-dermis rather than to the subcutaneous fat [135].
The mechanical properties of skin are a combination of its thickness and composition and these
properties may change continuously from early age [155]. A consequence of an aged epidermis
is that it becomes less resistant to shearing forces and tears more easily after trauma [97]. As
well as aging, skin properties have been shown to be influenced by anatomical skin site, gender,
hydration, swelling (from injury), scarring and sun exposure [37, 107]. It is sometimes difficult
to establish which of these effects are genetic and which are environmental.
There are many authors who have quantified skin properties of in vitro skin samples measure-
ments [31,32,156], although these experiments generally test for properties rather than function
and how the skin behaves in vivo [32]. More relevant are studies focused on gaining quantitative
data of in vivo behaviour of soft tissue [21,37,123,135,143]. The results obtained often rely on
the observation of indices, mainly skin stretch in millimetres and ratios, and are dependent on
experimental conditions. Many authors have described the difficulties in observing, describing
and standardising these indices and their interpretation [135].
Due to its highly nonlinear behaviour, authors often develop computational FE models of the
skin and adjust parameters by trial and error to match results from empirical testing. Using
these models reasonable approximations can be made for elasticity, but viscoelastic effects and
damage or failure of the skin is hard to predict given the uniqueness of the measured material and
parameters. Wilkes and Brown [31] concluded, in as early as 1973, that the extreme complexity
of the dermal and epidermal skin layers, and the possible variability between individuals, are not
always easy to extrapolate to other situations. Buehler [144] states that the need for on-going
convergence of biology, mathematics and engineering as well as computational and experimental
techniques are required for understanding complex material systems.
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2.4 Skin Penetration Mechanics
The mechanics of a penetration event are dependent on the delivery and geometry of the penet-
rator and the composition, thickness and behaviour of the material(s) being penetrated. Penet-
ration of soft-solid viscoelastic materials such as skin are complex. Research has been performed
for a wide range of needle-based and needle-free medical applications, as well as for more rudi-
mentary understanding of skin trauma from events such as stabbing or bullet wounds. This
section explores the research in each of these fields to identify the most applicable to the mech-
anics of a solid dose injection. The research within this section, unless stated otherwise, has
been performing using in vivo or in vitro human tissue. The following section (§ 2.5) will explore
the alternatives to using human tissue for penetration understanding.
2.4.1 Needle-Based Skin Penetration
Needles have been in use since the 19th Century. The understanding of needle-based skin penet-
ration, however, is relatively new to science. Historically, injections were delivered manually by
a trained practitioner. More recently it has become possible to perform percutaneous procedures
using visual methods such as CT scan, fluoroscopy and ultrasound, to understand positioning of
needles around anatomical structures under the skin. Although, these methods are often lengthy
processes dependent on successive image capture and incremental needle insertion steps [157].
There is now a technological pull to automate procedures for applications such as robot assisted
surgery [158–160], suturing [161] and blood sampling [162, 163]. These all require haptic feed-
back and need to understand forces of tissues to prevent cuts, insertions and needles deviating or
deflecting from an intended path. This knowledge has also led to the development of synthetic
phantoms for surgeons to train on prior to performing surgery [164].
The most prominent authors in the field of needle insertion and their research methods have
been summarised in Table 2.4. The experimental methods and equipment that is used varies
depending on the purpose of their research. Away from the surgical procedures listed, the
remainder of needle insertion research for drug delivery is focused on properties and geometry of
the inserted needles and less about response of the penetrated tissue [165–167]. Needle insertion
literature looks across a range of different parameters that may affect the penetration. Some of
these will be looked into in more detail in the following text.
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Author Needle Description
Velocity Depth
Test Bed Method
(mm.s−1) (mm)
Abolhassani [168] 18Ga 10 ≤ 80 Both Robotic
Brett [169] 18Ga Tuohy 60–150 ≤ 35 Tissue Robotic
Crouch [170] 18Ga Brachytherapy 3–21 ≤ 100 Phantom Robotic
DiMaio [171] 17Ga Tuohy 1–10 ≤ 70 Phantom Robotic
Frick [161] 20Ga Triangular 1–10 ≤ 20 Tissue Robotic
Hochman [172] 25–30Ga Dental 20 ≤ 20 Phantom Manual
Maurin [157] 18Ga Biopsy 15 ≤ 50 Tissue Both
Okamura [158] 18Ga Surgical 3 ≤ 20 Tissue Robotic
Table 2.4: A selection of needle insertion authors and their research methods.
Description of Needle Insertion
Needle insertion is usually described as two separate events; the term ‘puncturing’ refers to
making a hole in the outer layer of a tissue using the tip of a needle and the term ‘cutting’ refers
to piercing the inner layers of the tissue after puncture and during penetration of the needle
into the tissue [173].
The two phases are often indicated by the two peaks present on most needle-based skin penet-
ration graphs reported in literature and are a consequence of the initial penetration of the outer
epidermis and the emergence through the inner dermis into the underlying tissue. Despite the
vast difference in scale these observations have also been made for the penetration mechanics
of knife stabbing [152, 174]. The number and magnitude of the peaks present on a force vs.
displacement graph is dependent on the combinations of tissue and penetrator properties.
Brett et al. [169] describes the forces acting on a needle during an injection as a combination of;
the initial elastic response of skin prior to penetration, the rupture of the skin, the drag of the
skin (once penetrated) on the needle and the viscous response to cutting of underlying tissue(s).
Frick et al. [161] identified the importance of the slope regions of the pre-penetration (compli-
ance) and pre-terminal slopes (N.mm−1) on the penetration graphs and their material dependent
characteristics. The slopes of the force vs. displacement graph were not affected by needle ve-
locity but increased with axial force. The work of Frick et al., as is the case with most authors
in this field, is inconclusive as the research was problem-specific and limited to only two tissue
types and three displacement rates.
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Reported Penetration Forces
Maurin et al. [157] measured an average penetration force of 3.73N when injecting manually
through the skin and into the liver of an anesthetized porcine model. This force was reduced
to 1.89N when the injection was delivered robotically. Barbe´ et al. [175] used a similar model
to measure the viscoelastic effects that occur during manual penetration. The average peak
penetration force recorded was 5.69N. These studies follow very similar methodologies yet have
significantly different results showing that comparisons between authors’ work, regarding exact
figures for penetration, are difficult to establish. A study by Egekvist et al. [176] into human
skin delivering injections at 45° and 90°, at 2 to 19mm.s−1 using 27G to 30Ga needles reported
forces between 0.24–0.34N.
The exact amount of force to penetrate varies widely between authors, equipment and exper-
imental set up. Rather than report exact penetration values on needle-based delivery instead
general trends in the experimental conditions can be observed between the data sets. The forces
reported are particularly dependent on the condition and properties of the tissues tested as well
as the geometry and velocity of the penetrator.
In terms of biomechanical forces affecting injection, Diridollou et al. [100, 135] has shown that
the resistance to vertical forces applied to the surface of the skin is due to the combination of
the dermis and epidermis (particularly the stratum corneum) and not the presence of subcu-
taneous fat. This theory is supported by Brett et al. [169] who states that subcutaneous fat will
undergo a much higher strain than the epidermis and dermis as the mechanical properties of the
subcutaneous fat tissue are relatively simple when using a sharp-tipped penetrator. Jussila et
al. [140] report that intrinsic dermal elasticity has a greater contribution to the resistance to
stress. Compared to the skin, subcutaneous tissue is known to be relatively structureless and
may be considered homogeneous, isotropic fluid.
On an ovine model, Frick et al. [161] has shown it takes less axial force to penetrate skin (1.9N)
than tendon (5.3N). In the study the skin samples were tensioned with different axial loads,
which increased the force required to puncture tissue and also decreased the likelihood of the
tissue deflecting, making it more rigid. It is important to note that tissues in vivo are subject
to biaxial tension that allows them to keep their form, which is difficult to recreate in vitro.
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Effect of Needle Geometry
Okamura et al. [158] showed that the larger the needle diameter the higher the cutting and
frictional forces exerted on the needle become. Smaller diameter and bevelled tipped needles
have been shown to be more likely to bend than those with conical and triangular tips. The
total force acting on a needle is understood by Okamura et al. by Equation 2.2.
Fneedle(z) = Fstiffness(z) + Fcutting(z) + Ffriction(z) (2.2)
Where z is the position of the needle tip. Understandably, an increase in surface area will cause
higher tissue drag and require a higher penetration force. Hochman and Friedman [172] have
shown that asymmetric tipped needles are at risk from bending due to the higher force exerted
on one side as the needle alters the mechanical properties of the target. A bi-bevelled needle
removes the perpendicular forces that are responsible for this. Mayer et al. [177] observed that
the number of bevels will affect coring tendency. It is important to note that the resistance and
likelihood of deflection or coring will also be affected by the tissue a needle is inserted into [168].
Velocity Effect
Skin is known to be viscoelastic, for reasons described in § 2.3.2. The dual layers of the epidermis
and dermis cause skin to be supple at low strain but stiffen at higher strains. There is very limited
data available concerning needle insertion velocity as most research into automating injection
procedures has been performed to replicate manual delivery at low speed. Frick et al. [161]
concluded that varying the velocity at low speeds (<10mm.s−1) led to no significant effect on
penetration force in an ovine model. Conversely, Brett et al. [169] has shown that much higher
needle velocities result in lower peak penetration forces across a much wider range of velocities
up to 150mm.s−1 in a porcine model.
None of the authors in Table 2.4 have performed any experiments comparing delivery rates at
different orders of magnitude or greater than 1m.s−1. The design specifications of devices known
to deliver needles at high rates, such as spring-powered autoinjectors, are often more concerned
about the force required to vacate the drug from the syringe chamber at the desired rate, rather
than the relatively low force required to overcome the skin by a hypodermic needle.
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2.4.2 Needle-Free Skin Penetration
Needle-free technologies, although designed to penetrate the skin, do so via very different mech-
anisms to traditional needle-based devices. Due to the novel nature of each technology, and
commercial sensitivities, only sparse literature is available on how different devices overcome
the skin without the use of a needle. Much like the literature discussed in needle insertion,
authors often focus on the parameters applicable to a specific device rather than explore the
generic problem of drug delivery. Unlike the needle insertion, the mechanisms of needle-free
penetration of the skin are exclusive to the field of drug delivery. The applications and benefits
of different needle-free technologies have been discussed in § 2.2.3. This section collates the
literature that is available and how each technology overcomes the barrier properties of the skin.
Microneedle Penetration
The penetration mechanism of a microneedle patch should be similar to that described for needle
insertion. However, the reduction in scale results in the skin behaving differently. Typically
microneedles patches are delivered manually by pressing against the skin’s surface. The shallow
delivery means only the epidermis is penetrated and much of the elasticity of the dermis is
not encountered. Most of the research into microneedle penetration reported is based on the
principles of nanoindentation testing. Kendall et al. [38] have used probes with tips 2–5µm
diameter delivered into a murine model to establish the penetration parameters. This method
has since been improved by Chrichton et al. [130] to measure the individual effects of the skin
layers during penetration. Davis et al. [178] has injected human skin measuring penetration
forces of 0.1–3.0N and concluding that the insertion force was less than the fracture force of
the microneedle design used. Nanoindentation using a single probe does not necessarily explain
what happens when an array of microneedles is applied to the skin. This problem is to be
best understood using a finite element model, of which there are a several at early stage of
research [153].
Powder Injection
Powder Injection, or biolistics, has been studied in depth by Wrighton-Smith [3], Lahm [40] and
Kendall et al. [4, 179]. Solid microparticles of drug are fired at the skin with sufficient speed
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to penetrate the skin (>300m.s−1). The design of hand-held devices, also known as gene guns,
capable of delivering nominally uniform microparticle velocity distributions was achieved using
computational fluid dynamics (CFD). Powder injection is known to be affected by variations
in tissue mechanical properties that can cause a significant fraction of the drug payload to not
breach the stratum corneum [4].
Liquid Jet Injection
Liquid jet injectors have been around much longer than other needle-free technologies and have
been subject to considerably more research. Most liquid jet injectors are disposable single-use
cartridge injectors (DCJIs). Depending on the device being tested orifice diameters reported
in literature vary between 76–300µm and velocities reported are often between 80–200m.s−1.
These speeds are achieved using compressed gas or springs as the primary power source, though
other alternatives such as using a solid-state laser [180] and Lorentz force motor [181, 182] are
in development. Both would offer greater control during the delivery phase instead of the fixed
pressure profile caused by an exhaustible and decaying power source.
The majority of research in this field is focused on the parameters of liquid jet injector devices.
Some studies have looked at the implications of the target such as Linn et al. [86] who has shown
BMI and injection site have a significant effect on delivery success.
The dynamics of liquid jet injection are best understood by two different research groups who
propose slightly different descriptions for the cause of penetration; Schramm-Baxter and Mitrag-
otri et al. (Santa Barbara University) and Shergold and Fleck (Cambridge University). Other
research groups have been active prior to these two and between them best explain some of the
mechanistic understanding of the physical events during liquid jet injection.
The research conducted by Schramm-Baxter and Mitragotri et al. [1, 83, 183, 184] was intended
to optimise the Vitajet 3, a liquid jet injector, in collaboration with Bioject Medical Techno-
logies Inc. (Tualatin, OR). Their work showed that the general shape of a jet penetration and
dispersion into a polyacrylamide gel can be described as an introductory channel through the
skin followed by a large circular dispersion. This dispersion profile into the gel is two dimen-
sional as the fluid flow causes a fracture plane in the uniform material [183]. This would not
be expected in a porous organic tissue, where spherical or hemi-spherical distributions are more
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common as demonstrated in tests performed on porcine tissue. The penetration depth into the
skin depends on jet power, ejection volume and stand-off distance. At low powers (1.5W) the
jet penetrates a few microns, causing a shallow intradermal injection, at high powers (9.3W)
and (37.1W) subcutaneous and intramuscular depths [83].
The research conducted by Shergold and Fleck [2, 128, 185, 186] was intended to optimise the
IntraJect, a liquid jet injector, that reached the market as DosePro and is now owned by Zogenix
Inc. (San Diego, CA). The liquid jet was modelled on the mechanics of a punch. Shergold and
Fleck recognised there were no penetration models available to describe the phenomena as a
punch passes through a soft solid material. Punch testing is recognised in metallurgy, ceramics,
polymers and soil to derive the mechanical behaviour of different materials [187]. Although this
testing is normally performed on material samples, and not in vivo tissue.
Shergold and Fleck compared the penetration data for liquid jet injections against tests per-
formed using metal punches with equivalent diameters (0.3–2.0mm) and a conical tip. They
observed that the damage, and thus the penetration mode, to the skin was similar between the
liquid jet and conical-tipped punch injections. They also reported that this failure mode could
be observed on tests using silicone rubber. Shergold and Fleck proposed that penetration occurs
through the formation of a crack rather than a residual hole in the dermis [185]. A conical-
tipped punch penetrates the skin by the formation of this planar mode crack. The crack faces
are wedged open by a punch that advances (the skin does not tear as the extracellular matrix
prevents this). The planar crack will only close when either the punch is removed or, in the case
of jet injection, the delivery ceases. The penetration pressure required to form this crack was
shown to be sensitive to the diameter of the punch. In a later publication, Shergold and Fleck
quantified the penetration pressures for liquid jet injection as being twice of that required for a
conical-tipped punch of equal diameter [2].
Shergold and Fleck concluded the following when seeking to explain what had been observed;
the energy required to penetrate the skin is a combination of both the energy to crack the
skin and the energy to open the crack. The energy to create a crack should be proportional to
the skin toughness and the energy to open the crack proportional to the skin (and fat) shear
modulus and that the energy to create cracks is determined by the skin toughness which should
be proportional to Young’s Modulus (E). The Young’s modulus of skin may be affected by
velocity although there is no test data to support this theory at higher velocities.
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2.4.3 Other Means of Penetration
Other examples of understanding skin penetration for the purposes of delivering substances are
drug darts and mosquito bites. Drug darts are designed to remotely penetrate the thick hide of
large animals [188]. A mosquito proboscis is designed to pierce skin and deliver anti-coagulants
before blood is sucked. The proboscis has a very sharp fascicle that tapers from to less than
1µm over the last 50µm. The learning’s from mosquitoes may one day inform better microneedle
designs [189,190]. Other areas of skin penetration research are often based around more energetic
and traumatic events. Research in these fields is performed to understand how to better protect
against or prevent these modes of penetration.
Historically, to protect against projectiles such as arrows and projectiles, buff coats (2–4mm
thick leather) were used as armour. They were flexible but tough and capable of resisting sword
thrusts and early firearms by deflecting and absorbing energy [191]. Williams [192] has examined
proof marks and other forms of armour indentation on the ductile metal plates also used for
protection. Modern bulletproof body armour is designed with a hard glancing surface and to
be both shock absorbing and tough whilst remaining flexible and not fragmenting. DiMaio et
al. [193, 194] states that a bullet with a minimum velocity in the order of 70m.s−1 is required
(with sufficient energy density) to perforate the skin and underlying tissue. Typically slugs may
impact with an energy density of around 2.6–10.0J.m2 depending whether fired from a hand gun
or high-velocity rifle. Body armour is capable of resisting this impact but may still not be able
to protect against stabbing with a knife. For instance, a thrust with a sharp stiletto knife (with
a 0.25mm point tip radius) can be up to 200J.m2 [195].
From the research available on knife stabbing, skin tension has been shown to have a direct effect
on both the force and energy for penetration and that forces reduce with knife sharpness [196,
197]. Less force and energy are also required to puncture the skin when the plane of the blade
is parallel to a direction of greater skin tension (Langer’s lines) than when perpendicular [198].
Chadwick et al. [199] has shown that stabbing energy has 70J on the approach phase and
forces of up to 2000N seen during impact on targets with similar compliance to human tissue.
Interestingly, despite consistent manufacture companies fail to produce consistently uniform
blade points on knives that are nominally identical. The consequences of this are that the
penetration forces associated with identical knives can vary by as much as 100% [198].
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2.4.4 Pain Perception
An additional consideration on skin penetration is that the means of overcoming the skin must
be configured to deliver drugs without causing an unacceptable amount of pain to a patient,
either at the moment of injection or general trauma to the injected area or the discomfort that
may occur post-injection as the skin heals.
Perception of pain is a subjective area and will vary considerably between subjects. No amount
of testing on non-clinical models can account for it. It is also important to note that the
relevance of this to the design of a parenteral system depends on the pharmaceutical benefit
of the drug that is to be administered and the required dosing frequency. For instance, a
different response would be garnered from patients requiring daily or multiple daily injections
for therapeutic treatments rather than users who require emergency treatment for conditions
such as anaphylaxic or hypoglycaemic shock, which are treated with epinephrine and glucagon
hydrochloride, respectively. These emergency treatments are only expected to be administered
once in a life-threatening circumstance, therefore the issue of pain, understandably, becomes
less relevant. There is evidence to demonstrate that smaller gauge needles result in smaller
cuts and cause less pain during delivery [176, 177]. Greenspan and McGillis [200] have shown
non-invasively that as probe size decreases, from 4.87mm to 13µm, so too did pain. The study
also showed that the pressure threshold increased relatively little when performed on finger but
only with an applied force of 0.12N.
Needle-free technologies do not necessarily make for pain-free drug delivery solutions. With the
exception of microneedle patches, a hole must still be made in both the epidermis and the dermis,
which contains of a lateral density of nerves and blood vessels. Most needle-free injections last
for a shorter duration, measured in milliseconds, than the few seconds a manually delivered
needle is typically present under the skin. Reductions in nozzle orifices can reduce diameter of
the liquid jet which may reduce pain, similar to using a smaller gauge needle [83].
There is very little research into pain perception and allowable pain levels for needle-free tech-
nologies available in the public domain. Nearly all companies developing needle-free technology
state tests have been performed to prove that they are equivalent or less painful compared to
needle-based alternatives. For example, for the Glide technology, patients have perceived a
reduced pain sensation when compared to a 27Ga needle.
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2.4.5 Skin Penetration Summary
The mechanisms of skin penetration that have been reviewed are shown in Table 2.5 according
to the amount of energy and the sharpness of the penetrator used. This matrix also implies the
level of trauma each application is intended to cause to the skin. The Glide SDI device is unique
in that most methods to overcome the skin either, deliver a sharp penetrator at low speed or
accelerate blunt (by comparison) penetrators to very high speeds.
Needle-based penetration has been shown to be dependent on parameters such as penetration
force, needle velocity, geometry and the target properties. There is much less literature available
for needle-free drug delivery technologies as these systems are often developed commercially
and the research is not disclosed in the public domain to protect intellectual property. The
majority of skin penetration research is problem-specific and focused on iteratively changing
device parameters on a single target or test bed. Often several parameters change within a
single study.
From the investigations into needle-free penetration available the same generic problem has been
reported that skin, and its response to penetration, has been shown to vary. No studies have
solely investigated the issue of target variation across multiple samples of skin and the impact
this may have on penetration.
To understand penetration, most authors have avoided developing analytical models from first
principles; rather experimental data is used to generate empirical relations based on initial
assumptions. From all of the literature reviewed only the conical-punch penetration model de-
veloped by Shergold and Fleck [185] is compatible with solid dose injection. Though the geometry
and velocities are different the parameters governing solid dose injection may be quantifiable
through similar experimental method.
Penetration Sharp Penetrator References Blunt Penetrator References
High Energy
Ballistics [140,193,194]
Knife Stabbing [174,196,198] Liquid Jet Injection [184,201]
Powder Injection [3, 40,202]
Low Energy
Needle Insertion [168,170,172]
Surgical Incision [164] Conical-Punch Injection [185,186,203]
Mosquito Bite [189,190] Solid Dose Injection
Microneedle Patch [38,178]
Table 2.5: Matrix showing different skin penetration methods and fields of research.
Chapter 2. Literature Review 43
2.5 Skin Models
The mechanical properties of skin reported within this literature review were obtained from
measurements performed on in vivo human skin, unless stated otherwise. This data has been
mostly gathered using non-invasive techniques as the study of human skin by invasive techniques
remains difficult to ethically justify for exploratory means. This has meant many authors of skin
penetration literature have sought to use alternative skin models in their research.
Non-clinical models are used for a wide range of preliminary toxicology, pharmaceutical and
biomedical testing. These models can also be used in vivo and in vitro for the study of bio-
mechanical applications for specific applications where the functions of bones, organs and tissues
between the model and human are comparable. Synthetic materials or ‘phantoms’ are common-
place in needle-based penetration research as a repeatable and relatively inexpensive alternative
to biomaterials. This section will report on the alternatives available to in vivo human skin
models that have been reported within the field of parenteral drug delivery.
2.5.1 The Clinical Model
The clinical model refers to testing of humans in vivo at a clinical trial. Most of the data
reported for mechanical properties of in vivo human skin in § 2.3.2 has come from authors using
non-invasive techniques away from a clinical environment. As already explained, it would be
ideal to regularly test drug delivery systems and exploratory invasive measurements in vivo on
human volunteers, but there are many reasons why this would be prohibitive as well as the
obvious ethical and cost difficulties.
Within this review human skin thickness and mechanical properties have been shown to be
affected by numerous inherent variables such as ethnicity, gender, age and also many environ-
mental influences caused by differing lifestyles such as weight, BMI, UV exposure. Within a
clinical trial group there will be variation in each of these factors and to control this the trial
subjects are often stratified into groups according to known variables.
To study penetration mechanics of parenteral devices (§ 2.4) on the clinical model would first
require efficacy data demonstrated on alternative skin models to assure regulators ahead of
performing a clinical trial.
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2.5.2 Non-Clinical Models
Non-clinical testing concerns the use of animals as alternatives to humans for many research
applications including toxicology, pharmaceutical and biomedical testing. Non-clinical models
are sometimes referred to as ‘pre-clinical models’ if the data is to be used to prove efficacy ahead
of a human clinical trial. There are many models that can be and are used to investigate drug
delivery. Non-clinical model selection depends on a number of factors such as availability, cost,
ease of handling, investigator familiarity and anatomical or functional similarity to humans [206].
For parenteral drug delivery skin thickness is often a key factor. The epidermal thicknesses for
selected models are shown in Table 2.6.
Small mammals such as rabbit (Oryctolagus cuniculus), guinea pig (Cavia porcellus) and rat
(Rattus norvegicus) are frequently used by authors for dermal tolerability and other superficial
skin experiments as they are inexpensive and easy to handle [51,105,207]. These models are also
suitable for studying pharmacokinetics (PK) and pharmacodynamics (PD) with scaled doses.
Model Region Epidermal Thickness (µm) Reference
Human
Back upper trunk 43.4 ± 13.4 [204]
Front upper trunk 37.6 ± 11.1 [204]
Back lower trunk 43.2 [204]
Front lower trunk 46.6 ± 10.8 [204]
Abdomen 46.9 ± 2.3 [205]
Abdomen 49.5 ± 11.1 [105]
Thigh 54.3 ± 17.5 [204]
Upper arm 53.4 ± 25.9 [204]
Large White Pig
Rump 56.7 ± 3.1 [27]
Shoulder 59.1 ± 3.4 [27]
Mid-back 51.9 ± 1.5 [27]
Abdomen 46.8 ± 2.0 [27]
Miniature Pig Back 65.8 ± 1.8 [205]
Beagle Dog
Rump 27.7 ± 6.4 [27]
Shoulder 20.0 ± 3.6 [27]
Mid-back 21.2 ± 2.6 [27]
Abdomen 22.5 ± 2.4 [27]
Sprague Dawley Rat
Shoulder 2.9 ± 0.2 [27]
Mid-back 5.0 ± 0.9 [27]
Abdomen 5.6 ± 0.6 [27]
Table 2.6: Stratum corneum and epidermal thickness of different non-clinical models taken from
literature, including; Whitton and Everall [204], Bronaugh et al. [205], Panchagnula et al. [105]
and Monteiro et al. [27].
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Some models are particularly suited to certain research applications. An example of this is
the Ferret model (Mustela furo) which is primarily used to develop flu vaccines as they are
susceptible to the same virus strains as humans and show similar symptoms [208].
Larger models such as sheep (Ovis aries), beagle dog (Canis familiaris) and primates, are also
used as non-clinical models. Their increased blood volume means that the PK and PD data
collected is generally more accurate. The larger the mammalian model typically means the
thicker the skin. The skin penetration research reported in § 2.4 has been achieved on a variety
of non-clinical models. Different tissues have been sourced from different species depending on
the experimental set up and objectives. For the purposes of drug delivery research there are
examples as diverse as using the horse model (Equus caballus) for topical [209] and liquid jet
injection [84] research and, on an entirely different scale, the mouse model (Mus musculus) has
been used in the development of microneedle patches [8, 130].
Despite the wide array of non-clinical models available, it is often the skin of the domestic, or
Large White, pig (Sus scrofa) that is most frequently used as a substitute for human skin for a
variety of experimental objectives.
Porcine Model
Pigs are one of the earliest animals used in research. In Ancient Greece, Erasistratus (304–250
B.C.) used them to investigate the mechanics of breathing. The porcine model is well recognised
as an experimental animal model and has been used over many centuries for biomedical research
for applications in skeletal research, toxicology, pharmacology and organ transplants [27, 210–
213]. Pigs are also the only common domestic mammal with a thin hair covering similar to
humans. The reason for this resemblance is the fact that both species rely on fat, not fur, for
hair for insulation. The epidermis of both is unpigmented and the thicknesses and epidermal
turn-over time (time for division, maturation and shedding of cells) is similar. For these reasons
the porcine model has become the non-clinical model of choice for skin research [214].
Sullivan et al. [206] and Vardaxis et al. [215] both claim that anatomically and physiologically
pig skin bears many resemblances to human skin and can be considered more like human skin
than skin from other non-primate mammals. The porcine models used in literature are typically
the domestic, or Large White, pig that is grown to sizes of 70kg comparable to the body mass
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of a human model [212] and also the Miniature pig [213,216], which is smaller, easier to handle
and used for niche research applications.
As reported by Meyer et al. [217] and shown in Table 2.6, the epidermis of pig skin (70–140µm) is
similar in thickness to that of man (50–100µm in man). Although the cornified (most superficial)
cell layer is more compacted and thicker in pig skin but is still similar to human skin in frictional
areas. However, there are slight differences between porcine and human skin that make a direct
comparison impossible, such as the vasculature of the papillary dermis, chemical differences and
apocine sweat glands, whereas humans have an eccrine system [215].
Most pig research within the pork production industry has been conducted measuring the dorsal
sites between the shoulder and rump positions. This is because pigs and their meat are valued
according to the thickness of the subcutaneous fat around the carcass when sold. Wood and
Riley [218] showed that skin thickness varied between dorsal sites, being thicker in the shoulder
area than in the mid-back or rump in both uncastrated and castrated male pigs weighing 87kg,
as shown in Table 2.7. The skin was between 10–23.4% thinner in castrated males, an effect
ascribed to the action of androgens. The subcutaneous fat was thicker in the shoulder than
the rump or mid-back regions which were similar. Fat thickness was greater in castrated males
which therefore had thinner skin and thicker fat than uncastrated males, replicating what would
be expected in a female pig [218]. This example shows the experimentation possible through
using a non-clinical model. A gender effect has been detected in the skin thickness on humans,
as reported in § 2.3, but it would not be ethical to have performed such a clinical study to
explore the cause.
Wood et al. [219] has also shown the effect castration has on chemical components and distri-
bution of subcutaneous fat tissue. Areas of the shoulder, rump and belly all saw a reduction
Layer Site Uncast. ♂ (mm) Cast. ♂ (mm) % change Cast. Effect (P)
Skin
Rump 2.0 1.8 -10.0% n.s.
Mid-back 2.5 2.0 -20.0% 0.05
Shoulder 3.0 2.3 -23.4% 0.05
Subcut. Fat
Rump 12.6 15.8 +25.4% 0.01
Mid-back 12.3 15.0 +22.0% 0.01
Shoulder 28.6 30.5 +6.6% 0.05
Table 2.7: Thickness of skin and underlying subcutaneous fat in uncastrated and castrated 87kg
male pigs [218] (n.s. = P > 0.05).
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in water (19–31%) and an increase in lipids (9–20%), again eluding to an androgen led gender
effect. Wood et al. state that such effects have repercussions for the firmness and cohesiveness
of fat tissues and are likely to alter its mechanical properties. Meyer et al. [217] also report
that the subcutaneous fat layer of both pigs and humans shows distinct gender and age related
differences citing they are related to differences in the latticed and lamellar structure of the
collagen fibres and also to the formation of the fat chambers.
The appeal to various authors of using pig skin has often been due its superficial characteristics
linking it to human skin. The mechanical properties of the skin and its structures are not as
often investigated, although there are exceptions. Some studies have focused on categorising the
fundamental biomechanical properties of pig skin and compared this with human skin [128,213].
Kang and Wu [220] have used pig skin to show that resistance to creep is higher in direction of
Langer’s lines than that in direction perpendicular to Langer’s lines, which is also suspected of
human skin.
In terms of skin penetration, Brett et al. [169] reports higher penetration force using needles
into pig than into human skin, although for deep penetration they were shown to be equivalent.
Other authors have used pig skin to demonstrate trauma from bullet [140] or knife wounds [198].
Ankersen et al. [152] states that for knife stabbing pig skin has a much higher tensile strength
than synthetic chamois although the penetration force for the materials are similar. Ankersen et
al. concluded that pig skin is an acceptable simulant for human skin with respect to stress-strain
response and strength for knife penetration. For needle-free penetration there are several liquid
jet injectors available to vaccinate swine. They have the distinct advantage of removing the
needle from the delivery process and eliminating needle-fragments that can be found in pork
products [221]. Kendall et al. [179] also used pig skin to demonstrate biolistic delivery.
Despite pig skin being prevalent in skin research, most of the mechanical testing and data
produced tends to be for the superficial layers of skin or, adversely, at rates and energies or with
penetrators that are incompatible to the scale of solid dose injection. This is with the exception
of the research of Shergold and Fleck [2,128]. Finally, Vardaxis et al. [215] suggested to exercise
caution when designing an experiment in which pig skin is used as a model for human skin when
the results of the study are interpreted with regard to the human situation.
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2.5.3 In Vitro Skin Models
To further reduce cost, ethical implications and complexity of in vivo testing research can be
performed ex vivo, meaning the tissue remains in situ on the terminated model or, alternatively,
in vitro, where the tissue is excised and experiments are performed elsewhere. Human skin can
be sourced from cadavers or surgical waste from cosmetic procedures through contract research
organisations such as Biopta Ltd. (Glasgow, Scotland) and Biopredic International (Rennes,
France) [222,223]. However, supply and choice (particularly age) are limited by availability. For
these reasons, in skin from non-clinical models (§ 2.5.2) is often used as an alternative.
Testing biomechanical properties in vivo is preferable but not always possible. The mechanical
properties of skin are altered as soon as the tissue is excised, the circulation lost and the relative
skin tension relaxed. There are perfusion techniques to keep the skin ‘alive’ and hydrated during
in vitro testing [27], although this is only suitable for maintaining superficial properties of the
stratum corneum and used for investigating transdermal drug delivery [40]. For mechanical
testing, such as tensile testing, the skin must be removed and cut into uniform shaped specimens
that are tested until failure. Ni-Annaidh et al. [224] used this approach to show that Langer’s
lines had an effect on collagen orientation across 56 samples of in vitro human skin.
Many authors have researched skin penetration on tissue samples in vitro up to 6 hours after
death with meaningful results [43,169,184,220]. Past this time point the skin is usually preserved
and retained for future testing through chilling or freezing. This secondary process will alter the
skin properties as ice forms within the cells. Cryoprotective agents can be used to preserve the
barrier properties of the skin [3]. How the skin sample is thawed and the temperature it is next
tested at is also of importance, as demonstrated by Xu et al. [211] who has shown skin tissue
behaviour to be temperature dependent.
There is no established in vitro sample preparation for penetration testing. Each author uses
their own problem-specific method. While variation in the mechanical properties of skin is
known, as reported in § 2.3, sparse research has been performed to quantify it and its causes.
In vitro methods are immediately compromised as the response of the skin is altered through
excising, freezing, thawing and then how the specimen is supported in vitro during testing. The
difficulty of using in vitro alternatives to understand in vivo conditions is best summed up by
Edwards and Marks [32] who state in vitro testing tests properties rather than function.
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2.5.4 In Vitro Synthetic Models
Due to the costs, complexities and variation when using skin as a testing material, many authors
have sought to develop and use synthetic alternatives. The use of in vitro synthetic test beds,
also referred to as ‘phantoms’, are popular in the study of needle-based penetration and are
intended to simulate the response of real tissue. Most phantoms are used in medical literature
to reduce the demands for clinical and non-clinical testing and remove the problems associated
with sourcing human tissue [172].
The National Centre for the Replacement, Refinement and Reduction of Animals in Research
(NC3Rs) [225] promote the use of phantoms and novel mathematical approaches to ultimately
replace and reduce the use of animals. Applications range from providing robust alternat-
ives to animals to address basic research questions posed by the pharmaceutical and chemical
industries [226], to modelling whole organs to aid the training of gall bladder and liver sur-
gery [227]. Patents for the development training aids for needle penetration training date back
to 1964 [228–230].
As well as being ethical and easier to source than tissue, synthetic test beds are also used as they
provide a controllable repeatable testing environment, removing the complications associated
with the unpredictable inhomogeneous internal structure of real tissue [158]. There are two
approaches taken for judging the suitability of a phantom for skin penetration, either to mimic
the skin and create a multilayered test bed with representative mechanical properties, or to
devise a test bed purely on the basis that it provides similar axial forces to penetrate compared
to in vivo or in vitro skin.
The penetration research that has been reported in various phantoms can typically be grouped as
either being colloidal gel-based or soft solid polymers. Basic gelatine has been used by Hiemenz et
al. [159, 160] who observed that needle-based penetration profiles were unaffected by changes
in rate and concluded that the simple test bed material was unrealistic. Schramm-Baxter et
al. [183] performed work using polyacrylamide gels as a model test bed for several needle-free
fluid impingement applications. Gel-based material allows the modelling of a soft solid material
with the benefits of being transparent to view the penetration event. Other authors have used
nanoindentation to compare properties of artificial skin models to in vivo human skin data with
reasonable levels of success [124,146].
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A variety of silicone rubber phantoms of various specifications and thicknesses have been reported
within the needle-based and needle-free literature [158,168,186]. Kerdok et al. [231] has gone as
far as to devise the ‘truth cube’; a method of simulating the soft solid tissue deformation caused
by penetration using a test bed built in layers with fiducial markers positioned within each
layer. The fiducial markers are then tracked in 3D during insertion to determine the physical
deformation and response of the tissue phantom. Crouch et al. [170] used this ‘truth cube’ to
develop a finite element model (FEM) for needle insertion.
A radically different approach to creating a test bed is to synthesise in vitro skin from living
cells. Epidermal skin substitutes comprise of approximately 2–8 layers of autolagous cells. For
dermal skin substitutes a scaffold matrix is used which provides structural support [232]. The
purpose of these reproducible materials is to provide test beds for research in applications such
as wound healing, toxicology, dermatological and cosmetic testing. Unfortunately, because of
the way the biomaterials are grown in vitro, they do not have the mechanical properties of ‘real’
skin. They also tend not to be very robust to handle and have a short shelf-life [232].
Other research into creating synthetic skin is focused on the skin’s ability to self-repair and sense
its environment. Synthetic materials with microvascular networks, inspired by skin and capable
of healing themselves, are in development [233, 234]. There is also research into printing high-
performance flexible thin-film transistors from graphene that is hoped will become an intelligent
artificial skin [235]. However, this research is only in its infancy and applications are currently
limited to coating solid surfaces. It will be a long time, if ever, before these materials are flexible
enough to match the mechanical properties of skin.
There is no single gold standard human skin equivalent that has yet been developed capable
of fully replicating the properties of in vivo skin. Instead authors have developed their own
phantoms based on the problem-specific requirements of their research. Most applications are
superficial and the test bed development has been achieved from iterative empirical testing. The
major complexity of skin that has not been accomplished by any authors is that skin is composed
of different layers and each has different properties, as discussed in § 2.3.3. These layers cause
phenomena such as the two phase response being compliant at low strains but showing a marked
increase in stiffness at higher strains [152]. Instead of attempting to replicate this, many authors
are continuing to use FE modelling methods, as reported in § 2.3.2
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2.5.5 Model Comparison
Skin can be described as inhomogeneous, nonlinear, anisotropic, elastic and viscous [114, 152].
These conditions cannot be fully replicated in a synthetic phantom. This is why many authors
continue to use in vivo and in vitro non-clinical tissue for understanding the response of the
skin to penetration by different means, see Table 2.8.
The porcine model is the most similar to human skin as reported by Vardaxis et al. [215]. Other
authors have used the porcine model for purposes of researching percutaneous absorption [51],
wound healing [206, 215], burns injuries [214], skin graft survival, acute radiation overdose,
hypersensitivity reactions, frostbite and photoaging [104]. None of these applications are entirely
transferable to skin penetration research and only focus on the superficial similarities between
porcine and human skin. From the research reported here only Brett et al. [169] and Shergold
and Fleck [186] have used the porcine model specifically for the understanding of penetration.
As skin is also known to be affected not only by numerous inherent variables but also many
environmental influences caused by differing lifestyles, other authors have sought to use either
gel-based or silicone rubber based in vitro synthetic phantoms. Although these materials are
repeatable, ethical, cost-effective and easily accessed; there remain properties of fibrous skin
tissue and its structures, such as the two-phase response, that cannot be directly compared to
the relatively uniform response of a simple synthetic membrane [186].
Material Needle Liquid Jet Biolistics Conical-Punch
Tissue
Human skin in vivo SF SF SF
Human skin in vitro B SM WS
Human muscle and fat in vitro B SM
Pig skin in vitro B K
Pig liver in vivo M
Sheep skin and tendon in vitro F
Synthetic Phantom
Silicone Rubber O, C SF SF
Polyacrylamide Gel SM
Polyethyleneglycol L
Gelatine O, H
Table 2.8: Penetration mechanisms and the skin models used by selected authors; B - Brett [169],
C - Crouch [170], F - Frick [161], H - Hiemenz [159], L - Lahm [40], M - Maurin [157], K
- Kendall [179], O - Okamura [158], SM - Schramm and Mitragotri [183], SF - Shergold and
Fleck [186], WS - Wrighton-Smith [3].
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2.6 Chapter Summary
This literature review has shown Glide Pharma’s solid dose injection system to be novel. There
are numerous needle-free technologies that have been developed but only a few, predominantly
liquid jet injectors, have received market authorisation. Glide Pharma is only one of two com-
panies currently developing a solid dose injection system. Their technology is patented and the
system is a very different offering to that of the Bioneedle Technologies Group [12,13,90].
Human skin is known to be inherently variable both in its thickness and mechanical properties.
The human epidermal-dermal thickness reported in § 2.3 was approximately 2mm thick but
this varies with body site, age, gender, BMI and ethnicity [37, 97, 108, 111]. Subcutaneous fat
thickness also varies but has been shown to correlate with waist circumference [115].
The mechanical properties of human skin are difficult to test in vivo. Instead, many authors
have quantified skin properties using destructive tests in vitro [31,156], although these findings
test for properties rather than function and how the skin behaves in vivo [32]. The porcine
model is the widely reported as being the most similar to human skin and used as a non-clinical
alternative for testing by many authors [27,210–213,215].
The majority of needle-free skin penetration research reported is problem-specific. The value of
each set of results are determined and dictated by the test rig, test bed material and experimental
method used. The only comparable research available to that of Glide Pharma’s technology is
that of Shergold and Fleck [185] who investigated penetration with a conical punch whilst
emulating liquid jet injection. This research was performed at a different velocity range and
with a different penetrator geometry to the Glide SDI device.
From this review into parenteral delivery the similar problems have been reported where skin
has been shown to vary. Variation in skin thickness remains a problem for needle-based devices,
particularly in the selection of needle lengths [48, 62, 63]. However, needle-free devices are ex-
posed to variation in skin thickness and mechanical properties. The approach taken by authors
researching in the field has been to first generate empirical data, often requiring a novel or
adapted test rig to do so, and then to understand and model the target and penetration event.
This process will be applied to Glide’s technology, beginning in Chapter 3, through first under-
standing the current design and performance of the drug delivery system.
Chapter 3
Review of the Drug Delivery System
This chapter serves to introduce the Glide SDI drug delivery system, how the device technology
works and how well it has performed in initial evaluations. The data available from the two
clinical trials Glide has been analysed and evaluated to understand how the prototype devices
have performed on humans. The non-clinical trials that preceded this work have also been
examined to understand why apparently high levels of penetration success did not transfer to
the clinical trial results.
To establish the likely causes for failed injections the prototype devices, equivalent to those used
within the trials, have been tested to ensure that they were within specification and performed
capably. The key mechanical properties of the implants have been examined. Also the state of
skin knowledge within Glide for the clinical and non-clinical models at the time of the trials has
been detailed. This chapter concludes by outlining the necessary research approach required to
fully understand the drug delivery system and allow its improvement.
3.1 Description of Drug Delivery System
The Glide SDI technology is a needle-free drug delivery system for the administration of active
pharmaceutical ingredient (API) under the skin. The basic principle of operation is that a
wedge-tipped implant, 4mm long with a 0.85mm diameter, containing a drug is pushed through
the skin using a spring-powered delivery device. When the implant is pushed against the skin
by the device its sharp tip penetrates the skin and the implant is injected just under the skin’s
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surface into the subcutaneous tissue where it dissolves and the API is available for uptake into
the systemic circulation.
The Glide Solid Dose Injector (SDI) is a simple hand-held device that is actuated by pushing one
end of the device against the target site. The delivery device is comprised of two sub-assemblies:
a reusable spring-powered actuator and a disposable cassette containing the implant. The driving
spring is charged through the action of pushing the device against the skin so that the system
is inherently safe when not in use.
Instructions for Use
The basic steps that a patient or clinician is required to perform to use the Glide SDI are;
1 The cassette (containing the implant) is placed into the open end of the hand-held actuator,
as shown in Figure 3.1a.
2 The cassette end of the device is then placed against the skin at the target site and pushed
down, as shown in Figure 3.1b.
3 This triggers the internal mechanism that delivers the implant underneath the skin to a depth
of 1.5mm. Delivery takes 2ms [95] and is confirmed by an audible ‘click’. The red pin retainer
appears in a window on the cassette indicating the dose has been delivered.
4 The device is then removed from the surface of the skin. The skin closes over the end of the
implant, as shown in Figure 3.1c. The cassette assembly cannot be reused and discarded. The
reusable actuator is retained.
(a) (b) (c)
Figure 3.1: Images of injection procedure using a Glide SDI; (a) actuator and cassette assembled,
(b) actuator being pressed against the skin surface, (c) injection site.
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3.2 Drug Delivery System Performance
A performance review has been undertaken to understand how capable the current drug delivery
system was at delivering implants under the skin. This review was conducted using the data
reported from the clinical and non-clinical trials performed by Glide Pharma between 2008 and
2010. This data has been available since the trials and this performance review provided an
opportunity to establish the causes for penetration success and failure in human skin.
Non-clinical studies were performed in the run up to the clinical trials to demonstrate penetration
and bioequivalence. The device has been shown to work effectively into the inguinal site of the
porcine model. However, these results did not translate to successful injections in the two Phase
I clinical trials. At the end of this review a summary explains the factors that were thought
to have contributed to the improvement in penetration success, as well as the reasons why the
device still cannot deliver 100% of the time and the areas of further investigation required.
3.2.1 Clinical Trials
Glide Pharma have conducted two Phase I clinical trials with two different generic APIs. Both
studies were performed on behalf of Glide Pharma by Simbec Research Ltd. (Merthyr Tydfil,
Wales).
The first API to be delivered into man using the Glide technology was fentanyl in 2009 [236].
Previous studies had taken place delivering placebo implants though this was only for the purpose
of comparing pain sensation to a needle and syringe. Fentanyl is a potent, synthetic narcotic
analgesic for immediate pain relief [237] that can be delivered intramuscularly but, as it has a
small molecular weight, it is also suitable for transdermal and sublingual delivery (Figure 3.2a).
A second clinical trial was performed in 2010 using octreotide [238]. Octreotide is an octapeptide
that inhibits the release of human growth hormone (HGH) from the pituitary gland (Figure 3.2b).
It is used to treat acromegaly, gigantism, thyrotropinoma and has several off-label applications.
Octreotide is typically administered subcutaneously to the abdomen and typically subjects re-
quire 100µg injections 3 times daily.
Both clinical trials had dual purposes; to assess the safety and dermal tolerability of the Glide
SDI Technology and to demonstrate bioequivalence against existing off patent brand name drugs
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(a) (b)
Figure 3.2: Chemical structures of active pharmaceutical ingredients used in clinical trials by
Glide Pharma; (a) fentanyl [239] and (b) octreotide [240].
Sublimaze (fentanyl citrate) and Sandostatin (octreotide acetate). These already marketed drugs
were used as reference injections and both administered with a needle and syringe.
As well as qualitatively recording observations and subject feedback there were two necessary
quantitative methods used to determine the delivery success of injections in a clinical trial, these
being residual drug analysis and the pharmacokinetic data.
During the implant manufacture the formulation was mixed thoroughly to ensure the API is
distributed homogeneously within an implant. The amount of API residue detected was sub-
tracted from the expected dose and inferred as the amount of implant that was not delivered.
After an injection was performed the site and cassette were swabbed to detect any API residue
from the implant that had not been delivered under the skin. The maximum amount residue
allowed to remain outside the subject was <10% meaning a minimum of >90% of the intended
dose had been administered.
To demonstrate bioequivalence of the solid dose injection, pharmacokinetic (PK) data was col-
lected to demonstrate the absorption and distribution of API in the blood. Blood samples were
taken at different time points for 24 hours and tested for the concentration of API in the plasma.
The time point where the peak concentration was detected (Cmax) and the area under the curve
representing total effective dose over time (AUC0−t) have been compared to that of the reference
injection.
When injecting placebo implants neither quantitative method was viable without an API present
to detect.
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Fentanyl Clinical Trial (Phase I)
The fentanyl implants for the trial were manufactured containing 78.5µg of fentanyl citrate,
equivalent to 50µg fentanyl base. The implants were formulated with sorbitol, a sugar alcohol,
as the primary excipient. The study used a reference injection of 1ml Sublimaze (78.5µg fentanyl
citrate) that was delivered intramuscularly (IM) using a 23G 25mm long needle. The main
inclusion criteria for the trial was healthy male subjects between the ages of 18 and 45 years of
age and a body mass index (BMI) between 18–28kg.m2 [236]. Female subjects were excluded
from the trial as they were thought to have too much subcutaneous fat (>5mm) to make a Glide
SDI intra-muscular (IM) delivery possible.
Each subject at the trial was injected with the Glide device twice. The doses were administered
by a trained clinician by pushing the Glide SDI directly down at 90° on the upper lateral
thigh site to deliver an IM injection. On the abdomen, 10–12cm away from, but level with the
umbilicus, the SDI was pushed at a 45° angle onto the apex of skinfold (skin pinch) to deliver
the implant subcutaneously. A ‘wash out’ period between injections ensured results were not
contaminated by the previous administration.
During the trial, from the 18 injections administered to the abdomen 11 (61%) were observed
as being successfully delivered on the day. However, the residue analysis data and PK data
later showed that subjects 004, 010, 012, 013 and 018 had only received between 15–32% of the
intended dose. The residual drug analysis results, shown in Figure 3.3, proved that only 6 of
18 injections into the abdomen had delivered the minimum requirement of 90% of the intended
dose resulting in an actual penetration success rate of 33% [236].
Due to the compulsory data protection laws regarding subject data at clinical trials there was
little information available to indicate the condition of the subjects’ abdomen or skin composition
except BMI, height, weight and age. The data shown in Figure 3.3 has been ranked according
to the subject’s BMI and no pattern between penetration failure can be observed across the
18.1–28.6kg.m2 range. The estimated dose levels for subjects 001 and 017 were so low that it
may be possible (for these injections) that penetration had not have been initiated. Instead, the
fentanyl powdered on the surface of the damaged skin may have instead passed transdermally
through the skin into the systemic circulation.
The abdomen injections administered were intended to be delivered into a skinfold. During
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Figure 3.3: Residual drug analysis showing the estimated dose (%) into the abdominal injections
in the fentanyl clinical study - ranked according to BMI (kg.m2).
Figure 3.4: Mean (±SE) plasma concentration time plot of fentanyl following single dose ad-
ministration of 50µg (78.5µg fentanyl citrate equivalent to 50µg fentanyl base) in healthy male
volunteers [PK Population I - adjusted for estimated % of dose administered: Test 1 (n = 18),
Test 2 (n = 16), Reference (n = 18)] [236].
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the trial this was not always possible as some subjects found this too uncomfortable. Instead,
the device was pushed at a 90° angle directly against the abdomen. It was reported that the
implants delivered this way resulted in significantly higher PK parameters [236].
The residual drug analysis for the lateral thigh results (not shown) were better with 9 of 17
(53%) administrations delivered (one of the subjects had withdrawn from the trial) the minimum
requirement of 90% of the intended dose. However, only 2 of 17 subjects (12%) injected at both
sites received two successful injections.
The results of the pharmacokinetic (PK) data has been shown in Figure 3.4. The PK profiles
were adjusted for the estimated percentage dose administered based upon the residue analysis.
The adjusted mean Cmax values obtained following administration of Glide SDI to abdomen
and thigh sites were lower than those obtained following the Sublimaze IM injection (PK popu-
lation II: Cmax values approximately 34% and 39%, respectively). The study therefore did not
demonstrate bioequivalence. The difference in uptake of fentanyl could of been explained by
differences in the depth of delivery. The Glide implants only reached the subcutaneous tissue at
both sites (thigh and abdomen) whereas the Sublimaze injection was intramuscular and released
into the systemic circulation much quicker.
Octreotide Clinical Trial (Phase I)
The results of the first Phase I clinical trial showed that both skin penetration and bioequivalence
to an intramuscular injection was not possible to achieve in the clinic using the system as it was
configured. A second Phase I clinical trial was performed, this time to compare subcutaneous
delivery of implants containing 118µg of octreotide acetate. The reference injection of 1ml
Sandostatin (containing 118µg of octreotide acetate) was administered once using a 25G 25mm
long needle [238]. The octreotide implants were again formulated using sorbitol with the addition
of dextran, a complex branched glucan, to increase implant strength.
Glide Pharma also took the opportunity to make three design alterations to the device before
of the second clinical trial. The most significant of these was the reduction in force required to
actuate the device from ≈30N to ≈24N. The aim of this was to improve patient comfort during
administration. The actuation force was reduced without any change to the delivery force or
velocity. The impact of device alterations has been investigated in greater detail in § 3.3.1. The
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Figure 3.5: Residual drug analysis showing the estimated dose (%) into the abdominal injections
in the octreotide clinical study - ranked according to mean subcut fat thickness (mm).
Figure 3.6: Mean (±SE) plasma concentration time plot of octreotide following single-dose
administration of 100µg to healthy male and female volunteers [Test PK Population II - adjusted
for estimated % of dose administered (n = 12), Reference PK Population II (n = 12)] [238].
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non-clinical data produced in the lead up to the second clinical trial is reported in § 3.2.2.
The inclusion criteria for the octreotide clinical trial was healthy white Caucasian subjects
between 24 and 40 years of age with a BMI of between 20–28kg.m2. 18 subjects were selected
according to these criteria, 9 males and 9 females. The injections were intended to be subcu-
taneous at the abdomen site; the lateral thigh site was not used. The amount of subcutaneous
fat at the abdomen site of each subject was measured before injection using skinfold callipers.
During the clinical trial, before the octreotide implants were delivered, sordex placebo implants
were injected into 20 subjects to make them familiar with the system (2 subjects were surplus
and withdrawn before API injections). 17 of 20 (85%) of these injections were recorded as
successful deliveries. As it is not viable to perform PK or residual drug analysis on placebo
injections this result cannot be verified and the data remains qualitative.
During the administration of the clinical batch of octreotide implants, 12 of 18 (66%) injections
were observed as being successful. The residual drug analysis, shown in Figure 3.5, confirmed
this [238]. However, 6 of 18 (33%) only managed partial penetration and were unsuccessful with
>10% left on the skin surface. The estimated dose data shown in Figure 3.5 has been ranked
according to mean subcutaneous fat measurements taken from a calliper test. No pattern for
success or failure could be observed across the 14.0–26.7mm range or the BMI data (not shown).
There was however a noticeable gender effect as 8 of 9 (89%) of females injected were successful
compared to only 4 of 9 (44%) for the males.
As with the previous clinical study, the PK data shown in Figure 3.6 was adjusted. The Cmax
and AUC0−t for the 12 successful injections have been combined and correspond to the estimated
percentage dose administered based upon the residual drug analysis. This data fell within the
bioequivalence limits of 80–125% [241]. The PK profile for the octreotide implants delivered
using Glide technology, when delivered, was bioequivalent to the reference Sandostatin injection.
Unlike the fentanyl clinical trial this has been possible as both injections have been administered
and are suited to subcutaneous delivery. Despite the increased penetration success there were
still 6 subjects (33%) who were not injected successfully with 90% of an implant containing API.
The stronger formulation, device alterations and changes to the non-clinical procedures were still
not enough to ensure 100% implant delivery in the clinic, showing that a greater understanding
of the skin was required to improve the reliability of the drug delivery system [241].
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3.2.2 Non-Clinical Trials
Prior to the fentanyl clinical trial a substantial programme of non-clinical trials had been per-
formed by Glide Pharma to develop the drug delivery system. Rather than address all of the
non-clinical testing performed to date, this section provides background on the use of the porcine
model, the inguinal site and the results from the pivotal study undertaken between the clinical
trials. The non-clinical trials referenced here were performed on behalf of Glide Pharma under
strict home office licenses by Contract Research Organisations (CROs); Charles River Preclinical
Services (Edinburgh, Scotland) and Harlan Laboratories UK Ltd. (Belton, Leics.).
After extensive investigation by Glide Pharma, consultation with non-clinical experts and dis-
cussions with the MHRA, the models considered suitable for assessing the delivery of implants
using the SDI device were the canine (Beagle) and porcine (Large White) models [242].
The canine model was suitable for assessing dermal tolerability and pharmacokinetic profile
of implants as it was considered the most appropriate model to assess subcutaneous delivery.
However, due to the amount of hair on the model and the mobility of the skin the implants were
better delivered using a needle and trocar.
Consequently, the penetration testing using the SDI device was performed on the porcine model.
Pig skin has been widely reported in § 2.5.2 as being accepted as a useful and predictive model
for human skin. This usefulness is in terms of anatomical structure and physiological/cellular
responses, due to the similarity of the stratum corneum, epidermis, dermis, underlying tissues
and vasculature. From the advice Glide received from consulting veterinary advisors it was
suggested that pig skin is generally more difficult than human skin to penetrate with a standard
needle and syringe. This was interpreted by Glide that the SDI device was likely to achieve
comparable, or better, levels of delivery to humans compared with porcine model [242]; should
it be successful in pig skin.
On the porcine model Glide has proven with the SDI that the inguinal site (near the groin) is
more disposed to penetration than the belly, neck or rump sites. The inguinal site is not hairy
or exposed as the other site and was considered by Glide to be the closest tissue model to the
injection sites on a human [242].
An experiment performed on behalf of Glide Pharma by a CRO to measure the skin thicknesses
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of a sample of excised human male abdominal skin, found the thicknesses on a single sample
extremely varied and no comparison could be made to pig skin [243]. There remains little
quantitative data available in literature to suggest how applicable to the penetration mechanism
of the Glide technology the mechanical properties of pig skin are. It is unclear whether the
advice Glide Pharma received, suggested that better results would be observed on human skin
than the pig skin, was in reference to the inguinal site; or was a general comment referring to
the neck, belly and rump sites that would be more familiar to veterinarians as injection sites.
At the pivotal non-clinical study before the octreotide clinical trial a penetration success rate
of 95% (19 of 20) was achieved using the clinical device and sordex placebo implants at the
inguinal site. This was considered adequate to proceed with the second Phase I clinical trial.
At the same study 40% (4 of 10) penetration was reported into the neck site. This study was
performed on a single subject. The results of this penetration study of placebo injections were
confirmed only through observation of the trial as PK and drug residue analysis were not viable.
Work was performed in parallel at this time internally by Glide Pharma to develop an in vitro
test bed for the purposes of testing penetration with the SDI device. There are numerous benefits
of an in vitro test bed that have already been discussed in § 2.5.4. The main advantage to Glide
Pharma at this time would have been to provide a platform to screen implant formulations
before non-clinical studies. A 4mm thick silicone rubber (product no: R31-2186 supplied by
Primasil Silicones Ltd., Weobley, Herefs.) was selected based on the qualitative understanding
of injection. In the absence of quantitative data to describe penetration, a the material was
chosen as it demonstrated comparable penetration success (%) to that observed in in vivo pig
skin. The penetration parameters of this test bed has been further investigated in § 4.2.3.
It was evident from the clinical trial results that the relatively successful penetration (95%) at
the inguinal site of the porcine model did not correspond to similar, or better, levels in the
human clinical trials. The reliance on the inguinal data led to the system used in the octreotide
clinical trial not being capable of ensuring 100% penetration success into human skin. The small
amount of porcine model data (n = 30) was gathered on a single subject (n = 1). The clinical
trial was performed with 18 subjects suggesting that skin properties may vary more significantly
over a population than intra-site on the porcine model. An in vitro test bed could become a
useful platform to investigate penetration but required a quantitative understanding actual skin
to inform its design.
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3.2.3 Review of System Performance
The clinical trials did both report the drug delivery system to be safe to use and tolerable by
patients. However, skin penetration and delivery had been shown to be major issues with the
technology. The first clinical trial delivering fentanyl implants to the abdomen and the lateral
thigh sites resulted in penetration success rates of 6 of 18 (33%) and 9 of 17 (53%), respectively.
Before the octreotide clinical trial the implant formulation and device were altered. Despite
this, the penetration success rate for the injections into the abdomen only increased to 12 of
18 (66%). The lateral thigh site was not reused despite in the fentanyl trial producing better
penetration results. The low amounts of API detected in the PK data showed that implants
only reached subcutaneous depths rather than intramuscular.
The implants injected in the octreotide clinical trial were shown to achieve bioequivalence with
the subcutaneous reference injection. Thus demonstrating that an implant, once delivered, was
capable of delivering API as quickly as a liquid dose.
This review of the final outcomes has cast doubt on the way the porcine model was used in
pre-clinical trials. During the development of the system there was a belief that the inguinal site
would be an indicator of likely penetration success into human skin at the abdomen site. The
choice of the inguinal site was originally made as a consequence of the ability to produce positive
penetration data (95%) at it. Other sites, such as the neck (40%), on the model proved more
challenging to the system. This approach conflicted with the advice received from consultants
regarding pig skin being more difficult to penetrate (with a needle) than human skin. The results
from the clinic would suggest this advice was in reference to more recognised injection sites of
the neck, rump and belly of the porcine model.
There are also limitations to the qualitative methods Glide Pharma has used to record penetra-
tion success. Quantitative methods such as residual drug analysis have proven more useful for
assessing penetration compared to subjective observations. The PK analysis, although incredibly
powerful, is only applicable to successful injections.
Although the injection success rate improved between the trials, it was not clear whether this
was a consequence of alterations to the device design, implant formulation or the introduction
of females in to the second clinical trial. Further investigations into the performance of each of
the system components were necessary to establish the causes for the failed injections.
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3.3 Drug Delivery System Components
The purpose of this drug delivery system review was to assess the current performance of the
drug delivery system and understand each of three components that comprise the system; the
device, the implant and the skin, as shown in Figure 3.7.
Figure 3.7: Glide SDI drug delivery system model, as first shown in § 1.2.
Although there was a clear improvement in penetration success between the clinical trials, results
have shown that the technology still had skin penetration issues as 6 of 18 (33%) subjects were
not injected successfully. The changes made to each of the system components were investigated
to establish their contribution to the improved penetration success rate. This review of what
was known of the drug delivery system was intended to highlight the areas where additional
research was required in order to resolve the issues remaining for the needle-free technology.
An optimal drug delivery system requires a device that can compensate for the variation in
properties of both skin and implant formulation. The better defined each of these components
are, and their effect on penetration, the greater opportunity there is to optimise the system. The
relationship between the three components is complex. Some examples of design requirements
and parameters, but not all, are shown in Table 3.1. Defining or altering a design requirement
or parameter is likely to directly impact another.
Device Implant Skin
Actuation force (N) Tensile strength (MPa) Force to penetrate (N)
Injection depth (mm) Young’s modulus (MPa) Deflection to penetration (mm)
Delivery velocity (m.s−1) Dissolution (AUC0−t) Stiffness (N.mm−1)
Energy available (mJ) Length (mm) Skin thickness (mm)
Cassette dome area (mm2) Tip angle (°) Toughness (kJ.m−2)
Table 3.1: Glide SDI drug delivery system component examples of design requirements and
parameters.
Chapter 3. Review of the Drug Delivery System 66
3.3.1 Device
Rather than cover all the device development this section focuses on the design alterations made
between the two trials. Over the two clinical trials the penetration improved from 33% to 66%.
It was important to establish whether this was due to the device alterations and whether the
device performance contributed to the 6 failed octreotide injections.
To achieve this the performance of both the fentanyl and octreotide clinical devices had to be
understood. Each alteration has been detailed and its effect on the actuation force, repeatability
or delivery velocity measured. This testing has been performed on prototype devices, equivalent
to those used within the trials, to ensure they were within specification and performed capably.
The 6 octreotide clinical devices that were used for the failed injections have been examined to
establish whether they were misassembled.
Actuation Mechanism
Before the investigations into the alterations of the device the following steps describe the
actuation mechanism of the fentanyl clinical device. The general assembly of the prototype
device is shown in Figure 3.9. The force to actuate and each of the phases of actuation is
labelled in Figure 3.8.
1 The cassette (containing the implant) is placed into the open end of the hand-held actuator
and clips into the finger clip on the front piston.
2 When the cassette end is then placed against the skin inside the actuator the cassette sub-
assembly pushes the front piston and the spindle. The spindle is set at an angle created by
a slewed front spring, and transmits the force through the rear piston compressing the 25N
rear spring. The rear spring is pre-compressed by 13N to reduce the stroke required.
3 When the cassette moves into the actuator by ≈13mm the 45° angled chamfer on the spindle
interacts with the corresponding feature on the alignment sleeve. This cam action then aligns
the front of the spindle until it overcomes the slew in the front spring, similar to that in an
automatic centre punch [94].
4 During the spindle alignment phase the spindle must overcome the friction across the surface
Chapter 3. Review of the Drug Delivery System 67
of the front clip piston. In the fentanyl clinical device 6N is required to do this, as shown
in Figure 3.8. At ≈30N the spindle aligns and the device is triggered. The spindle passes
through the front piston and is accelerated by the expansion of the 25N rear spring.
5 The rear piston pushes on the spindle as it travels through the front piston and impacts the
rear surface of the pin component (part of the cassette sub-assembly). This impact is reduced
by a shock absorber component, a 0.5mm thick disc of silicone rubber. The pin pushes the
implant from the implant holder into the skin.
6 The system comes to rest with the LCP pin 1.5mm under the surface of the skin. This means
a 4mm implant would be delivered to a depth of 5.5mm through the skin in an ideal delivery.
7 The hand-held device is then removed from the surface of the skin, as this happens the slewed
front spring then resets the device. The total time for an actuation and the implant to be
delivered is known to take <2ms [95].
8 The cassette sub-assembly is removed from the actuator and discarded and the reusable ac-
tuator is retained.
Overcoming  
pre-tension  
phase 
Spindle alignment phase 
Actuation Force (Fa) 
Figure 3.8: Force versus time plot for actuation of fentanyl clinical device labelled with phases
of actuation. Test performed slowly on a Lloyd LFPlus at 1mm.min−1 so each phase could be
clearly captured.
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Device Alterations
Prior to the octreotide clinical study there were three design changes made to the prototype
device, none of which were intended to alter the delivery velocity or aimed to significantly
enhance the penetration success. They only served to increase comfort to the patient, aid the
resetting of the device and reduce stress on the implant. The alterations made were as follows;
Alignment Sleeve Cone Angle To reduce the force necessary to actuate the device the
angled chamfer within the sleeve was decreased from 45° to 37.5°. This allowed the spindle to
align more readily once the cassette has been pushed down by ≈13mm, causing less friction on
the metal clip component and reducing the actuation force and the sensation to the patient.
Front Spring Slew Angle In preparation for the octreotide clinical study an infrequent
resetting problem was identified with the prototype devices that may have been exacerbated by
the changes made to the alignment sleeve. The root cause of the problem was the slew angle of
the front spring. The front spring has no effect on the injection of the drug as its main purpose
is to return the spindle and the front piston to the rest position ready for the next actuation.
The slew of the front spring was increased from 7.5° to 10°. Repeated testing was performed on
a Lloyd LFPlus to prove the device resets and was durable.
Shock Absorber A thicker 2.5mm thick Viton rubber was chosen to replace the 0.5mm
silicone rubber shock absorber. The thicker damper reduced the acceleration gap between the
spindle and the pin. The Viton material also has a lower Shore A hardness that reduced the
impulse felt by implant due to the sudden acceleration phase of the pin and thus the maximum
stress placed on the implant during acceleration is lower. This also reduced the noise of the
audible ‘click’ during actuation. The cassette sub-assembly is classified as a medicinal product,
single-use and discarded between actuations therefore it was not required to prove the durability
and repeatability of the component.
An extensive amount of testing was performed to satisfy both Glide Pharma, and the relevant
regulatory bodies, that the performance of the device was not diminished by the alterations and
the device remained safe.
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Device Actuation Force and Energy
The alignment sleeve angle was changed to reduce the force on actuation to improve patient
comfort. The reduction of the chamfer on the alignment sleeve cone angle from 45° to 37.5°meant
that the spindle more readily aligned itself. To compare the both alignment sleeves against each
other two assembled devices were placed on a Lloyd LFPlus Material Testing Machine and cycled
10 times each over a displacement of 14mm at 1mm.min−1. The results have been plotted in
force against extension and are shown in Figure 3.10.
This testing verified that the spindle alignment phase for the octreotide clinical device had
reduced to ≈24N compared to the ≈30N for the fentanyl clinical device. The octreotide clinical
device was more efficient, requiring 20% less force to actuate and still delivers the same force as
the rear spring that has been compressed by the same displacement. The 6N removed was force
wasted overcoming unnecessary friction. The Lloyd LFPlus has also been used to plot the force
against extension for the loading of the rear spring. The area under the curve equated to the
work done. The results (not shown) demonstrated that both devices have ≈148mJ of energy
available in an actuator.
Fentanyl clinical device (Fa ≈30N) 
Octreotide clinical device (Fa ≈24N) 
Figure 3.10: Force versus displacement profile for actuation of clinical devices produced on the
Lloyd LFPlus produced at 1mm.min−1. Repeat tests of the fentanyl and octreotide clinical
device (n = 10) showing the ≈6N reduction in Fa brought about by the reduction in alignment
sleeve cone angle.
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Device Reliability and Consistency
To verify that the alignment sleeve and front spring alterations performed as intended additional
cyclical compression tests were performed using the Lloyd LFPlus. This simulated the number
of actuations expected over a prototype device’s lifetime. This was compared to the performance
of the previous fentanyl clinical device. The purpose of this test was to see how repeatable the
actuation force was for the different device configurations.
Twenty different devices, 10 equivalent to those used each of the fentanyl and the octreotide
clinical trial, were assembled with a cassette body and placed on the Lloyd LFPlus. The devices
were compressed cyclically by 14mm at a rate of 300mm.min−1 for 100 actuations. The peak
actuation force measured for each test was recorded. The results as per device are shown in the
box plot in Figure 3.11. The alteration to the front spring removed any resetting issues from
the device resolving the minor and infrequent problem that had been observed in the fentanyl
clinical devices.
This experiment tested 20 different actuators and both clinical device configurations were subject
to 1,000 repeat tests. The mean for the fentanyl clinical device configuration was 30.6N ±2.1
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Figure 3.11: Box plot showing actuation force data, Fa, for 10 different fentanyl and octreotide
clinical devices (n = 100). Box plots show the first and third quartiles, the median (horizontal
line) and the mean (3 symbol) of the data. The upper and lower whiskers indicate the range of
the data.
Chapter 3. Review of the Drug Delivery System 72
and the octreotide clinical device configuration was 23.9N ±1.1. The box plots show that the
ranges of data for the peak actuation force are smaller for the octreotide devices, proving the
configuration performs more consistently. The change to the alignment sleeve cone angle meant
the actuation of the device was more controlled and less reliant on friction.
The effect of removing ≈6N actuation force from the skin also was intended to improve patient
comfort and make the device more efficient to use. The effect of reducing this force and pressure
on the skin dynamics and the penetration event at this stage was unknown. Further investigation
was required to establish whether it made an injection with a solid dose more or less difficult.
Delivery Velocity
The actuation force has been shown to have been reduced and more repeatable with the alter-
ation made to the alignment sleeve. This alteration was not intended to change the delivery
velocity of the clinical devices and high speed photography was used to confirm this.
The SDI device was mounted in a bespoke jig and clamped to a bench, as shown in Figure 3.12a.
This jig held the cassette sub-assembly (containing the pin and implant) fixed relative to the high
speed camera lens, providing the datum required for calculating the difference in displacement.
The hand-held actuator was pushed onto the cassette to actuate the device. The LCP pin within
the cassette sub-assembly was filmed through cutaway windows machined into the cassette body
and the actuator.
When the device was triggered the pin was driven by the spindle and the force transmitted to the
implant. Knowing the velocity of the pin was sufficient to establish the velocity of the implant
as it would be delivered to the skin. All actuations had the device components firing into air.
The spindle had a mass of 3.3g whilst an implant only ≈2mg therefore it was not significant
to the delivery velocity. In order to focus and track the pin on the high speed images fiducial
markings were placed on the pin shaft.
The scene was lit using an ARRILUX 400 Pocket PAR Light. The experiments were filmed
using a Photron SA3 high speed camera with Nikon 50mm f1.8 lens and a 25mm extension
tube. The extension tube fitted between the camera and lens. The farther away the lens is,
the closer the focus, the greater the magnification. This combined with the 50mm lens resulted
in ×5 magnification gain. The actuations were filmed at 75,000fps, with a 256 × 128 pixel
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Figure 3.12: (a) High speed camera set up for clinical device delivery velocity investigation;
(b) The starting position for the pin observed through cutaway components, (c) the pin moves
forward as device is actuated fiducial marker is being tracked, (d) as first marker is out of view
another is tracked for the latter part of the pin motion.
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Figure 3.13: Average velocity versus displacement plot for three different fentanyl and octreotide
clinical devices fired into free air. Implant travels within cassette until 3.5mm where it emerges
and would contact the skin. For both device configurations this appears to be ≈6m.s−1 (0.5mm
longer travel for the octreotide device is due to the different shock absorber thickness). Devices
were filmed using a Photron SA3 high speed camera at 75,000fps.
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resolution and a pixel size of 22µm. Resulting in a viewing window of 5.6mm × 2.8mm, as
shown in Figures 3.12b–d. The 9mm travel of the pin exceed the viewing window therefore
the forward movement of the pin was tracked initially on one fiducial marking (Figure 3.12b),
when this feature disappeared from view (Figure 3.12c) another was used (Figure 3.12d). The
difference in displacement between the fiducial markings was accounted for in the data analysis.
Three different devices of the fentanyl and octreotide configurations were tested. The videos
were analysed using Phantom Cine Viewer v2.0 software (Vision Research Inc., Wayne, NJ) that
was preferred over the proprietary Photron software. Each high speed video was edited to the
140 frames that captured actuation. The pin motion was converted into ≈420 x-y coordinates
(3 per frame) and transferred into Microsoft Excel (2010) and the velocities calculated. The
results for the mean average of the delivery velocity profiles are shown in Figure 3.13. A 5-point
moving average has been applied to smooth the steps in the data caused by the fixed pixel size
(22µm).
During the acceleration phase the implant travels within implant holder for the first 3.5mm of
movement before exiting the cassette sub-assembly. At 3.5mm the implant tip impacts the skin.
The resulting profiles in Figure 3.13 show that the implant, in both device configurations, would
be delivered at a velocity of ≈6m.s−1. The 0.5mm difference in displacement was due to the
different shock absorbers used. The feature at the end of the profiles (9mm) was due to the pin
retainer deforming as the system is brought to rest. Overall it appeared the alterations to the
device did not significantly alter the delivery dynamics. The octreotide prototype devices used
at the clinic had the same delivery velocity as used in the fentanyl trial; but a lower force to
actuate, less shock loading on the implant and the removal of a resetting issue.
Device Assembly
Despite the actuator being reusable, each injection performed at clinic for both trials was per-
formed using a unique device as required by the regulators. Each injection was traceable to the
actuator that was used to deliver it. After failing to establish reasons why the device perform-
ance may have altered in any of the clinical devices, the assembly of those used in the octreotide
clinical trial was investigated. The devices had been manually assembled prior to the clinical
trial. A non-invasive means of inspecting the actuators was required to perform this so the 18
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devices were subject to X-ray inspection. X-ray analysis allowed for inspection of the spindle,
its position and angle (caused by the slewed front spring), without the need to disassemble the
device which would relieve the precompression of the rear spring.
This work was performed at X-Tek Systems Ltd. (Tring, Herts.). A 450kV microfocus X-ray
system was used to inspect the assembly of the devices, the resulting images for the 6 devices that
failed are shown in Figures 3.14a–f. The images conclusively show there was nothing detected
within the failed devices to indicate that the assembly was at fault for failed deliveries. All
devices had correctly reset and all components were present and in their correct place.
(a) Device 4 (b) Device 5 (c) Device 6 (d) Device 9 (e) Device 15 (f) Device 27
Figure 3.14: X-ray images of actual devices used for the 6 failed deliveries in octreotide clinical
trial. There are no noticeable assembly errors within these devices that would be considered
responsible for the failure. Device numbers are unique to each device and do not correspond to
the subject number they were used to test.
Device Summary
All of the investigations into the differences between the clinical device configurations showed
that they had not been significantly altered by the design changes, except the intentional reduc-
tion in actuation force.
The devices have been shown to be repeatable and the design did marginally improve between
trials in terms of consistency of actuation force and ability to reset. However, little reason was
found to establish why the injection success rate had improved between the two clinical trials
or any causes for why the device would be at fault for the 6 of 18 (33%) failed injections at the
octreotide clinical trial.
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3.3.2 Implant
The Glide implant is a novel dosage form and is designed to perform two tasks with conflicting
requirements. The implant and its tip must be sharp and strong enough to be inserted through
the skin and, when the whole implant resides in the subcutaneous layer, it must also dissolve in
the water present delivering the API to the systemic circulation.
The strength of the implant and the rate at which the API disperses can be controlled by the
excipients added to the formulation. The excipients can be added to the formulation to bulk out
the API, aid manufacture, alter material properties and control dispersion or improve stability.
To manufacture the implants the formulation is mixed into a homogenous paste. This paste
is then cold ram extruded by a scaled down production machine into 0.85mm diameter rods.
These rods are cut to shape by hand using a hot-blade and rudimentary hand-held jigs. A typical
implant measures 3.5–4.0mm long with a 46° wedge-tip and weighs ≈2mg, an example is shown
in Figure 3.15a. Glide has experimented with different shaped tips but for both clinical trials
were performed using 46° wedge-tip design. All implants are manufactured by Glide Pharma.
Implants extruded in this way are typically fibrous where the fibres are aligned in the direction
of extrusion, as shown in the scanning electron microscope (SEM) image in Figure 3.15b. This
extrusion can also lead to pores forming within the implant shown in 3.15c. The porosity, unless
(a)
(b) (c)
Figure 3.15: (a) Microscope image of whole implant ×5, (b) SEM image of implant tip ×140
and (c) SEM image of implant cross-section ×215.
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reduced or controlled, may lead to unpredictable mechanical properties or dispersion rates.
The optimal implant dimensions and a commercially scalable manufacturing process are still
under development. Research into techniques such as injection moulding, hot or cold extrusion
and mechanical and laser cutting is being conducted in parallel with this thesis. Although these
techniques are widely used in industry, precision at the required physical scale for an implant
and the response of various formulations (API and excipient) to the different techniques requires
further understanding.
Implant Failure Modes
When the system fails to deliver, the typical outcome is some, or all, of the implant is powdered
on the skin’s surface. When penetration does not occur readily on the surface of the skin there
are several implant failure modes that have been observed and considered;
• The implant buckles due to eccentric loading during interaction with the skin.
• The implant fails under compression on the skin surface after failing to penetrate.
• The integrity of the tip fails and the blunted implant fails to penetrate.
In reality, delivery failures are most likely to be a combination of these modes. However, there is
little data available to confirm this, only that which is recorded qualitatively through observation
during testing. Ideally, the implant would be retrieved and viewed to determine how it first failed.
However, this is difficult due to the implant’s size and the excipients used are often brittle and
powder on the surface of the skin.
Mechanical Properties
Currently, there is a lack of evidence to explain how implants fail after an event. There are
methods used to test the intrinsic mechanical properties of an implant before injection to estimate
how likely it is to survive an injection. Unfortunately all of the tests developed are destructive,
meaning that estimates can only be made to batches of implants produced from the same
extrudate. The mechanical tests to be used on the implants are yet to be defined and remain
linked to the development and requirements of the chosen manufacturing process. The novelty
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of the dosage form and the demands of the penetration event have require parallel research to
identify the most important mechanical properties of an implant and how they are best tested.
The implant material can be tested for maximum compressive strength. These tests are achieved
on a Lloyd LFPlus materials testing machine using small 2mm flat-tipped rods from a batch
of implant material. The shorter the rod, the less likely it is to fail through buckling. The
maximum compressive stress, σ, is a good indicator of the strength of a formulation, but not
necessarily the strength of an implant. This assumes a worst case scenario (WCS) and the cross-
sectional area of delivering a blunt 0.85mm implant. In reality the geometry and frangibility of
the implant tip and the interaction with skin still require further research in order to ascertain
an accurate stress value.
The Young’s modulus of the material (E) is thought to indicate the stiffness of the implant
and thus its resistance to failure through Euler buckling modes. The buckling stresses in an
implant are also highly dependent on the implant length and the way the implant is considered
to be fixed, pinned or held at each end [244]. The Young’s modulus is currently derived using
a three point bend test performed on 4mm rods of extruded implant material. The maximum
compressive stress (σ) and Young’s modulus (E) for placebo implants made from 100% excipient
are shown in Table 3.2.
The strength of an implant is restricted by the formulation of API and excipients required
to deliver the desired pharmacokinetics to a patient for the intended therapeutic effect. Often
simple sugar-based excipients (sorbitol, dextran) are very soluble making them suitable to deliver
APIs that require quick release profiles, similar to that expected from a liquid dose delivered by a
needle and syringe. Larger complex polymer-based excipients (still under development) are more
suited to sustained release of potent APIs delivered over a longer time period. Table 3.2 shows
that polymer-based implants perform better in mechanical testing than sugar-based excipients.
Material Components σ (MPa) E (MPa) Batch No.
Sorbitol Sorbitol 20 ± 4 329 ± 107 51/82-1
Sordex Sorbitol, Dextran 29 ± 8 325 ± 135 51/85-1
Mandex Mannitol, Dextran 42 ± 8 432 ± 111 51/90-1
Polymer 1 Undisclosed Polymer 62 ± 8 501 ± 73 50/12-1
Polymer 2 Undisclosed Polymer, Mannitol 126 ± 9 N/A 77/81-1
Table 3.2: Mechanical properties of placebo implants made from various excipients, maximum
compressive stress (σ) and Young’s modulus (E ) and Glide Pharma internal batch number.
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For the clinical trials the fentanyl implants were sorbitol-based and the octreotide used sordex-
based implants. It was necessary for the implants to be formulated with sorbitol in the fentanyl
clinical trial as the reference injection was intramuscular (Sublimaze) and the implants would
need to dissolve rapidly. However, it appears this may have compromised the strength of the
implants. The introduction of dextran to the excipients in the sordex-based octreotide implants
was in response to the poor penetration results from the previous trial. Also, the Sandostatin
reference injection in the second clinical trial was delivered to the subcutaneous layer which
meant the API release did not have to be as quick.
The values reported in Table 3.2 show a large amount of variation. These properties can be
altered considerably depending on the proportion of API and excipients present in a formulation
as well as the manufacturing process used. The former of these may explain why a higher
penetration success of placebo sordex implants 17 of 20 (85.0%) was observed at the octreotide
trial compared to the clinical batch results of 12 of 18 (66.7%).
The implant strength or resistance to buckling could have been affected by implant diameter.
The implant batches used at the clinical trial had mean diameter values of 0.80mm and 0.84mm
for the fentanyl and octreotide implants, respectively. It is unlikely that this 40µm difference in
diameter was more significant than the introduction of dextran to the formulation. It is unlikely
that Glide Pharma would seek to exceed the current implant diameter. 0.85mm is comparable
to the outer diameter of 20–21G needles (0.91–0.82mm). Increasing the diameter would require
the compromise of increased penetration forces and, probably, patient pain.
Implant Summary
The implant design, formulation and manufacturing process remain in development as do the
testing methods to fully characterise implants. From what was known of the mechanical prop-
erties of the clinical implant batches the sordex-based octreotide implants were stronger and
more likely to survive penetration than those used in the fentanyl clinical trial. This may have
contributed to improving the penetration success rate, although this can only be assumed in
the absence of quantitative data capable of describing the forces during an injection. The use of
sordex improved the compressive strength of the implants but this alone did not lead to a 100%
penetration success rate and could not explain the 6 of 18 injections that failed.
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3.3.3 Skin
The skin is the component within the system that the device and implant must both work
together to overcome. This must be achieved in a controlled manner to ensure the implant
resides at the intended depth for dissolution so that the API can reach the systemic circulation
at the desired rate.
The performance of the SDI device and the properties of the implant can be determined by Glide
Pharma, the skin is the only component of the drug delivery system that cannot be controlled.
Instead it must be understood and accounted for in the designs of the device and implant.
Clinical Trial Data
Analysis of the clinical trial results in § 3.2.1 has shown that the penetration rate improved
between fentanyl and octreotide clinical trials, from 33% (6 of 18) to 67% (12 of 18) respectively.
For a parenteral drug delivery device to be widely adopted it must work on all types of skin.
At the clinical trial there was the opportunity to select the subjects who participated. The
main criteria specified by Glide Pharma was that all subjects tested were White Caucasian and
between 18–45 or 24–40 years of age with a BMI of 18–28 or 20–28kg.m2, for the fentanyl and
octreotide clinical trials respectively. This criterion was thought to have an indirect effect on
controlling the skin properties of these subjects.
In the fentanyl clinical trial there was no attempt to directly measure any properties of the skin
at the abdomen target site. This was rectified in the octreotide trial where the thickness of a skin
pinch at the abdomen was measured using callipers. Although this provided some measure of the
skin thickness, calliper measurements have been reported in literature as inherently unreliable.
Booth and Paton [101] state that when using callipers there is always some degree of compression
of the subcutaneous tissue which can lead to inconsistent measurements.
When the penetration success was compared against the limited amount of subject data available
no relationships could be observed with respect to the direct and indirect factors that could have
described the skin. This may have been due to the understandably small data sets available
from the Phase I clinical trials or could reflect accurately that none of these criteria can be used
to predict penetration success.
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Figure 3.16: Residual drug analysis showing the estimated dose level (%) into the abdominal
injections in the octreotide clinical study, a male versus female comparison.
The only selection criteria that appeared to show a relationship was the gender difference present
at the octreotide trial. 89% (8 of 9) injections were successful in female subjects while only 44%
(4 of 9) were successful in male, as shown in Table 3.3. However, there is no way to claim this
finding to have been significant as the sample size was so small.
Table 3.3 does question what exactly led to the improvement of the penetration success rate at
the octreotide clinical trial as, despite strengthening the implants and alterations to the device
and test protocol, the penetration success rate in male subjects only rose from 33% (6 of 18) to
44% (4 of 9). The alteration to the skin component, through the inclusion of female subjects,
may have had the greater impact on penetration success of the system of all the changes made
between the two clinical trials.
Penetration Success Rate Male ♂ Female ♀ Total
Fentanyl Trial 33% (6/18) N/A 33% (6/18)
Octreotide Trial 44% (4/9) 89% (8/9) 67% (12/18)
Total 37% (10/27) 89% (8/9) 50% (12/36)
Table 3.3: Clinical trial penetration success, a male versus female comparison.
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Non-Clinical Trial Data
The porcine model is likely to be the best non-clinical model for testing needle-free penetration,
however, the mechanical properties of pig skin and its response to solid dose injection are un-
known. The current practical testing method, small sample sizes and qualitative data collected,
has been shown to be unreliable in predicting success in the human model, as reported in § 3.2.2.
The inguinal site, where much of the testing has been performed, appears to have favourable
properties for injection making the site suitable for PK and dermal tolerability testing but un-
suitable to test the system for penetration. Particularly when other skin sites may offer more
challenging conditions.
Glide Pharma’s knowledge of the porcine model up to this point was based on a qualitative and
anecdotal understanding of penetration. In the absence of any quantitative means of assessing
penetration the understanding was comparative, relating the performance of different configura-
tions to each other whilst attempting to achieve 100% penetration success. Each porcine model
tested was only specified by weight (typically 25kg) and species. There were no other controls or
methods to characterise the skin at each trial [245–247]. If the properties of the skin at different
sites across different models varied, this would be likely affect the trial results but the effect of
the skin would be undetected.
Measuring Skin Penetration
The development of the needle-free system appeared to have discounted how important the role
of the skin was to effective penetration. Compared to the implant and device, where the key
mechanical properties or performance metrics have been defined, little has been measured or
understood of human or pig skin properties and how these properties may affect penetration.
Glide Pharma has relied on an empirical approach to the system development. Multiple config-
urations of implants and device prototypes have been tested to determine which combinations
may lead to the highest penetration success on the porcine model. The numbers of repeats has
remained low (typically n = 10–20) as there was a practical limit to tests that can be performed
on each model. The more configurations tested the lower the number of repeats possible.
When the device delivers or fails to deliver an implant into the skin it remains difficult to
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establish why either outcome has occurred. If an implant made from a sugar-based excipient
fails it often powders on the skin’s surface. From here it is not possible to interpret which failure
mode the implant may have succumbed to, as discussed in § 3.3.2. Even if an implant remains
intact and fully or partially injected little data has been recorded except this observation.
The method of specifying the input and qualitatively recording the output gives no understand-
ing of what could have occurred during a test. Ideally an empirical approach such as this
would be compensated for by performing many repeats in order to gather statistical signific-
ance between the data sets. However, this is not always possible on in vivo the non-clinical
model and impossible on the clinical model. For these reasons the system development has been
incremental.
No relationships were observed between the clinical trial penetration success data and the meas-
ures of BMI or subcutaneous fat thickness of the subjects. What was required was a quantitative
means of measuring penetration and understanding the forces during solid dose injection. This
would establish the penetration parameters during delivery and, if an injection failed, be able
to describe at what point during the injection and the conditions that had led to this failure.
This quantitative information could then be compared to the known properties of the skin to
establish the conditions required for penetration.
Accounting for Skin Variation
Quantifying the parameters during an injection is key to better understanding the skin and the
effect it has on the drug delivery system. Just knowing the magnitude of these parameters would
not be sufficient, the amount by which they are expected to vary by should also be known. Skin
variation has been suspected of causing failed injections before the fentanyl clinical trial was
conducted [245].
From this review into what was known of the system at the time of the clinical trials, it appeared
that there was evidence for variation in properties of the skin used during testing and develop-
ment. This may have caused penetration failures at the clinical trials. If it can be assumed that
the device and the implant batches behave consistently, the failures observed in the non-clinical
and clinical trials within this chapter may be in part due to the design of the system not being
able to account for the variation in the behaviour of the skin. This variation is likely due to the
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inherent biological variation in skin properties as reported in detail in § 2.3.
Assessing the non-clinical trial data would suggest there has been intra-test site variation as the
system appears to have worked between 40–95% of injections depending on the test site, implant
and device configuration. Some areas on a single test site appear impenetrable by the device
whilst others do not. An understanding of inter-test site and intra- and inter-model variation
was harder to detect as few control experiments exist between the non-clinical trials.
The clinical trial data is more complete and has a larger subject sample size (n = 36). From the
fentanyl clinical trial there was evidence of inter-subject variation where 53% (9 of 17) and 33%
(6 of 18) of subjects received injections to the upper lateral thigh and abdomen, respectively. The
fact that only 12% (2 of 17) of these subjects received both injections also indicated inter-test
site variation within the same data set.
The results from the octreotide trial that suggest a possible gender effect may be explained the
female skin having conditions that fall more favourably within the allowable range of the device
and implant performance window. This may be due to the female skin at these sites being
thinner [108, 219] and requiring less energy to penetrate [198]. The properties of the male skin
sites may have been of a different magnitude or demonstrated a wider variation that the implant
and device could not account for.
Skin Summary
This review of the skin has highlighted a knowledge gap within the drug delivery system ap-
plication and design. Whilst measures have been taken to understand the implant and device
components, little research has been performed into the mechanical properties of the skin and
how it may have affected implant penetration and device performance at both the clinical and
the preceding non-clinical trials.
Accounting for skin variation across a population is an area of generic importance for all novel
parenteral drug delivery devices. From the qualitative data available reporting penetration
success rates it appeared that there may be evidence for skin variation being a leading cause
for failed injections where the skin conditions fall outside those allowable by the current device
and implant designs. To prove this, quantitative data was required to better understand skin,
its response to penetration and how much this can vary by.
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3.3.4 Review of System Components
The investigations into the performance of the device, implant and skin at the time of the clinical
trials has shown the following;
The prototype SDI devices, equivalent to those used within the clinical trials, have performed
consistently and within specification. It was unlikely that the devices’ performance varied over
the injections administered in the clinic.
The mechanical properties of the implants made for the trials were reviewed for dimensional
accuracy, compressive strength and Young’s modulus. The addition of dextran for the octreotide
trial did improve the strength of the implants compared to sorbitol-based fentanyl implants, but
this alone was not enough to ensure a 100% injection rate. Work outside of this thesis will
continue to develop stronger formulations and a commercially scalable manufacturing process.
At the clinical trials two batches of implants were delivered using two separate prototype device
configurations. These were tested on 36 different subjects resulting in a 50% delivery rate. The
methods used to define the skin at clinic (age, BMI, skin calliper testing) were not able to
establish a single cause of failure. It is likely that the different skin properties (n = 36) due to
inherent biological variation was the largest cause of failed deliveries. From the subject data
recorded only gender (male 44%, female 89%) has shown a marked difference in penetration,
although the numbers are too low to be claimed as significant.
Unlike the device and the implant there was no primary data available on the mechanical
properties of the skin and its response to the Glide SDI. Without this, it was not possible
to determine the performance window of the implant or the device within the drug delivery
system. The significance of improvements to implant compressive strength or reduction in
device actuation force cannot be verified without quantitative data available for the skin and
how it responds to penetration, in both the porcine and human models.
It appeared that the device and implants performed capably at the trials and a deviation in
these components was not the cause for failed penetrations. Instead the more likely cause for
failures was that the system design could not account for the variation in mechanical properties
of human or pig skin. In order to improve the performance of the drug delivery system, further
understanding of skin penetration and how it is affected by biological variation was required.
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3.4 Chapter Summary
In order for the system to successfully deliver drugs, the role of each component and its per-
formance within the system must be fully understood.
Implants and devices equivalent to those used during clinical trials have been shown to be
performing as intended. Therefore it can be assumed that the failure rates observed in the non-
clinical and clinical trials appear to have been caused by the intra-test site, inter-test site and
inter-subject variation of skin properties for the injected porcine and human models. Certain
skin sites were impenetrable with the current implant and device design. Due to the small data
sets and qualitative manner the penetration data was recorded it is not possible to know the
conditions at the sites where penetration did not occur.
The differences in response to penetration are likely to be a consequence of the biological vari-
ation within skin. Currently the system has been developed with limited quantitative under-
standing of the penetration parameters of skin and how they may vary. This has meant that the
system only works in sites where the skin conditions fall within those allowable by the device
and implant specifications, such as the inguinal sites of the 25kg porcine model. To guarantee
delivery in different site conditions and models significantly more understanding is required of
skin properties and their variation.
Accounting for skin variation across a population is an area of generic importance for all novel
parenteral drug delivery devices. Typically this is solved either by using a sharp penetrator,
such as a hypodermic needle, or alternatively many needle-free technologies use high velocities
or energies to ensure delivery into all skin types. Glide Pharma’s technology, in its current form,
has neither of these options available.
To improve the penetration performance requires a consideration of the whole of the delivery
system. There are many interacting factors within the system. For example, simply increasing
the mechanical strength of the formulation, by using polymer-based excipients, will affect the
pharmacokinetics of an implant and limit the API applications of the technology. Instead,
the performance window must be established for the system whereby the most suited implants
can be reliably delivered using a device capable of accommodating or overcoming the inherent
biological variation in the skin. To achieve this a greater quantitative understanding is required
of solid dose skin injection and the effect of variation.
Chapter 4
Investigations into Skin
The analysis of the drug delivery system in Chapter 3 highlighted the knowledge gap in the
understanding of skin, its properties and the effect it has on solid dose injection. The literature
review had shown this to be a problem that had concerned other needle-free technologies.
This chapter covers early experimental work in skin properties and penetration using simple
mechanical test rigs. A parallel work package has also been performed to identify a suitable
imaging method to capture penetration or images of an implant under the skin. The exploratory
work here led to the justification of a novel skin penetration test rig.
4.1 Introduction
The skin penetration mechanics of solid dose injection are unique to the Glide technology, as
concluded in Chapter 2. After reviewing the literature of existing needle-free technologies the
only similar research in the field was that of Shergold and Fleck [185,186].
During their research into the mechanics of liquid jet injection Shergold and Fleck used a test
rig that fired a conical-tipped punch into skin, a diagram of this is shown in Figure 4.1a. The
experiments were performed at different rates and with a conical-tipped and blunt penetrators.
This model did not account for the effect of force applied to the skin surface to actuate the SDI
device during injection. This force (currently ≈24N) is likely to have an effect on the skin during
solid dose injection, as shown in Figure 4.1b.
Currently, on too many occasions, the implant fails to be successfully delivered to the skin by
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(a) Conical-tipped punch. (b) Glide solid dose injection. (c) Failed injection.
Figure 4.1: Diagrams comparing current punch penetration understanding; (a) conical-tipped
punch penetration model [185, 186], (b) SDI injection where a force is applied to the delivery
site during implant (punch) penetration, (c) a failed partially penetrated implant.
the SDI device, as described in § 3.2.3. When this happens, either the implant powders on
the surface of the skin or, if the implant remains intact, it can partially penetrate the skin, as
shown in Figure 4.1c. The causes for this were thought to be device and implant specifications
not being able to tolerate the variation in porcine and human skin. However, this cannot be
proven until quantitative data is produced to better understand skin properties and its response
to penetration.
The results from other authors in the field of skin penetration did not directly translate to this
research problem, although the methodologies they used did.
Skin is a complex material and can be described as nonlinear, anisotropic, viscoelastic, incom-
pressible and highly dependent on the environment [119]. In order to understand the effect it
has on novel needle-free technologies many authors [3, 132, 153, 201] have sought to first col-
lect empirical data using bespoke, problem specific test rigs and then use this data to create
analytical model(s) to understand the phenomena that occur during injection.
Two approaches have been used in this chapter to explore and explain skin penetration;
• Empirical tests using simple test rigs and existing measuring equipment have been per-
formed. Penetration experiments into synthetic materials were based on prior understand-
ing of in vivo human skin behaviour from non-penetrative testing.
• Research into imaging techniques was undertaken to establish whether any information
can be gathered during or after an injection to understand why a failure may occur.
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4.2 Initial Investigations into Skin Properties and Penetration
As reported in Chapter 2, there were no suitable data sets or test rigs that could be easily
translated to the field of solid dose injection. The majority of literature reported needle pen-
etration data, into skin, that had been produced on bench top testing machines at velocities
≤20mm.s−1 [103, 157, 158, 161, 169]. Although these testing machines are extremely accurate,
their size limits testing to synthetic materials and in vitro skin samples. The majority of the
understanding Glide Pharma has of skin has come from the in vivo skin penetrative testing in
clinical and non-clinical trials. However, this approach has not yet provided enough knowledge
of skin or penetration to allow the needle-free technology to be optimised.
At this stage in the research a series of experiments were performed to explore methods of how
quantitative data could be produced to better describe solid dose injection. In particular, the
aim was to understand both the effect that the SDI device may have on the skin and the effect
the skin may have on the SDI device.
4.2.1 Approach
The most direct approach to testing would have been to perform a programme of extensive
penetrative tests on in vivo human skin, as shown in Step 5 in Figure 4.2. However, this
approach would have been both impractical and unethical. Instead, the initial step was to
perform non-penetrative testing on in vivo human skin first. This knowledge has then been
developed using synthetic materials for penetration testing. With each step a problem specific
test rig has been built to best simulate solid dose injection.
The implant properties have been discussed in § 3.3.2 and are variable depending on the for-
mulation and manufacturing process. As the implant is still in development, and to isolate the
skin and synthetic material response, from this point forward they will be considered isotropic
and well manufactured and replaced by a metal probe in each of the test rigs.
The penetrative skin tests within this thesis has been limited to the porcine model. Penetration
work in vivo on human skin has not been considered for practical, regulatory and cost reasons.
This exploratory research was performed to justify the development a novel skin penetration
test rig necessary to perform testing on in vivo pig skin.
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Figure 4.2: Diagram showing approach to investigate skin properties and penetration.
The approach that has been used during this section to investigate skin properties and penetra-
tion is shown in Figure 4.2. It was necessary to perform each step in order to inform and justify
the development of the test rig and test bed materials required for the subsequent step.
The following investigations have been performed in this order;
1 Non-penetration onto skin (human) - A simple hand-held test rig has been made to
safely investigate the response of skin and how it can be affected by variables such as BMI,
test site and actuation force.
2 Non-penetration onto synthetic materials - Using the same test rig, the non-penetrative
experimental method was performed on a silicone rubber test bed that had been used by Glide
Pharma and its response was compared to measurements for in vivo skin.
3 Penetration into synthetic materials - A bench top testing machine was used to accurately
record penetration profiles into various combinations of silicone rubber test bed materials in
order to describe the events during penetration.
4 Penetration into skin (porcine) - At this point a complex electromechanical test rig was
required to further develop penetration understanding on in vivo pig skin.
5 Penetration into skin (human) - Not covered within the scope of this thesis.
This section documents the investigations that have been possible through steps 1–4 to better
understand the skin and penetration. Penetrative experiments on human skin remain outside
the scope of this thesis. Instead the research up to step 4 will provide a knowledge base for
Glide Pharma to pursue the following step as further work as, when and if it is required.
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4.2.2 Non-Penetrative Skin Experiments
The most practical and ethical place to start investigating skin properties was to safely perform
non-penetrative testing of human skin. To do this a simple test rig was designed capable of
applying a force simulating the actuation force (Fa), applied to the skin by the Glide SDI
device, while measuring how taut the skin became. Testing has been performed in quasistatic
conditions, therefore discounting the rate effects that may occur with a dynamic delivery.
Quasistatic Non-Penetrative Test Rig
The Quasistatic Non-Penetrative Test Rig, as shown Figure 4.3, was constructed out of readily
available components at Glide Pharma. The purpose of the test rig was to apply an actuation
force to the skin (with a cassette) whilst the peak force required to displace the skin by 1mm,
at a test site where the system would be used, could be measured.
A blunt 0.85mm Ejector Pin (part no: Z441 supplied by Hasco-Internorm Ltd., Daventry,
Northants.) became the metal probe used to displace the skin. This probe was attached
to a Digital Force Gauge (model no: RSFG-5000 supplied by RS Components Ltd., Corby,
Northants.). To ensure the skin was not penetrated the probe travel was mechanically limited
to 1.5mm by the addition of a rubber bung. To measure the actuation force a scale was marked
on the side of the cassette body. This scale corresponded to the rating of the spring, as measured
on a Universal Materials Testing Machine (model no: LFPlus supplied by Lloyd Instruments
Ltd., Bognor Regis, W. Sussex). The cassette retainer simply kept the assembly of components
together between tests and did not interfere with measurement.
The handle on the test rig was used to apply the actuation force (Fa) to a set depth that
corresponds with the scale, as shown in Figure 4.4b. Then the hand-held digital force gauge
with blunt metal probe attached passes through the cassette body and used to displace the skin
by 1mm (Fd), as shown in Figure 4.4c. When the clearance between the force gauge and the
rubber bung was adjudged to be 0.5mm by the operator, the test rig was withdrawn from the
skin and the peak force displayed on the digital force gauge was recorded. The actuation force
for each test was known. The human error associated with the manual method of data collection
method was mitigated by repeating each test ten times and calculating the mean. The error
bars applied to the graphs represent the standard error of the mean (SEM).
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Figure 4.3: Image showing assembly of Quasistatic Non-Penetrative Test Rig.
(a) (b) (c)
Figure 4.4: Diagram showing operation of Quasistatic Non-Penetrative Test Rig; (a) test rig
placed on the skin surface, (b) actuation force, Fa, applied to the skin, (c) peak force required
to displace 1mm of skin, Fd, measured using blunt metal probe attached to the force gauge.
Results
The force required to displace the skin by 1mm (Fd) has been measured with actuation forces
(Fa) of 5N, 10N, 20N and 30N having been applied. In vivo skin measurements have been taken
on two white male subjects, S1 (24 years) and S2 (27 years), with body mass indexes (BMI)
of 26.6kg.m−2 and 18.6kg.m−2 respectively. The results indicate that skin behaviour may be
dependent on the following;
Test Site The skin test sites were on the upper arm, lateral thigh, lower lumbar and near the
umbilicus. The results for S1 shown in Figure 4.5, indicate that Fd was affected by both Fa and
test site. The skin on the upper arm and lateral thigh behaved similarly, as did the lumbar and
near umbilicus sites. Generally the skin sites on the limbs were leaner and the skin required a
greater Fd to displace the skin, even at lower Fa. The sites on the abdomen (lumbar and near
umbilicus) were more mobile requiring less Fd to displace and were not as affected by increasing
Fa. This was probably due to the higher presence of subcutaneous fat at these sites.
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Figure 4.5: The effect of inter- and intra-population on the upper arm, umbilical, lumbar and
outer thigh on Subject 1 (male, 24 years, BMI 26.6) and Subject 2 (male, 27 years, BMI 18.6).
Both performed using the Quasistatic Non-Penetrative Test Rig to measure Fd at intervals of
5N, 10N 20N and 30N.
Population The tests were repeated on a subject (S2) with a lower BMI, these are shown in
Figure 4.5. Data points could not be obtained beyond 20N on the abdomen sites as the subject
felt too uncomfortable. The results correlate well showing that the test sites behave similarly.
The leaner sites on the limbs require greater Fd to displace with increasing Fa. For both subjects
the data for the test sites on the abdomen, an area where more subcutaneous fat is present,
were less responsive to increasing Fa. There is little difference in Fd noticed between Fa values
of 20N and 30N (S1) meaning the Fa of the Glide device could possibly be lowered to 20N and
not effect delivery and also improve patient comfort.
Manipulation There are two methods that are generally used during parenteral delivery,
either pinching the skin at the test site and injecting into a skinfold or to apply tension across
the surface of the skin at the site. Both of these methods were tested on the skin near the
umbilicus on S1 and the test rig was used to measure the effect. The results are shown in
Figure 4.7a. Applying tension to the skin increased Fd and the error bars confirm this effect.
Gathering the skin and subcutaneous tissue into a pinch lowered the Fd required to displace the
skin. In both instances it proved too uncomfortable for the subject to measure Fa > 20N.
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(a) (b)
Figure 4.6: Different cassette shapes with (a) 18mm standard dome and (b) modified 8mm
dome. The effect of reducing the cassette dome on skin behaviour is shown in Figure 4.7b.
Cassette Shape The front part of the standard cassette body has a 18mm dome that
distributes the actuation force across the skin surface (Figure 4.6a). A cassette dome was
modified and reduced to 8mm (Figure 4.6b). This modification reduced the surface area and
would increase the pressure applied to the skin during use. Tests with the modified cassette
has been compared to the standard cassette on the abdomen sites, these results are shown
in Figure 4.7b. The modified cassette meant more pressure was applied at each Fa interval,
consequently the skin was less mobile and a greater Fd was required to displace the skin.
This result indicates that reducing the cassette dome surface area can make the skin tauter
at a lower actuation force. The tauter the skin, the more likely it may be that penetration is
initiated. For an Fa of 30N using the standard cassette on the umbilicus site gave an equivalent
result, Fd = 3.8N, with the standard cassette that could be achieved with an Fa ≈ 11N using
the modified cassette, as indicated by the red line dotted line on Figure 4.7b.
Summary
The experiments performed using the quasistatic non-penetrative test rig confirmed that the
actuation force does have an effect on the tension across the surface of the skin. The error bars
applied showed that the simple rig made good distinction between the further effects of changing
the target site, subject, cassette shape and local manipulation of the skin.
The results were of interest but inconclusive unless a larger population could be tested. BMI
does not reflect the composition of different target sites and is only a measure of a subject as
a whole. Despite the limitations, being quasistatic and non-penetrative, the experiment gave
an insight into skin behaviour. The testing method proved to be a safe and repeatable and
generated preliminary data on human skin. More work was required to understand the effect
this may have on penetration and the consequences of a dynamic delivery.
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(a) The effect of manipulating the skin at the near umbilicus test site.
0
1
2
3
4
5
6
7
8
0 5 10 15 20 25 30 35
F d
 -
 F
o
rc
e
 r
eq
u
ir
e
d
 t
o
 d
is
p
la
ce
 s
ki
n
 1
m
m
 (
N
) 
Fa -  Actuation Force (N) 
S1 - Lumbar S1 - Near Umbilicus
S1 - Lumbar (Modified Cassette) S1 - Near Umbilicus (Modified Cassette)
(b) The effect of reducing the cassette dome surface area.
Figure 4.7: The effect of (a) manipulating the skin through pinching and stretching during
a measurement and (b) reducing the cassette dome surface area. Both performed using the
Quasistatic Non-Penetrative Test Rig to measure Fd on Subject 1 (male, 24 years, BMI 26.6) at
Fa intervals of 5N, 10N 20N and 30N.
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4.2.3 Non-Penetrative Synthetic Experiments
Before penetrative experiments could be performed on synthetic materials, it was important to
understand how similar a non-penetration response there was between Glide Pharma’s current
test bed and the in vivo human skin. For penetration testing of different implant formulations
Glide Pharma have used a 4mm thick silicone rubber (part no: R31-2186 supplied by PSTL Ltd.,
High Wycombe, Bucks.). This material was similar to that used by Shergold and Fleck [128].
The test method involved placing a 4mm thickness over a 20mm hole in a test tube rack, that
intended to provide similar compliance to that of the skin.
The same test method was used as in the previous section on the in vivo human skin. Different
actuation forces (Fa = 5–30N) have been applied and the force to displace the material by 1mm
using a blunt metal probe (Fd), has been measured using the Quasistatic Non-Penetrative Test
Rig. For comparison, different thicknesses of silicone rubber and methods of support were used
(1mm on 10mm thick foam sponge, 8mm on bench top) to provide extremes. The results from
this study are shown in Figure 4.8 and have been compared to the in vivo lumbar and umbilical
skin data from Subject 1.
Generally the silicone rubber data corresponded well with the skin results. The greater the Fa
the higher the Fd required displace the silicone rubber. The only profile to differ from this trend
was the test bed used by Glide Pharma. The reason for this was thought to be due to the way
the material was supported. Figure 4.9a shows an SDI device pressing down an 8mm thickness
of silicone rubber on a bench top. Figure 4.9c illustrates that the effect the support has on the
material was that it becomes compressed requiring more force to displace. Figure 4.9b shows
an SDI device pressing down an 4mm thickness of silicone rubber unsupported over a 20mm
hole in a test tube rack. When the material is not supported underneath, tension builds and
increases with actuation force, as illustrated in Figure 4.9d. This is not true of the skin which
is supported underneath by musculature, thus rendering the current test method used by Glide
Pharma inaccurate compared to the expected response of in vivo skin.
Silicone rubber can mimic in vivo skin behaviour, as shown by the 8mm thickness response. This
study has shown that the approach to designing a test bed must be informed by quantitative
data and a greater understanding of silicone rubber, its response to penetration and the effect
of actuation force was required before it could be achieved.
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Figure 4.8: Non-penetrative synthetic material testing. Quasistatic Non-Penetrative Test Rig
used to measure Fd of silicone rubber (R31-2186) at different thickness (1mm, 4mm and 8mm)
with different methods of support at Fa intervals of 5N, 10N 20N and 30N. In vivo lumbar and
umbilical skin data from Subject 1 (male, 24 years, BMI 26.6) included for comparison purposes.
(a) 8mm silicone rubber, supported. (b) 4mm silicone rubber, unsupported.
(c) Effect of being supported. (d) Effect of being unsupported.
Figure 4.9: The effect of support on behaviour of silicone rubber during penetration.
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4.2.4 Penetrative Synthetic Material Experiments
The next step taken was to begin to understand penetration. This experimental approach
would first be performed on a synthetic material, silicone rubber, rather than on skin. The
non-penetrative investigations had assumed that the tauter the material, the higher the Fd and
the more likely penetration was to occur. The aim of this investigation was to test this theory
as well as observe the events during penetration of a soft-solid.
The Digital Force Gauge was replaced by a Lloyd LFPlus Universal Materials Testing Machine to
more accurately measure and plot force and displacement. Testing machines similar to this have
been used by other authors for the same purpose for needle insertion research [161,169,170]. To
simulate a delivery with the SDI device on the Lloyd LFPlus an additional test rig was required.
Lloyd LFPlus Mounted Penetration Test Rig
This test rig, shown in Figure 4.10, was an iteration of the hand-held test rig used in § 4.2.2. It
was constructed out of components machined to order by AC Precision Ltd. (Standlake, Oxon.).
Another blunt 0.85mm Z441 Ejector Pin was used as the metal probe.
The test rig was mounted on the jaws of the Lloyd LFPlus. The silicone rubber samples were
placed within the test rig with a 7mm foam sponge underlayer and then on expanded polystyrene.
The foam sponge provided some compliance as demonstrated by the test in § 4.2.3. The wingnuts
were then used to lower the top plate, compressing the spring and applying the actuation force.
Figure 4.10: Image showing assembly of Lloyd LFPlus Mounted Penetration Test Rig.
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On the lower jaw attachment of the test rig there is a 2mm hole so that the probe can
penetrate the full thickness of the sample. The blunt metal probe penetrated the silicone rubber
at 10mm.min−1. The data was recorded and plotted using the NEXYGENPlus software (v1.1).
Results
The experiments were performed with two variables, material thickness (2mm and 4mm thick
R31-2186 silicone rubber) and the actuation force at intervals of 0N, 20N and 30N.
The force displacement profile for 2mm thick silicone rubber with Fa = 0N is shown in Fig-
ure 4.11a. On the profile there are several notable features on that have previously been observed
by other authors [169,186,197], these being;
A Elastic deformation as the silicone rubber deflects until penetration is initiated.
B Simultaneous puncture of the front and rear surface as the probe passes into the foam sponge.
C The blunt penetrator tears through the compressed thickness of foam sponge.
D The penetrator encounters little resistance as it passes through the expanded polystyrene but
is subject to the drag force exerted by the penetrated silicone rubber.
The forces recorded with a blunt penetrator were much higher than those in needle penetration
literature. Comparing the profiles for the 2mm (Figure 4.11a) and 4mm thick silicone rubber
(Figure 4.11b) shows the peak penetration force (≈12.5N) was unaffected by material thickness.
The displacement where the material was penetrated was different, the 2mm thick material was
breached after stretching for 10mm and thicker 4mm sample only by 7mm.
In Figure 4.11 both profiles were generated with no actuation force applied, Fa = 0N. The plots
for 20N (Figure 9.6) and 30N (Figure 9.7) are shown in Appendix B. Increasing Fa reduced the
elastic phase before peak penetration force (point A) as the material was pre-compressed.
In the 4mm thick sample the forces beyond penetration were twice as much (≈6N) than the
2mm sample (≈3N). The thicker the material had a larger penetration crack surface area that
led to an increased drag force on the metal probe once penetrated.
The force displacement profiles generated by the Lloyd LFPlus proved useful in understanding
penetration. Testing, however, was limited to a low velocity range and selection of materials.
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(a) 2mm thick silicone rubber with Fa = 0N. Labels A, B, C, and D indicate penetration events.
(b) 4mm thick silicone rubber with Fa = 0N.
Figure 4.11: Penetration force displacement profiles produced using Lloyd LFPlus Mounted Pen-
etration Test Rig and a blunt (0.85mm) penetrator on silicone rubber (R31-2186) of different
thicknesses (a) 2mm and (b) 4mm, with Fa applied of 0N.
Chapter 4. Investigations into Skin 101
4.2.5 Penetrative Skin Experiments
After performing penetrative experiments into synthetic materials the next logical step was to
continue this understanding into in vivo skin. However, to perform this work a more advanced
test rig was required.
A skin penetration test rig that could capture force displacement profiles and be used on in vivo
human skin would be ideal. Such a test rig could also be used to measure the effect of variables
such as age, gender and ethnicity, while also measuring the influence of device variables such
as cassette shape, actuation force and delivery velocity. However, realistically, at this stage in
the understanding solid dose injection it would be a far more attainable research aim to first
understand the skin and identify the effect its inherent variation has on delivery.
Also invasive experimental work of this nature would not be possible to perform on man in the
first instance. Instead the test rig and method would first need to be demonstrated using the
porcine model which is known from § 2.5.1 to be a viable non-clinical model for human skin.
Although Glide Pharma have conducted experiments into pig skin before, as discussed in § 3.2.2,
these did not produce any useful quantitative data to describe the penetration.
4.2.6 Review of Skin Properties and Penetration
Through following the experimental approach steps 1–3, shown in Figure 4.2, the skin has been
shown to differ between individuals, location of test site on the body, through manipulation
(pinching and stretching) and by modifying the cassette shape. Further investigations have
shown that some of this behaviour can be replicated using silicone rubber. This exploratory
work was achieved with simple test rigs within the capabilities of the Lloyd LFPlus.
Research into the penetration in in vivo skin remained the next logical step to further this
understanding. More penetration experiments could have been performed on silicone rubber.
However, without any in vivo quantitative data available in literature or at Glide Pharma, it
would be difficult to progress. The work achieved within this section has shown the benefit of
producing quantitative data to measure the properties of skin and justified the need for a novel
skin penetration test rig. This test rig would need to be capable of capturing force displacement
profiles into in vivo skin whilst simulating a solid dose injection.
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4.3 Initial Investigations using Skin Imaging Techniques
Visibly observing solid dose injection in skin is not possible as skin is opaque. Instead other
means of viewing either penetration or an injected implant under the skin have to be considered.
This section covers exploratory work with ultrasound and histology techniques and the values
of other such imaging techniques reported in literature.
4.3.1 Ultrasound
Ultrasound scanners are relatively low cost, non-invasive and the equipment can be portable.
Ultrasonography is a common technique used in assessing skin thickness by many different
authors [63, 101, 108, 109]. It also can be used in real-time for applications such as guiding
needles under the skin [248]. Ultrasound can be used to measure the effect of compression on
tissues underneath the skin. Smith et al. [113] measured skin to muscle fascia distance at various
sites and compared this data with measurements of uncompressed tissue at the same site. The
results showed that distances from skin to muscle fascia were reduced by 33% (17–45%) as a
result of the compression.
It was not possible to locate a high frequency (15–30Mhz) ultrasound machine that could be
used to detect implants under the skin surface. An Acuson Ultrasound System (model no:
128/XP10 supplied by Siemens Medical Solutions USA Inc., Mountain View, CA) with a 7–
10MHz frequency was accessed as an alternative. As expected, it proved difficult for the scanner
to accurately detect the shallow depths necessary to capture an implant (<5mm). However,
the machine could still be used to investigate the effect of compression at different target sites.
Ultrasound scans were taken at the abdomen (male, 24 years, BMI 26.6) with the transducer
either resting on the skin surface or forced against it, as shown in Figures 4.12a and 4.12b
respectively.
On the images measurement 4 represents the 12.6–12.9mm thick muscle layer, measurements
1–3 represent the combined skin and subcutaneous fat. When compressed the total thickness of
these measurements 1–3 reduced from 19.8mm (Figure 4.12a) to 14.2mm (Figure 4.12b) showing
a reduction of 28%. While similar to the findings of Smith et al., this result is not useful to
Glide Pharma unless the force on the transducer was also measured. This study also showed
how difficult detecting the boundaries between the skin layers can be at low resolution.
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(a) Relaxed abdomen site.
(b) Compressed abdomen site.
Figure 4.12: Images taken from an ultrasound scan performed on an abdomen (male, 24 years,
BMI 26.6) and showing the tissue; (a) relaxed with the transducer resting on the surface and
with (b) transducer forced down at the site and compressing the tissues present between the
skin and the muscle layers.
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4.3.2 Histology
Histology is the process of using microscopy to study cells and tissues in vitro, often after they
have been excised, sectioned and stained. It has been used by other authors to assess skin trauma
and drug delivery for other needle-free technologies [3, 40, 78]. Glide Pharma have previously
used histology to assess the dermatological response of the skin to a solid dose injection rather
than to understand what happens to the implant during or after an injection.
A similar histology method has been used but with a different purpose that is to view an
implant under the skin’s surface and not just the inflammatory response of the skin. The
current octreotide prototype SDI device was used to inject two types of (undisclosed) polymer-
based implants into in vitro pig skin. When sectioned it was intended that implants would be
visible under the skin and the delivery depth, orientation and mechanical trauma to skin could
be analysed.
Preliminary experiments ruled out the possibility of using cryopreservation methods to fix the
skin samples. When frozen the skin samples became opaque making it difficult to judge the ori-
entation prior to sectioning. It was intended for the skin samples to be sliced perpendicular using
the skin surface as a datum in order to capture the implant sectioned down its length. Instead
the samples were suspended in a fixative that prevents the distortion of cellular components by
denaturing and cross linking proteins.
Method
The in vitro skin used was from the neck site of a porcine model (≈25kg, male, Large White)
typically used for penetration studies at Glide Pharma. The skin had been excised, frozen
and stored from a previous study at Harlan Laboratories UK Ltd. (Belton, Leics.). The skin
was thawed from frozen (-10°C) to room temperature (21°C), shaved and pinned out on 20mm
thick expanded polystyrene sheet. The following steps were then performed under laboratory
conditions at Glide Pharma;
1 The current octreotide prototype SDI device (Fa ≈ 24N) was used to inject implants
(4mm × 0.85mm) into the skin at sites approximately 2cm from each other.
2 The entry hole of each injection was marked on the skin using indelible pen.
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3 A total of 10 polymer-based implants of each type were injected.
4 Each test site was then excised and trimmed into 1cm3 skin samples using a surgical scalpel.
5 The skin sample was contained, labelled and fixed using a 10% neutral buffered Formalin
solution (4% formaldehyde) supplied by Sigma Aldrich Ltd. (Poole, Dorset).
The 20 skin samples were sent for sectioning by courier to Charles River Preclinical Services Inc.
(Edinburgh, Scotland). Charles River was under careful instruction to perform the sectioning
perpendicular to skin surface. The samples were sliced in to 5µm slices using a microtome,
floated on a 45°C water bath, embedded in wax and mounted on a slide with a cover slip. The
sections were not stained. This process was according to Charles River’s standard operating
procedures; SOP/PAT/120 V10, SOP/PAT/034 V2 and SOP/PAT/123 V9.
Results
In total 200 microscope slides were returned from Charles River, each site had been sectioned into
10 slices. For the histological examinations and photography an Axiovert 135M Light Microscope
made by Zeiss SMT GmbH (Oberkochen, Germany) was used. The slides were viewed using
x200 and x400 objective lenses, 1mm ball bearings were used for scale. To observe full skin
thickness multiple images were stitched together in Microsoft Powerpoint (2010).
The image in Figure 4.13a shows an 8mm section through the skin. The image is clear and
the stratum corneum, epidermis, dermis, subcutaneous and muscle layers can all be seen with
very good resolution, particularly of the collagen in the dermal regions. Many of the returned
slides showed this. Figure 4.13b shows the only example (from the 200 slides) of an implant that
has been intercepted under the skin. The image shows a polymer implant partially sectioned
(≈2mm) down its length residing in the subcutaneous fatty layer.
The low yield of implants captured on the slides meant that the histological method would need
revising. Some of the polymer-based implants dissolved during the fixing process, others may
have been disturbed during slicing on the microtome or were simply not intercepted during
the sectioning. The possibility of flurotagging the implants to make them traceable does exist,
however, even if detected it was difficult to imagine a method where the sectioning could regularly
slice implants down their length so that the full delivery depth can be measured.
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Figure 4.13: Microscopy images of histology work on neck skin from porcine model (≈25kg,
male, Large White) captured using a Zeiss Axiovert 135M Light Microscope with (a) x200
magnification clearly showing the layers of the skin and (b) x400 magnification showing ≈2mm
of an implant (circled) detected under the skin’s surface.
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4.3.3 Other Techniques
There are other medical imaging techniques that have been considered for understanding in
vivo tissue. Optical coherence tomography (OCT) is an interferometric technique that uses
light waves to determine tissue composition. It is capable of higher resolution than ultrasound,
although the depths that OCT can study are limited to <1.5mm [249].
High spacial magnetic resonance imaging (MRI) is capable of resolutions of about 100µm, high
enough to differentiate between the epidermis, dermis and subcutaneous fat layers [250]. The
magnetic fields used in MRI would not make it possible to inject an implant in real-time using an
SDI device that contained metal components. Positron emission tomography (PET) works by
detected pairs of gamma rays that would be emitted indirectly the radiotracer that would need
to be within an injected implant. High resolution computed tomography (CT) uses a series of
X-rays taken in 1mm thick two-dimensional slices that are taken around a single axis of rotation
and built into a 3D image [251].
With each of these methods MRI, PET, and CT it is likely that an implant would need to
be reformulated so that it is denser and more detectable by the scanner. Also, as none of the
equipment is portable, the use of an in vivo porcine model presents practical problems, while
the use of in vivo human skin for exploratory research presents obvious ethical problems.
Due to the many disadvantages given for the various imaging techniques, some authors research-
ing needle-free applications prefer to work with translucent materials such as gelatine and film
the delivery using a high-speed photography [183, 207]. Whilst this may visually demonstrate
the performance of a device there are few assurances that the synthetic material will have com-
parable properties to in vivo skin.
4.3.4 Review of Skin Imaging Techniques
There is no one in vivo non-invasive imaging method that is entirely suited to the problem or the
scale required. Each technique would require experimentation and refinement to detect a 4mm
implant under the skin’s surface. Access to the higher resolution equipment necessary would be
expensive. The most affordable method considered was histology which, although capable, is
invasive and has been proven to be a case of ‘finding a needle in a haystack’ by its very nature.
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4.4 Chapter Summary
This chapter has documented the exploratory work that has been achieved to investigate skin
properties and penetration. Preliminary data has been produced using the Quasistatic Non-
Penetrative and Lloyd LFPlus Mounted Penetration Test Rig to capture the response of in vivo
skin and synthetic materials. This work has also highlighted the limits of using conventional
techniques and equipment in the understanding of the novel nature of solid dose injection.
Non-penetrative work on human skin has revealed that skin behaviour changes with actuation
force. The greater the actuation force the more taut skin becomes. Although repeating this
work on the Lloyd LFPlus has shown that this does not lower the force to penetrate, instead
it reduces the compliance of a material before penetration. The skin behaviour has also been
shown to differ between individuals, location of test site on the body, through local manipulation
(pinching and stretching) and with modifying the cassette shape. The results at this stage were
far from conclusive. It was not clear how much of this was due to the natural variability of
the skin. This initial experimental work has shown the benefit of collecting quantitative data
to describe skin properties. The approach required a series of simple test rigs designed to work
within the limitations of a Digital Force Gauge and a Lloyd LFPlus. To better understand
penetration properties a novel test rig was required capable of performing in vivo measurements
and at a velocity more representative of the Glide SDI device.
The parallel work package to explore the suitability of imaging methods, to capture penetration
or images on an implant under the skin, ruled out all techniques but histology. A significant
refinement of the histology method used would be required for it to be of practical use. Instead
of trying to understand an injection, with a solid dose, through observation alone it would be
better to derive the parameters from the penetration event itself. A novel test rig that could
produce force displacement profiles, as the Lloyd LFPlus does, would remove the need to detect
an implant under the skin as quantitative data would be available to describe how its delivery.
Understanding skin properties and how they respond to penetration remains an attainable re-
search goal. The difficulty for a needle-free technology will be to design a mass-manufacturable
system with device and implants capable of high delivery reliability across all types of skin. To
continue the understanding requires a novel skin penetration test rig. Chapter 5 documents the
justification, development and build of such a test rig.
Chapter 5
Design and Validation of a Novel
Skin Penetration Test Rig
This chapter is dedicated to detailing the engineering design and other activities that arose
during the development of a novel test rig, including the specification, delivery, software de-
velopment and general operation. It also outlines the methods by which the test rig has been
validated and the results and interpretation from an initial investigation into silicone rubber.
5.1 Justification
In Chapter 4 it has been shown that there are many parameters that affect the delivery of a
solid dose injection and further understanding was required before the design changes to the
Glide SDI or other such devices can be recommended. An initial understanding of the skin
was achieved using a simple non-invasive hand-held test rig to measure the peak force when
deflecting skin in vivo by 1mm under quasistatic conditions. Despite the limited data set, the
results have shown that skin tension changes with actuation force, Fa, and the greater the force
the more taut skin becomes.
Other investigative work produced penetration profiles using the Lloyd LFPlus Materials Testing
Machine at low speeds into synthetic materials showed that material thicknesses and composition
also have a significant effect when using a 0.85mm 46° wedge-tipped probe.
Attempting to understand injection depth and success through viewing an implant post-injection,
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either using non-invasive or invasive methods, has proven problematic due to the small scale of
the implant and shallow subcutaneous delivery depth into mobile tissue. It was concluded that
the best way to further understand skin penetration was likely to be to dynamically measure
the forces acting on an implant as it was injected.
This work was a logical continuation of the initial investigations, achieved using the skin test
rig (quasistatic, non-penetrative, hand-held) and Lloyd LFPlus (dynamic, penetrative, bench-
top). Further, in order to generate accurate dynamic penetrative in vivo skin data, a suitable
hand-held test rig was required for use in non-clinical studies.
Reviewing the literature has shown that the majority of research within the field of skin
mechanical properties has been performed using bench-top sized testing machines at velocit-
ies ≤20mm.s−1 [103,157,158,161,169]. Whilst these machines are extremely accurate, they are
not suited to the work required by this thesis as their large size and lack of portability renders
in vivo work impractical, limiting testing to in vitro skin samples.
What was required was a test rig similar to a dynamic ‘Penetrometer’. This type of test rig is
used to measure the strength of soil and other materials [252, 253]. A Penetrometer is usually
dropped on the test material or pressed against it and the depth of the resulting hole is measured.
There are many types of Penetrometer and applications range from assessing the playability of
cricket pitches to measuring the moisture content of soil on other planets. There remains only
one example in literature where similar technology was used in the field of skin penetration.
This was a hand-held test rig developed by Shergold [185, 186]. However, this design would
require considerable modification to use with both implants and probes delivered through an
SDI cassette component.
A design concept for a novel dynamic in vivo skin penetration test rig, the ‘Penetrometer’, is
shown in Figure 5.1. The design integrates features from the test rig used by Shergold and the
skin test rig used in Chapter 4. Shergold’s inclusion of a linear variable differential transformer
(LVDT) and load cell provides a means to dynamically capture the force, displacement and
velocity of the penetrator; whilst the skin test rig would allow for a cassette to be attached and
an actuation force, Fa, to be applied to the skin during injection.
The test rig was required to output a file plotting the force encountered by the penetrator against
displacement as it penetrates the skin or a synthetic substitute, at a known velocity. The graph
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Figure 5.1: (a) The proposed concept for the Penetrometer, adapted from a test rig built by
Shergold [185,186] to include a mechanism to apply actuation force, Fa, and make measurement
of penetration force, Fp, possible (b) as a metal probe is delivered simulating an injection.
Original image used with the author’s permission.
Figure 5.2: The desired graphical output from the Penetrometer allowing for an Fa to be de-
livered by the cassette, adapted from Fp against d graph of Shergold’s [185,186]. Original image
used with the author’s permission.
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plot was also required to be independent of the skin deflection caused by actuation force through
the cassette face, as shown in Figure 5.2.
It was predicted that a similar sequence of penetration events, as identified by a number of
authors in other applications [161,169,186], would be observed during a penetration test. These
being; skin deflection caused by the penetrator tip, penetration initiation, peak penetration
force, emerging through the material and the friction on the penetrator also. This had not yet
been achieved by any authors for solid dose injection or during a delivery whilst a considerable
actuation force is imparted onto the skin.
5.2 Specification
The specification for the Penetrometer test rig is shown in Table 5.1. It was intended that
the test rig incorporated the accuracy and functionality of a material testing machine but in a
portable hand-held format.
Ability Unit Comment
Velocity measured range 1–100mm.s−1
Implant & probe dimensions ≥4mm × 0.85mm
Delivery depth ≥9mm
Penetration force measured range 0–30N Manually applied
Penetration force accuracy ± 1N
Actuation force measured range 0–30N
Actuation force Accuracy ± 1N
Must accept current cassette shape 7mm
Time for a graph to output to PC ≤60s
Working environment – Non-clinical setting
Working temperature 15–30°C
Size of overall unit – Portable
Size of hand-held unit <1.5kg
Power supply 240V
Table 5.1: Penetrometer Product Design Specification.
The most important aspect of the specification was that the force, displacement and velocity be
measured during a penetration test. Software was developed in parallel to be able to pre-set the
maximum penetrator velocity and delivery depth. The actuation force could either be pre-set
or measured during injection. The test rig was intended to be able to deliver implant and metal
probes as well as evaluate alternative cassette designs.
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Despite the SDI operating at ≈6m.s−1 [95] this test rig was initially only specified to operate at
≤100mm.s−1. This decision was taken since it was felt that achieving control at higher velocities
would have required a more expensive solution.
To maintain portability, the test rig would comprise of a hand held unit and a bench-top control
box that contained the necessary controllers, power supply and data logger. The hand held unit
collects and transmits data via USB to a Laptop PC. It was preferable that the data be read
and manipulated in Microsoft Excel (2010).
Ideally, the test rig should have been able to perform testing on in vivo human skin. However,
at this stage in skin understanding and to reduce the cost and complexity of test rig and
accompanying software, it was decided that the test rig was only to be specified for in vivo
and in vitro testing on non-clinical models and synthetic materials.
5.3 Design and Development
The Penetrometer specification outlined in Table 5.1 was given to 42 Technology Ltd. (St.
Ives, Cambs.) to build the test rig. The chosen design solution was an electromechanical
one comprising of a linear actuator that could provide and measure the force to penetrate at
velocities ≤100mms−1. The linear actuator was suspended in a hand-held unit via a spring
assembly making it possible to simulate the actuation force, Fa, present during an injection by
the current prototype SDI device.
As well as achieving all of the parameters outlined in the specification, the major benefit of
using a linear actuator was its flexibility. The actuator served both to drive the test rig and
measure the resistance simultaneously. The actuator’s performance is dependent on the control
software, unlike a purely mechanical solution that may have required change parts. The design
and development of the Penetrometer was performed in two steps; the design and assembly of
the hardware and the programming of the bespoke software required to drive the linear motor
and capture the results. The following section details this development.
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5.3.1 Hardware
The Penetrometer has 31 components in total, 23 of these are unique. The final design contained
a mix of bought in (17) and machined parts (14) that were assembled and tested by 42 Technology
Ltd. The final design of the hand-held unit is shown in Figure 5.3a, a full technical drawing is
shown in Figure 9.2 in Appendix A. The most important components and sub-assemblies and
why they were chosen or designed are discussed in the following text;
At the core of the Penetrometer is a SMAC CAL36 Series Electric Cylinder, or linear actuator,
(part no: CAL36-025-51FS3A supplied by SMAC Europe Ltd., Crawley, W. Sussex). A linear
actuator was chosen as it has the ability to both do work and simultaneously provide feedback.
With a DC 48V power supply the model chosen can deliver a peak force of 28N using a single
coil and a displacement resolution of 1µm. The actuator is fully programmable in force, position
and velocity and would typically be used for inline tests during high speed manufacture such
as; height gauging, measuring thicknesses or to perform repetitive testing and record failure
criteria [254]. Linear actuators are superior to cams and pneumatic cylinders in performing
these tasks due to their greater flexibility and control, respectively.
The actuator has a maximum stroke length of 25mm, but it is possible to start and stop this travel
at any point along the stroke. The moving parts within the actuator weigh only 0.08kg, cause
no internal moment and are low friction allowing for the application of very light forces. The
drive shaft that extends from the motor has a female mounting part suitable for the mounting of
a probe catch mechanism. The drive shaft has an internal return spring that acts as a fail-safe
retracting the shaft if the power is cut.
All CAL36 Series Electric Cylinders are capable of 50g acceleration meaning the actuator can
more than achieve the initial specification of 100mm.s−1. The actuator is also designed with
internal permanent lubrication for ultra-long life expectancy (100 million cycles) making it ideal
to be placed at the core of a test rig. The main body of the model chosen is 155mm long, 36mm
diameter and weighs 0.95kg. It is these dimensions that dictate the main body shape of the
Penetrometer hand-held unit.
The actuator was housed inside the Handset Body of the test rig which was designed to be
an ergonomic and hygienic surround. The overall length of the Penetrometer is 320mm with a
55mm diameter making it capable of being held and operated comfortably in one hand as shown
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Figure 5.3: CAD diagram showing Penetrometer hand-held unit assembly and sub-assemblies;
(a) Fully assembled test rig, (b) Reveal of spring cage sub-assembly that makes it possible to
deliver an Fa, (c) The core of the test rig comprises of a linear actuator fixed to a metal probe.
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in Figure 5.5b. The hand-held unit body was machined in two parts, from aluminium, and
pressed together; making a smooth casing for the actuator such that it can be easily cleaned.
This was true of all the external features of the test rig, which have all been designed from simple
shapes to facilitate the cleaning required, given the non-clinical environment in which the test
rig was expected to operate. This hand-held unit body was designed to ‘float’ independently
from the linear actuator. The outer housing was only held in place by the spring assembly and
could slide on two nylon bearings up to 10mm over the cassette holder’s shaft.
The front spring hanger is screwed to the foremost part of the hand-held unit body and provides
internal features for the attachment of springs, that form the spring assembly. The spring
assembly can comprise of between 1–6 extension springs that are used to maintain an actuation
force onto the skin’s surface through the cassette face prior to injection. The other ends of the
springs are secured to the rear spring hanger. This component also acts as a conduit for three
leads to pass into the 2 meter umbilical and into the bench-top unit.
The springs (part no: LE026C11S supplied by Lee Springs Ltd., Wokingham, Berks.) have a
rating of 0.088N.mm−1 and are pre-tensioned to maintain an actuation force between 10–60N
over the 10mm distance that the handset body can slide over the rear spring hanger. This
motion is indicated by the red arrows in Figure 5.3b. The force maintained on the skin via the
spring assembly is transmitted through the rear spring hanger and into the load cell bolted to
the actuator. The load cell (part no: FR251 UFR0H supplied by NovaTech Measurements Ltd.,
St. Leonards, E. Sussex) is capable of measuring up to 100N ±0.5% in compression.
The cassette holder on the front of the Penetrometer has been designed to receive the standard
cassette or any cassette shape with the same shaft geometry. As the cassette holder is screwed
onto the front of the actuator the cassette remained fixed relative to the actuator body. It is
hollow allowing the drive shaft and probe pass through it and the cassette. The cassette retainer
(a) Align cassette. (b) Insert cassette. (c) Slide retainer across.
Figure 5.4: Insertion procedure of cassette into Penetrometer.
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(a) The Penetrometer test rig (hand-held unit and bench-top unit) and accompanying laptop.
(b) The Penetrometer hand-held unit. (c) The Penetrometer in purpose-built stand.
Figure 5.5: Images showing full build of Penetrometer.
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(a) The wedge-tipped metal probe and striker probe configurations.
(b) Implant. (c) Probe tip (side). (d) Probe tip (front).
Figure 5.6: Images of implants and wedge-tipped metal probes configurations.
provides a simple method of locking the cassette in place by creating a temporary interference
fit with the viewing window that is usually used to observe whether the injection has been
completed. Figures 5.4a–5.4c show step by step how the cassette can be changed.
At the core of the Penetrometer is a metal probe fixed to the linear actuator’s drive shaft, as
shown in Figure 5.3c. When the test rig was fired it is intended to simulate a solid dose injection
with the same cassette shape and actuation force. The resistance sensed by the probe during
delivery (to a set depth and velocity) is transmitted to the actuator and converted into a force.
The probes were made available in two types whether the implant or the probe itself was to
serve as the penetrator.
• The striker probe is a machined component designed to replace the role of the spindle
in the SDI, pushing the LCP pin forward through the cassette to deliver an implant.
The striker probe remains in contact with the LCP during delivery making it possible to
measure penetration using Glide implants.
• The wedge-tipped probe(s) were manufactured by machining tips onto ejector pins (part
no: Z441/0.85X63 supplied by Hasco-Internorm Ltd., Daventry, Northants.) typically used
for injection moulding tooling; these have the advantage of being dimensionally accurate,
infrangible, wear resistant and relatively inexpensive.
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How these different probe configurations compare is shown in Figure 5.6a. Both probe types
have the same groove feature at their base that interacts with the probe catch. Any difference
in overall probe length could be compensated for within the software.
It was intended that the majority of the experimental work was to be performed using wedge-
tipped metal probes as they represent a highly repeatable penetrator capable of investigating
skin penetration. The implant specification, as discussed in § 3.3.2, remains undefined and the
strength of the implant, and how frangible the tip will be, cannot be known until the final
manufacturing method has been established. The use of wedge-tipped metal probes to replace
the implant would mean that any variation detected would likely be the result of the skin’s
behaviour and not related to the manufacture or formulation of an implant.
A 46° wedge-tipped metal probe is shown in Figures 5.6c–d. This probe was to be used in place
of the current Glide 46° implant design shown in Figure 5.6b. It is possible to cut any angle
onto the tip of a metal probe. Using metal probes in this way allows the solid dose injection
to be modelled under best-case conditions where it can be assumed the friction would be lower
than an implant. The tip would remain sharp throughout injection unlike the frangible tip of
the implant. The tip of a probe would not change direction unlike an implant which could
disconnect from an LCP pin during delivery.
The probe catch and probe release mechanism work together to allow for easy replacement of
the metal probes. The probe catch is screwed directly into the female feature on the drive shaft
of the actuator and was comprised of 3 balls that grip the groove feature located at the base
of all metal probes. This simple spring-loaded mechanism could be disengaged by the probe
release only when the actuator was fully extended and stationary through a deliberate mode in
the software. This mechanism ensured that the probes could not leave the Penetrometer as they
travelled forward at high speed.
An instrument case (part no: 28-753 supplied by RS Components Ltd., Corby, Northants.)
provides a portable bench-top unit to receive the wiring from the hand-held unit and house a
48V power supply, a signal amplifier for the load cell and a Controller (part no: LAC-1 supplied
by SMAC Europe Ltd., Crawley, W. Sussex). The LAC-1 is a one axis stand-alone integrated
controller/driver, with input/output (I/O) capabilities. The controller has been programmed
with proprietary SMAC software controlling the position, velocity and force of the linear actuator
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Figure 5.7: Penetrometer wiring diagram.
and a built in amplifier to measure feedback. How these electronic components are connected
is shown in the wiring diagram in Figure 5.7. The bench-top unit outputs via USB to a Laptop
used to drive the software.
A simple stand was made from extruded aluminium to mount the Penetrometer in a vertical
position. This is shown in Figure 5.5c. It provided an alternative mode of operation from
the hand-held use making it suitable for repeat testing on synthetic materials in a laboratory
environment. When fixed vertically the mechanical arrangement of the test rig was similar to
the Lloyd LFPlus Testing Machine used to achieve the graphs shown in § 4.2.4 and § 4.2.3.
However, it is capable of much faster delivery speeds capturing penetration profiles of different
materials '50 times faster (1m.s−1) than the 20mm.s−1 top speed of the Lloyd LFPlus.
5.3.2 Software
With the hardware assembled software was then required to control the Penetrometer. The linear
actuator in the hand-held unit was controlled by the bench-top unit which was programmed via a
laptop. The laptop serves as the user interface, programmer, output data storage and graphical
user interface. The software was developed incrementally during the practical experimental
programme, it started as a simple control and output application and has developed into a
dual serial interface controller and data analyser. The software was written in a combination
of Microsoft Excel, Microsoft Visual Basic, C++ and proprietary mnemonic type command
instructions used to program the LAC-1.
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Initial Low Speed Software (≤100mm.s−1)
The Penetrometer was designed to work at speeds up to 100mm.s−1. This led to a test rig being
designed around a linear actuator; an electromechanical solution to supply both the driving force
and force measurement system. At a low speed range the LAC-1 controller can be programmed
in Position Mode (using the mnemonic command PM). In position mode the controller generates
movement of the actuator as commanded by the software at a set velocity, determined by the
command SV. The position of the actuator drive shaft is continually fed back by the linear
encoder to the controller in a ‘closed-loop’ system. The position of the actuator piston is
monitored by the PID loop and the force output is controlled to match the actual movement to
the required movement. The current (I) supplied to the coil to maintain this driving force for
the system is monitored, captured by the LAC-1 and translated into a force reading.
The controller has registers that can be used for storing data and parameters, performing math-
ematical operations and controlling command execution. The registers can be manipulated by
several commands and can also be used to replace the argument in most commands. A simple
graphical user interface (GUI) was developed in Microsoft Excel (2010). A communication pro-
tocol written in Visual Basic made it possible to easily program and control the test settings
between the GUI and the registers within the controller.
Laptop Environment Instrument Case 
Test Settings 
‘GO’ 
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L/S Data 
FN (counts) 
H/S Data 
d (counts) 
H/S Data 
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[Excel] 
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Figure 5.8: Block diagram showing the Penetrometer software topology and data transfer
between key software modules.
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Figure 5.9: Test performed into silicone rubber at 10mm.s−1 using low speed software; the
current drawn as the motor maintains the set speed was inferred into a force profile.
A set of mnemonic type command instructions reside behind the GUI spreadsheet. These
commands and the registry addresses are detailed in full in Appendix C. This main program is
comprised of a series of macros MD0 to MD20 uploaded into the LAC-1 at the start of testing.
After the main program loads, the command AR adjusts the values in the registers attributed
to the start position (AR11), end position (AR9) and speed (AR13) required for each test. The
data flow between the various components of the system is shown in Figure 5.8.
The start position should have the metal probe 2mm sub-flush to the end of the cassette. Within
the main program macro 12 (MD12) contained the commands PM and MA@9. This sets the
actuator into position mode and commands it to travel to the target whilst maintaining the
set speed. The resistance the motor encounters in maintaining this speed is fed back to the
controller by the command RW548. Another command, RL494, reports the position of the drive
shaft to with an accuracy of 1µm. The actuation force, Fa, during an injection is captured by
the load cell and the signal amplified and recorded into register 1554. All the data is collected
in the LAC-1 and transferred into the results sheet to be plotted as both F against d and v
against d as shown in Figure 5.9. The increase in velocity correlates with the penetration events
through the silicone rubber before the PID loop re-establishes the target speed.
During initial trials using the functioning Penetrometer at the intended low speed range (1–
100mm.s−1) it proved difficult to inject implants through a selection of silicone rubbers. Slowing
down the injection event from 6m.s−1 to 0.1m.s−1 had significantly increased the time period
that the implants were placed under load. It was also likely that the implants were blunter
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than first thought when compared to the metal probe based literature and experimental work
described in Chapter 4. The solution was to increase the speed the Penetrometer could function
at and to better simulate a full dynamic solid dose injection.
Improved High Speed Software (>100mm.s−1)
The option to speed the Penetrometer up was made possible through the flexibility of the
electromechanical design and choice of linear actuator. No change parts were required, only
alterations to the software design. It was possible to increase performance of the motor through
switching the controller operating mode from position mode to torque mode, using mnemonic
commands PM and QM respectively.
When operating in torque mode (command QM) the controller could be programmed to accel-
erate the actuator over the full 25mm possible travel. Without PID control, when the controller
is programmed to achieve a set velocity of 1m.s−1 (command SV13107200) the actuator will
surpass this speed. The feedback facility runs ‘open-loop’, ignoring the linear encoder data,
making it impossible to regulate the velocity and the motor simply continues accelerates (com-
mand SA26214). As there was limited feedback of the current fluctuation in this mode, only a
few force data points were generated (command RW548) at a resolution of 1.66mm. This was
insufficient to be able plot. It was hoped that the force could be inferred instead from the change
in velocity during injection providing better quality displacement data could be acquired.
This led to a standalone micro-controller (part no: P32MX340F512 PIC Development Board
supplied by RS Components Ltd., Corby, Northants.) being introduced to the system. This
micro-controller directly monitors the linear actuator encoder and captures the velocity and
displacement data it outputs. The micro-controller software was written in C++ and controlled
via the same VB communication protocol as the GUI. The data captured shows the number
of 20µs pulses (50kHz) counted during a set number of absolute position changes (command
RL494). The number of absolute position was typically set at 160µm with 1µm data resolution.
The data resolution increased tenfold which made it possible to plot valid velocity profiles. In
torque mode the controller generates a current through the actuator coil producing a constant
force on the end of the drive shaft. If there is no resistance to movement, the rod will accel-
erate due to the applied force. Therefore it could be assumed that any velocity lost from this
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Figure 5.10: Tests performed into air and silicone rubber using the high speed software.
trajectory could be inferred as the force resisting the movement. This movement, both resisted
and unresisted, can be observed in the two different plots in Figure 5.10.
The acceleration is velocity dependent and so decreases as the velocity increases, hence the need
for a calibration curve. In order to achieve a range of ‘delivery velocities’ the origin of the y-axis
was set at the point where the penetration test begins. For instance, for the 1m.s−1 setting a
5.8mm stand-off was applied to achieve the set speed at the same time as the probe emerges from
the cassette, as shown in Figure 5.10. The stand-offs necessary for a range of speeds between
0.8–1.8m.s−1 were established through empirical testing.
(a) Velocity Calculation
The low speed software utilises the mathematical capacity of the LAC-1 to output decimal values
for velocity. The high speed software is only capable of transferring the velocity raw data from
the linear encoder into the results sheet in hexadecimal format. The data requires converting to
decimal in Microsoft Excel (2010).
The data dumped into the results spreadsheet contains a time value, p, being the number of
20µs pulses, t1, counted over the actual distance travelled, δd, between samples. The controller
was programmed to sample 160µm steps. Using the actual value travelled was more accurate
and the difference only ±1µm. The values for p and δd arrive in a data string that is parsed
from hexadecimal to decimal values in microns. p and δd are outputted from the Penetrometer
and converted into the results sheet calculating v, through the following set of equations;
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v =
δd
t
(5.1)
v =
δd
t1 × p ×K × 10
6 (5.2)
v =
δd
20× p ×
100
25850
× 106 (5.3)
The constant in Equation 5.2, K = 10025850 , is a necessary calibration factor based on actual
measurements during the development of the software. The formula was multiplied by 1 × 106
to convert the velocity readings into millimetres per second (mm.s−1).
(b) Force Calculation
The linear actuator only emitted limited data in open-loop torque mode as the current fluc-
tuations could not update quickly enough. Instead the force was inferred through the change
in v as the Penetrometer encountered resistance. The force to penetrate has been derived by
determining the deceleration at different points along the displacement during penetration.
Figure 5.11: Physical diagram of Penetrometer force.
When the Penetrometer is fired into a surface, a change in velocity is detected. The force that
the motor applies must be discounted from the result in order to detect the penetration force,
Fp. The total net force, FN , sensed by the Penetrometer is a combination of motor force, Fm,
required to drive the actuator less the penetration force, Fp, encountered. This relationship, as
shown in Figure 5.11, can be described by the following equation;
Fm = FN + Fp (5.4)
∴ Fp = Fm − FN (5.5)
The net output of the Penetrometer is reported back in hexadecimal and used to calculate
velocity, v, and time, t. As the mass, m, of the moving Penetrometer components, the drive
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shaft and probe catch sub-assembly are known to weigh 0.1kg therefore the net force, FN , can
be calculated using the equation;
∴ FN = ma = 0.1
dv
dt
(5.6)
To establish the total motor force, Fm, the moving mass is known to be m = 0.1kg, however the
acceleration, a, is unknown. The acceleration is not constant, it is velocity dependent. In order
to better describe a under these conditions empirical testing was performed and the quadratic
equation has been applied, shown in Equation 5.10, to a quadratic line of best fit (Equation 5.8)
rather than being derived from first principles.
Fm = ma (5.7)
v = it2 + jt+ k (5.8)
a =
∂v
∂t
= 2it+ j (5.9)
a =
∂v
∂t
= ±
√
j2 − 4i(k − v) (5.10)
∴ Fm = m
√
j2 − 4i(k − v) (5.11)
∴ Fm = 0.1
√
112.732 − 6.16(9.78− v) (5.12)
The Penetrometer was fired at 1m.s−1 into air both vertical, with the cassette end pointing down,
and at 45° from vertical orientations to establish whether gravity had an effect, the resulting
graph from this experiment is shown in Figure 5.12. The values from the line of best fit on this
graph (i = 1.54, j = 112.73, k = 9.78) can be used to describe a. The results also show that
orientation has minimal effect on the operation of the test rig. The Penetrometer was to be used
at 45° orientation but could also be operated vertically.
Through calculating Fm and FN it was possible to solve for Fp to plot the force resisting the
acceleration of the motor for each δd step and plot a force profile.
Fp = Fm − FN (5.13)
Fp = 0.1
dv
dt
− 0.1
√
112.732 − 6.16(9.78− v) (5.14)
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Figure 5.12: Penetrometer calibration curve to eliminate effect of moving mass showing the lines
of best fit for the test rig when held vertically and at 45° angle and fired into free air.
The graphs produced from this equation were highly dependent on the sample rate and accuracy
of the velocity data captured. Therefore a stringent calibration exercise was required to validate
the accuracy of the Penetrometer output.
(c) Sample Rates
With the high speed software dependent on velocity it was important to establish the correct
sampling rate. Before the introduction of the micro-controller the Penetrometer was limited
by the 200µs (5kHz) clock in the LAC-1. The clock on the micro-controllers was much quicker
and capable of counting 20µs pulses. The ability to alter the sample rate was built into the
GUI, the ‘set speed’ button programs in the sample rate as well as the target velocity in the
controller. A comparison of the sample experiment performed using various d increments is
shown in Figure 5.14; this includes the original sample rate of 1.66mm before the introduction
of the micro-controller.
After experimenting injecting silicone rubber at 1m.s−1 with different sample rates it was decided
the data would be measured in 160µm intervals. This sample rate was chosen as it yields ≈100
data points per graph over the 15.8mm travel for each experiment (including stand-off). The
software took<60 seconds to perform the test, capture the data in the micro-controller, dump the
data into the results file and plot an F against d graph. This was a specified software requirement
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due to the need to conduct in vivo non-clinical experiments efficiently and effectively.
When a results file was generated the raw data and a 5-point moving average (5PMA) were
automatically plotted, as shown in Figure 5.13. The 5PMA was used to smooth the data. Each
graph was observed during testing, if there any significant deviation between the raw data and
5PMA the experiment the test result was either investigated or repeated. Figure 5.14 vindicates
the use of a 160µm sampling interval in conjunction with a 5PMA as it is shown to convey the
penetration profile most clearly.
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Figure 5.13: An initial Penetrometer graph showing velocity and inferred force result.
0
2
4
6
8
10
12
14
16
18
20
0 1 2 3 4 5 6 7 8 9 10
Fo
rc
e
 (
N
) 
Displacement (mm) 
40μm (20pt moving average) 80μm (10pt moving average) 160μm (5pt moving average) 
320μm (3pt moving average) 480μm 1600μm  
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(d) Graphical User Interface
After establishing the communication protocols between the various sub-systems within the
Penetrometer the final software component that was required was an Excel-based graphical user
interface (GUI). A basic GUI had been designed whilst the software was in alpha phase. This
was enhanced further into a beta version reducing the complexity of the GUI so that it could
be operated with ease and minimal training.
The beta version of the GUI is shown in Figure 5.15a. The GUI serves to program the LAC-
1 controller with the test settings and provide a control panel to drive the linear actuator.
The buttons available to the user instruct the motor to go to the start, end and probe change
positions, set the speed and begin or stop the test. The data resolution (in microns) could be
entered here too.
Using a unique test number, the GUI pulls all the settings for each test from a larger Test
Schedule, as shown in Figure 5.15b. When the  button is clicked the settings for the next
test according to the schedule are inputted automatically. If settings for this test are different
to the last or planned to be performed with a different cassette, probe design or at a different
actuation force this is indicated on screen with a red flag.
Once a test was complete it appeared on a results sheet like those shown in Figure 5.15c–d.
This shows all of the test settings as well as a v against d and F against d plot with an overlaid
5PMA. The maximum force registered and the velocity registered at the y-axis intercept are
also indicated.
The beta version also served to make the software more robust and less susceptible to failure.
This was achieved through reducing the capabilities of the software. Although the Penetrometer
could perform at different speeds and with many configurations, this was not necessary as the test
rig was focused on understanding the skin which required many repeats with basic configurations.
This led to the software being configured to work at a single speed, 1m.s−1, with the standard
SDI cassette and, initially, only metal probes.
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5.4 Validation
The output of the Penetrometer required checking to ensure that the assembly and software was
capable of measuring accurately the required outputs during skin penetration. With the high
speed software it was vital that the v and d data was accurate as the F data was calculated
from it. The validation of the Penetrometer required two different methods, one for velocity and
one force. The velocity of the linear actuator was tracked using high speed photography and
the force output was confirmed using a bespoke test rig capable of logging force data at speeds
of 1m.s−1. The method of determining actuation force, Fa, when the Penetrometer was pressed
on a surface has also been verified.
5.4.1 Velocity (v)
The Penetrometer, as already described, runs two different versions of software. At low speeds,
in position mode, the velocity is controlled by the controller. When the high speed software is in
torque mode the motor simply accelerates for the intended target travel distance (≤25mm) and
the force is inferred from the drop in velocity as the metal probe is resisted pushing through a
substrate. In order to validate the velocity output from the linear encoder for both operational
modes the simplest method was to film the test rig during operation.
Method
The Penetrometer was fixed horizontally in a bench-mounted vice. The scene was lit using an
ARRILUX 400 Pocket PAR Light so that the metal probe could be observed clearly against a
white background. The experiments were filmed using a Photron SA3 high speed camera (HSC)
with Nikon 50mm f1.8 Lens and a 25mm extension tube. The extension tubes fitted between
the camera and lens. The farther away the lens was, the closer the focal point, the greater the
magnification. This combined with the 50mm lens resulted in x5 magnification gain. The set
up for the for the experiment is shown in Figure 5.16.
The Penetrometer was fired a metal probe at 6 different speeds between 10–1600mm.s−1 into free
air. The lighting conditions and frame rate were experimented with (between 500–16,000fps) to
ensure the study resulted in 3 clear videos of each of set up. The repeats helped determine how
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Figure 5.16: High speed camera set up for velocity calibration experiment.
reliable both the Penetrometer and experimental method were. The videos were captured using
Photron software supplied with the camera. Each video was captured by manually triggering the
camera and the Penetrometer software at the same time. The videos were then trimmed to the
relevant number of frames that covered the actuation and saved accordingly. This experimental
work was performed at the Sports Technology Institute, Loughborough University.
Data Analysis
The videos were analysed using Phantom Cine Viewer v2.0 software (Vision Research Inc.,
Wayne, NJ) preferred over the proprietary Photron software. The wedge-tipped end of the
metal probe was manually tracked as it emerged from the cassette, as indicated in the images
in Figures 5.17a–c.
(a) (b) (c)
Figure 5.17: HSC images of a metal probe emerging from cassette filmed at 12,000fps.
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The known cassette dimensions were used as a datum and to calibrate the distance tracked
within the software, resulting in a 45µm pixel size. The software outputs a ‘.csv’ format file of
the raw coordinate vs. time data. This data was then processed using Microsoft Excel (2010).
The measurements in the data analysis were limited by the 45µm pixel step size of each image
which created steps in the data. Therefore trends in the data were analysed by taking a five
point moving average to obtain a smoother graph.
Results
The velocity, v, against time, t, profiles generated from the high speed data analysis were overlaid
on those captured by the PIC micro-controller, shown in Figures 5.18a–b. The resulting graphs
from the studies performed at 10, 50, 100 and 1600mm.s−1 are shown in Appendix E. The results
show the v against d trajectories outputted by the Penetrometer and HSC were similar.
Any discrepancies within the graphs were believed to be a consequence of the resolution of the
HSC work being limited by the 45µm pixel step size. The HSC data was not as accurate as
the Penetrometer’s linear encoder that has a resolution of 1µm. Also, it was noted that in
both operational modes the software performed as intended either maintaining a low speed or
accelerating over the target distance. The feature apparent at the end of all of the high speed
graphs was due to the drive shaft immediately retracting at the end of a test.
The Penetrometer had been shown to work with the high speed software at three separate speeds.
There was nothing to suggest that the data could not be interpolated between the 400mm.s−1
gaps. However, after viewing the velocity results and understanding the effect the data sampling
had, the decision was made to focus on software stability (rather than flexibility) and using the
single delivery speed of 1m.s−1.
Using the test rig at 1m.s−1 with 6.25kHz sample rate yielded enough data to view the penetra-
tion event and could be processed and graphed in under a minute, an important consideration
knowing the time pressures during a non-clinical trial.
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Figure 5.18: Force vs. displacement graphs from Penetrometer velocity calibration experiment.
Data captured using Penetrometer and High Speed Camera (HSC) simultaneously.
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5.4.2 Penetration Force (Fp)
The Penetrometer was initially built as a portable test rig to measure penetration forces at
low speeds. During its development the Penetrometer software was adapted to be capable of
delivering of speeds of 800–1600mm.s−1 and does not now depend on the LAC-1 controller to
calculate the force. The velocity-based method it does use required calibrating at >1m.s−1 over
10mm displacement. One of the primary reasons the Penetrometer was built was due to the lack
of off-the-shelf equipment capable of measuring force over a large displacement at speed. Testing
machines such as the Lloyd LFPlus are only capable of registering force at rates of mm.min−1,
consequently what was required was a test rig that could capture rates in the region of m.s−1
to match the Penetrometer performance.
Force Calibration Test Rig
As both velocity (v) and displacement (d) data had already been validated through the HSC
work. This meant only force (F ) against time (t) required calibration and a simple load cell-
based test rig could be built to measure this. An initial concept sketch for this test rig is shown
in Figure 5.19a, before it was developed into the final design shown in Figure 5.19b.
The finished assembly of the bespoke test rig is shown in Figure 5.19c. It was comprised of an
analogue load cell capable of high data resolution. The load cell (part no: F308-Z4115 supplied
by NovaTech Measurements Ltd., Crawley, E. Sussex) is capable of 100N compression force but
was intentionally calibrated to 50N (+10V = 50N) to make the cell more sensitive to the lower
(a) Concept. (b) Design. (c) Finished assembly.
Figure 5.19: Images of the Calibration Test Rig.
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range. The load cell was secured to a machined steel mounting block that acted as a base and
also protected the cell from side loads during storage.
The load cell was connected to a Data Logger (part no: 200L Expert Key supplied by Delphin
Technology AG, Bergisch Gladbach, Germany) via an Amplifier (part no: SGA/D supplied by
Mantracourt Electronics Ltd., Exeter, Devon). The data logger was controlled using Delphin
ProfiSignal Go Software. A spring was placed between the cassette and the load cell to allow the
Penetrometer to extend and to transmit force between the test rigs without causing any damage.
The F against t plots produced by both the P1.0 software and captured in the ProfiSignal
software should be the same on both sides of the spring. As a spring was used both graphs were
also expected to be linear.
Method
The Penetrometer was placed on the purpose built stand and held vertically over the calibration
rig. In order to push on the spring, the Penetrometer used an entire modified cassette instead
of the metal probe. The whole cassette was pushed out by a metal striker probe into the spring
below. The calibration rig was positioned directly underneath the Penetrometer on top of a
thin silicone rubber sheet to prevent the test rig from moving during testing. The set up for the
experiment is shown in Figure 5.20. This experimental work was performed in on site in the
laboratory at Glide Pharma.
Figure 5.20: Calibration test rig set up for force calibration experiment.
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20 repeat tests were performed firing the Penetrometer at 1m.s−1 into the spring on the test rig
positioned underneath it. Each test was captured through manually triggering the ProfiSignal
Go Software and the Penetrometer software at the same time. The data logger was set to record
at 20kHz. The Penetrometer recorded the data at 6.25kHz.
Data Analysis
The force output of the Penetrometer was plotted against time. An example graph of test 308 is
shown in Figure 5.21a. The graph produced was linear, as expected, and the whole event lasted
≈12ms. The data logger outputs the raw data in a ‘.csv’ file format containing F against t data
and plotted using Microsoft Excel (2010). No smoothing of the data was necessary due to the
extreme sensitivity of the load cell.
The impulse sensed by the load cell during test 308 shown in Figure 5.21b over 1 second.
Figure 5.21c shows clearly the load cell being loaded and unloaded as it has been impacted by
the Penetrometer. Reducing the time axis down to a period of 12ms as Figure 5.21d shows how
comparable the force data from both test rigs were for test 308.
Results
The overlaid force, F , against time, t, plots from all 20 tests performed and the readings from
both test rigs are shown in Figure 5.22. The graph shows that the force readings of the Pen-
etrometer were close to those produced by the calibration test rig. The test rig readings were
measured using the calibrated load cell and the noise in the calibration data is likely to be from
the vibration of the spring in the experimental set up. The accuracy of the Penetrometer over
the course of an injection can consequently be assumed to be within ±1N.
The effects of the moving masses were calculated to determine whether they may be significant
to the outcome of the test. The mass, m, of the modified cassette and spring were known to be
1.43g and 1.29g, respectively. An acceleration value, a is 94.96m.s−2, was taken from real data.
The maximum total force that the moving components may have on the system were calculated
to be 258mN. This result was not considered significant across 25N as it registered as only 1%
of the overall force.
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5.4.3 Actuation Force (Fa)
The load cell assembled within the Penetrometer hand-held unit was designed to help control
the ‘actuation force’ during each injection, this being the amount of force by which the test rig
is pressed against the skin as it is fired. The test rig can be used with 1–6 pre-tensioned springs
in place to help measure the resistance. The software did register this force from the load cell as
it arrived in counts. The results of a simple calibration exercise are shown in Figure 5.23a. The
relationship proved to be linear and the calculation was embedded in the software to convert
force data from counts to Newtons.
y = 0.0597x + 5.5105 
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Figure 5.23: Calibration and method of indicating actuation force, Fa; (a) Actuation force load
cell calibration plot, (b) Cross-hairs on rear spring hanger.
Unfortunately the load cell became damaged during the initial experimental phase and a decision
was taken to continue testing without replacing it. However, enough tests had taken place before
this feature stopped working to establish that using 2 extension springs and pressing the hand-
held unit down by 5mm simulated≈24N actuation force, that of the SDI prototype configuration.
Cross hairs were manually drawn on the rear spring hanger, shown in Figure 5.23b, to indicate
5mm displacement to the user.
Using this visual method only approximated the actuation force (Fa) to be 24N. Although this
was not much of a concern as the force to actuate the simple mechanical mechanism in the
current prototype SDI device had also been shown to vary slightly. For continuity, Fa, despite
not being responsible for ‘actuating’ the Penetrometer, as it is for the SDI device, will remain
known as the ‘actuation force’.
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5.5 Operation
After completing the design, development, build and calibration phases of the Penetrometer the
test rig could be used for penetrative testing. This section defines the current capabilities of the
Penetrometer and how it was operated.
Current Capabilities
The software design decision to increase the target velocity of the test rig led to a compromise
in its stability. Although calibration had demonstrated that the test rig can travel at a range
of velocities between 0.01–1.8m.s−1, and output accurate v and d data, the software was not
robust enough to perform multiple repeats at these settings. The decision had been taken to
focus on achieving a single speed, 1m.s−1, repeatably. This reduced the demands sufficiently on
the GUI and simplified the requirements on the software.
The handset configuration was set up as close to the SDI prototype device as possible. The
current standard SDI cassette shape was used to deliver a 46° wedge-tipped metal probe to a
depth of 10mm. Although the Glide implant is only intended to be delivered subcutaneously,
the linear actuator has an allowable travel of 25mm; therefore to yield more data about the
behaviour beyond the subcutaneous layer, of skin, each test will go to a chosen set depth of
10mm. The force calibration experiment was conducted using this handset configuration at
1m.s−1. The software was shown to be reproducible and robust over multiple tests. Being able
to generate reproducible data was key to the experiments into skin. Any deviation observed
when penetrating objects in the test results would be due to the variation of the material being
tested.
The Penetrometer hardware met the design specification and was suitable for use in the labor-
atory on in vitro and synthetic materials and the test rig was portable enough to be transported
to non-clinical testing sites for in vivo work.
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Assumptions
There were several assumptions when using the Penetrometer to simulate a solid dose injection;
The penetration event initiated by a wedge-tipped metal probe was intended to simulate delivery
of an implant of the same design, albeit in the best case scenario (BCS) with the implant tip
being infrangible and the machined surfaces causing minimal friction. Without the feedback
from the load cell the actuation force, Fa, applied to the material could only be approximated
to be 24N when held still by the operator during actuation.
It was assumed that impacting a soft-solid material at 1m.s−1 with a probe was representative
of a 6m.s−1 SDI delivery. There may be rate effects associated with the viscoelastic response
of soft-solid materials. Although from the literature reviewed in Chapter 2 there was little to
suggest the rate effects would be an issue within this velocity range.
The final assumption was that the performance of the Penetrometer and metal probe were
sufficiently repeatable so that any variation detected could be attributed to the material being
penetrated.
Safety
Despite the Penetrometer’s design specification varying, no compromises were taken in the safety
of the test rig. The Penetrometer has several safety features built into the hardware and software
to make sure it does not damage itself or the user. These were as follows;
• Idle Mode - The software switches off power to the linear actuator if the GUI was inactive
for 5 minutes. This ensures that the motor does not overheat whilst stationary.
• Probe Catch - This ensures that a probe cannot leave the test rig during an actuation and
only when stationary and manually allowed to do so.
• Force Limit - If the probe is impeded sufficiently to register a force, currently set at 24N,
that could damage the linear actuator a fail-safe mode automatically retracted the probe.
• Hygiene - All external parts of the Penetrometer and the metal probes are sterilisable and,
if required, can be autoclaved after in vivo skin experiments.
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5.6 Initial Penetration Study into Silicone Rubber
The Penetrometer was first tested with a synthetic material before being used into skin. This
initial set of experiments had three purposes; to establish how repeatably the Penetrometer
performs into a control material, to explore the parameters that could be measured from the
resulting penetration profiles and to establish how time-efficiently the Penetrometer could be
used before a non-clinical study into in vivo skin.
To meet these objectives this work was required to be conducted in a a controlled environment
using a suitable synthetic material with uniform mechanical properties. As reported in Chapter
2, many different synthetic materials have been used by authors to simulate skin. The behaviour
of silicone rubber, a soft-solid, has been shown to be different from that of strong ductile solids
such as metals, soils and polymers and exhibits a similar penetration mechanism to skin [186].
5.6.1 Method
A clear 3mm silicone rubber sheet with 60° Shore A Hardness (Product no: FQ-T050 supplied
by J-Flex Rubber Products Ltd., Retford, Notts.) was selected from a range available. The
silicone rubber selected had a tensile strength of 10.5 MPa and tear strength of 14.7N.mm−1.
The silicone was placed over a 20mm thick expanded polystyrene sheet (supplied by The Poly-
shop Ltd., Worthing, W. Sussex). The polystyrene provided stiffness to the test bed and pre-
vented any damage to the metal probe once it penetrated. An experiment in § 4.2.3 had already
established the need to have another layer underneath the silicone material to better simulate a
delivery into in vivo skin supported by subcutaneous tissue and muscle.
(a) (b) (c)
Figure 5.24: The equipment used in the initial penetration study; (a) Silicone rubber sheet with
grid marked on expanded polystyrene, (b) 46° wedge-tipped probe front view and (c) side view.
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On the expanded polystyrene a simple 9cm2 grid was marked up with the 100 test sites, as
shown in Figure 5.24a. Each point in the grid was labelled A1–J10 and could be viewed through
the clear silicone rubber during the testing. The high number of repeats was required to fully
test the Penetrometer and establish a comprehensive data set that was to be used as a control.
A 46° wedge-tipped probe, shown in Figure 5.24b and 5.24c, was used as the penetrator. Images
were taken of the probe before testing to establish whether it blunted between experiments. The
standard cassette shape was fitted onto the front of the handset. The Penetrometer was suspen-
ded vertically in the support stand and pressed down onto the material with ≈24N actuation
force during each test.
The 100 tests were performed systematically across the grid from A1 through to J10. The
Penetrometer software was programed to deliver the probe at 1m.s−1 for all tests. The tests were
performed according to the Penetrometer equipment operating procedure (EOP) as described
in Appendix D.
5.6.2 Results
The resulting penetration profile from the first test into the silicone can be observed in Fig-
ure 5.25. The force against displacement plot shows the expected features from a penetration
event, these have been highlighted and are described as;
A An elastic deformation occurs as the skin deflects until penetration initiation. Point A is
where the peak penetration force is encountered.
B The silicone then ruptures, and the probe pushes through the back surface. How this feature
appears will likely depend on the thickness of the material penetrated.
C Once the probe emerges through the silicone rubber it remains subject to the drag force
through the soft-solid material.
D Any rise in force over this phase from C–D would be due to the viscous response of the
underlying tissue. In this case the expanded polystyrene does not exhibit this behaviour.
These features have been adapted for solid dose injection from the model proposed for hypo-
dermic needle injection by Brett [169].
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Figure 5.25: Penetration profile using a 46° wedge-tipped probe delivered through 3mm silicone
over 20mm expanded polystyrene at 1m.s−1. Raw data with 5-point moving average overlaid.
Including the features A, B, C and D as described by Brett [169].
The profiles from all 100 repeat tests are shown in Figure 5.26. As the Penetrometer was
shown to be repeatable through the calibration work any variation encountered was due to the
performance of the silicone during penetration at 1m.s−1 with a 46° wedge-tipped probe. The
correlation between the profiles appears to show that the Penetrometer and the silicone perform
repeatably. The slight divergence in the profiles beyond penetration was likely to be caused
by the imprecise nature of the relatively, to a needle, blunt penetration event and the slight
differences in drag and resistance from the expanded polystyrene underlayer.
For a better overview, all 100 repeats tests have been summarised into the three profiles shown
in Figure 5.27. This shows the average force encountered during injection as well as the highest
and lowest forces detected at each displacement across all tests.
The average profile provides an indication of the typical penetration profile through the silicone
rubber. The maximum and minimum show the variation in possible loads on the probe as it
passes through the silicone.
The total time taken for the 100 injections was 90 minutes. As well as generating silicone
control data it was important to establish how efficiently the test rig could be used. The
software remained stable and all planned injections were performed. The current method would
be acceptable for future work onto in vivo skin in a non-clinical environment.
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Data Analysis
Each of the penetration profiles produced during the silicone penetration study has been collated
and processed using Microsoft Excel (2010). The parameters that can be measured on every
penetration profile are shown in the Figure 5.28 and explained in Table 5.2.
Symbol Meaning Unit
Fp Peak force to penetrate N
σp Peak stress to penetrate MPa
dp Deflection to penetrate mm
Wp Work done to penetration mJ
Wi Work done to a 5.5mm injection depth mJ
Fsc Average force of sub cut after penetration N
k Skin stiffness N.mm−1
Table 5.2: Penetration parameters collected during each test, as shown in Figure 5.28.
The values of σp, dp and Wp are all depend the magnitude of the forces at point A, the peak
force required to penetrate the skin, Fp. This may not necessarily be the force where penetration
has been initiated. Instead, it is the peak force encountered during the penetration event and
the point where the implant is placed under the greatest load. This penetration force can be
converted approximately into a peak penetration stress, σp, using the following calculation;
σp =
Fp
A
(5.15)
σp =
Fp
pi × 0.4252 (5.16)
This assumes a worst case scenario (WCS) and the cross-sectional area of a blunt 0.85mm
implant. In reality, the geometry of the implant tip and interaction with a soft-solid material
would require further research in order to ascertain an accurate stress value.
The forces and WCS stress value, σp, outputted from the Penetrometer are relevant to the
implant design problem Glide is trying to solve. Accounting for the WCS and applying a safety
factor will allow Glide to develop implant formulations that can better cope with the stresses
anticipated during penetration.
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The deflection to point A, dp, indicates how far the probe (or implant) has travelled when it
encounters the peak force, Fp. The Penetrometer was never expected to be sensitive enough to
detect when penetration is actually initiated. Instead, and importantly to Glide, it can detect
when the peak force and the displacement that this occurs at. This is particularly relevant to
the delivery of 4mm implants as they may buckle and encounter a high force very late during
injection. The work done to penetrate Wp has been calculated from the cumulative force on the
probe registered until dp.
The total work to inject the probe to a 5.5mm depth, Wi, is the total energy required for a Glide
implant of the current 4mm design to be pushed in by 1.5mm under the skin; as is the case in
the current SDI cassette design.
The parameter Fsc is the average force during the C–D phase, representing the level of resistance
that the subcutaneous region provides. The stiffness of the material, k, is the stiffness of a
material as the implant impacts it, whilst an actuation force is applied. It was measured and
used to inform the design of a representative synthetic test bed in Chapter 6.
The results from the data analysis of the silicone testing is shown in Table 5.3. These numbers
will act as a control throughout all further experimental work with skin.
Parameter Mean ±SD Unit
Peak force to penetrate 16.3 ± 0.4 N
Peak stress to penetrate 28.8 ± 0.7 MPa
Deflection to penetrate 2.2 ± 0.2 mm
Work done during penetration 24.0 ± 3.5 mJ
Work done during injection 58.8 ± 1.9 mJ
Average force of sub cut after penetration 10.2 ± 0.6 N
Table 5.3: The results for each penetration parameter from the initial penetration study using
silicone rubber, Mean ±SD (n = 100).
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5.7 Chapter Summary
This chapter has shown how the need for a novel skin penetration test rig arose and has been
justified, specified, designed, built, programmed and, most importantly, validated before its use
on skin. The calibration experiments were critical to ensuring that the output from the bespoke
test rig was accurate and that it was capable of detecting the forces during a solid dose injection.
This was demonstrated to be the case and the test rig has been proven to be reliable.
During the software development, the Penetrometer’s velocity was increased to 1m.s−1. Al-
though not capable of a range of velocities, as originally intended, it was more important that
the test rig was repeatable and the penetration properties of materials, and how they vary,
were captured. This work has been conducted at a single speed. Further work to expand the
capabilities of the Penetrometer could later be undertaken but only when the skin behaviour is
better understood.
The test rig has proven capable of measuring force profiles similar to those reported for skin
penetration [157,158,161,169]. The profiles feature four distinct stages, these being; the elastic
deformation before penetration is initiated, a peak force detected during penetration, the force
then falls as the probe passes through the material before emerging with only drag detected as
the probe passes into an underlying layer. What differentiates the Penetrometer performance
from test rigs previously used in literature is the combination of the relatively fast delivery of a
unique penetrator (a wedge-tipped probe) into a soft solid material whilst a force, Fa, is applied
to the surface through the cassette face. The test rig portability meant it could be used to
conduct experiments on skin in vivo.
Analysis of the force profiles produced by the Penetrometer into a silicone rubber have shown it
was possible to measure several parameters during penetration. The average penetration force,
Fp, is now known to be 16.3 ±0.4 N (x¯ ± σ) and occur after a deflection, dp, of 2.2 ±0.2 mm.
The energy required to inject to a depth of 5.5 mm, representative of an SDI injection depth, is
58.8 ±1.9 mJ albeit the metal probe performance is likely to be superior to that of an implant.
The experimental method employed on the synthetic material, including the provision of 100
repeats and the use of a grid pattern, has proven to be valid and achievable ahead of work to
be performed onto skin in Chapter 6. It was anticipated that skin would behave differently and
that a greater variation would be detected across the measured penetration parameters.
Chapter 6
Investigations into Skin Penetration
The Penetrometer has been built and proven capable of capturing penetration profiles in silicone
rubber. This chapter documents its use conducting investigations into in vivo skin to generate
quantitative data to describe penetration into a porcine model as the best available substitute
for human skin.
Two separate studies have been performed; the first to understand the existing test site, the neck
of a 25kg porcine model, historically used by Glide. The second study explored the suitability
of other possible test sites, the effect of model size and amount of variation. The data generated
led to the design and proposal of an in vitro test bed as an alternative to in vivo skin.
6.1 Introduction
Initial investigations into skin properties in Chapter 4 showed that to measure the forces during
in vivo skin penetration a novel test rig was required. Chapter 5 has documented the build
and verification of this test rig known as the Penetrometer. This chapter details the subsequent
investigations into skin penetration that have been performed to quantify and understand the
role of the skin in the needle-free delivery of a solid dose.
The basis for selecting the skin of the porcine model as a non-clinical skin model has been
revisited. The in vivo and in vitro testing penetration methods are outlined, as are the data
analysis methods that have been applied. The number of repeats used for the methods (n = 100)
has been kept intentionally high to ensure that sample groups are representative and variation,
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if present, could be detected.
The investigations have been split across the following two separate studies;
1 The initial penetration study was designed to investigate the intra-site variation on the in
vivo neck site of a 25kg male porcine model, how penetration properties altered in in vitro
skin and how variable the data was compared to the silicone rubber results from § 5.6.
2 A further study was designed to compare two different sized models across three different test
sites to understand whether size and site altered the penetration characteristics. The data
collected was compared to the initial study results for the purpose of detecting the intra-model
variation.
The findings from the two studies are summarised and the implications of using in vivo skin
as a penetration test have been discussed. Based on the data available, further experimental
work has shown how a relatively simple in vitro test bed can be developed. Such a test bed can
be used as a tool to develop the implant and SDI device design by removing the effects of skin
variation, simplifying device testing and evaluation.
6.2 Non-Clinical Model Selection
The porcine model is a widely accepted non-clinical model to study a range of medical applic-
ations such as cardiovascular disease, kidney stones, communicable disease and obesity [212].
Typically the most reported porcine models are the domestic Large White pig (Sus scrofa) and
the Minipig, a breed specially developed for medical research [213,217].
As reported in § 2.5.2, pig skin is readily available and shares comparable microscopic character-
istics with human skin [215]. These attributes make the porcine model suitable for research into
cutaneous pharmacology, toxicology, wound healing, sunburn assessment, suturing and trans-
dermal drug delivery [27, 206]. It is worth noting however that most of this research seeks to
exploit only the superficial similarities between the models and not the mechanical properties.
Few authors have reported the mechanical properties of pig skin and fewer still have performed
research into penetration mechanisms similar to the Glide SDI device [43, 128]. Therefore it is
necessary to produce first-hand data to quantify and understand skin penetration with a solid
dose into the porcine model.
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Historically Glide has tested the system performance on the porcine model, as detailed in § 3.2.2.
The inguinal site was favoured when conducting pharmacokinetic (PK) studies, due to the
vasculature of the underlying tissue. The inguinal site is not hairy and is not exposed to the
elements and so has a similar structure, look and feel to human skin. The current prototype
SDI device did deliver implants successfully to this site. The test site was then moved to the
neck where both PK and dermal tolerability could be assessed from the same injection.
The neck skin proved more difficult than the inguinal site, as did the rump. Whether an implant
could penetrate the neck became considered overtime the standard penetration test for how well
the drug delivery system performed. Prior to the Octreotide clinical trial, a success rate of 40%
(4 of 10) had been achieved at the neck site of the porcine model. At the time pig neck skin was
anecdotally thought to be more difficult to penetrate than human skin. However, the lack of
successful penetration into human skin at clinic, only 66% (12 of 18), showed that belief to be
unfounded. For this reason quantitative data of skin penetration at the three test sites (inguinal,
neck, rump) was required to determine how useful each site truly was to test penetration.
The porcine models used by Glide were Large White pigs of either 25kg for penetration testing
or 75kg for PK studies. This weight is representative of an adult human and the blood volumes
are equivalent. The gender of the models tested was never specified. This may have affected the
interpretation of the results of previous penetration studies since skin thickness has been reported
to be influenced by gender. Wood et al. [219] reports that on average male skin (epidermis and
dermis) is thicker than female skin, citing the presence of androgens as the cause. Laurent et
al. [108] has also observed this same trend in human skin thickness, for subjects between ages of
18 and 70, that males have thicker skin than females (n = 205 ♀, 137 ♂). Since skin thickness
is known to correspond to larger penetration forces [198], all experimental work in this chapter
has been conducted using a male porcine model.
It remains likely that the porcine model is the most suitable skin model for Glide. However,
much more must be known about the skin; its response to penetration, how this varies within
a test site, across sites and across models. The two studies described in this chapter have been
conducted across three Large White male pigs. The initial study was performed on a ‘small’ 25kg
model (H12a). The second study used a ‘large’ 76kg model (H14b), to discover whether skin
thickness or age may affect penetration, and another ‘small’ 26kg model (H14a), comparable in
size to the H12a model, was used as the control between the studies.
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6.3 Methods
The skin penetration experiments were designed to be as similar as possible to previous Glide
SDI non-clinical penetration testing. However, the Penetrometer took the place of the SDI and
a 46° wedge-tipped metal probe has replaced the implant. With these two parts of the system
capable of behaving repeatably, any variation detected would be due to the response of the skin.
The testing method has been adapted from that used on the silicone rubber testing reported in
§ 5.6.1.
At each test site a sample size of 100 penetration tests was collected across a 9cm2 area. Each
individual test was spaced 1cm away from the last. To achieve this on in vivo skin a 10 × 10
gridded template was made, shown in Figure 6.1a. Each penetration test was given a coordinate
(A1 to J10) and the orientation, shown in Figure 6.1b. These coordinates were fixed throughout
regardless of the test site and whether it was on the right- or left-hand side of the model. Using
a grid in this way meant each test was traceable to its location within the test site. The value
of this has been explored in Chapter 7.
The injections were performed sequentially from A1 through to J10. Randomised methods were
considered but dismissed as given the limited time and pressures working on a non-clinical model
they would likely increase the opportunity for manual error. Instead, controls were put in place
to ensure the sequence of the tests did not bias the results. The results from all tests were viewed
at the end of each study to check for any experimental or time based effects. Also images were
taken of the probes before and after each study to ensure they did not blunt.
(a) (b)
Figure 6.1: (a) Image of the 10 × 10 silicone gridded template used to mark out the skin test
sites, (b) diagram showing the orientation of the test site coordinates with respect to the model.
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Also included in the method was a step where a Glide operator assessed the skin testing site and
marked off areas that an SDI device would not normally be tested. This subjective assessment
is typically performed prior to non-clinical work to remove the influence of the presence of
underlying structures or visible skin damage. This experimental step was performed only on the
neck sites of the two small models, H12a and H14a. Data analysis later in § 7.2.3 has shown
how worthwhile this measure was.
The step by step instructions of the in vivo and in vitro penetration testing methods are illus-
trated in Figure 6.2.
6.3.1 In Vivo Penetration Testing Method
This method was performed with the Penetrometer configured with the standard cassette profile
pressed with ≈24N actuation force and delivering a 46° wedge-tipped metal probe at 1m.s−1 to a
depth of 10mm. This test configuration was intended to emulate an SDI injection albeit slower,
deeper and with a sharper penetrator.
All non-clinical in vivo experiments were performed under license by a Contract Research Or-
ganisation (CRO), Harlan Laboratories UK Ltd (Belton, Leics.).
The model was first anaesthetised, weighed and placed on a table. The skin was shaved to
remove hair from selected test sites. The following steps were then performed;
1 The 9cm2 gridded template, shown in Figure 6.1a, was placed on the skin surface.
2 The 100 tests were marked using indelible pen each 1cm apart in a 10 × 10 grid according to
the orientation shown in Figure 6.1b.
3 For the neck site of H12a and H14a only - a Glide Pharma operator then indicated any areas
that would not usually be tested due to detectable underlying features or visible skin damage.
4 100 tests were performed using the Penetrometer, in sequence from A1 through to J10, in
accordance with the Equipment Operating Procedure in Appendix D.
5 After the study was completed the model was sacrificed and each test site was excised.
6 The skin was then pinned out on expanded polystyrene, to retain its shape, and placed on
wet ice for transportation before being stored in a freezer at -8 to -10°C until required.
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It was possible to carry out this full method on two test sites per model within the total
permissible study time window of ≈3 hours. The full method was used for all in vivo neck and
rump site testing. The inguinal site was only subject to 10–20 tests for comparison purposes
and for this reason the tests were neither gridded nor the skin excised.
The excised skin samples were cooled, at a slow rate, on wet ice and then in the freezer at -8 to
-10°C. Freezing the skin may damage the skin cells as they experience osmotic dehydration [3].
At higher cooling rates the opportunity for the water to pass out of the cells is limited and
cryoprotective agents could be used to preserve the barrier properties of the skin. However,
due to the size of the excised skin samples, it was not possible to freeze them with the basic
equipment available at the CRO facility. Cutting the skin sample into smaller pieces to freeze
was not practical either as this would significantly alter the behaviour when later performing in
vitro experiments.
6.3.2 In Vitro Penetration Testing Method
The non-clinical in vitro method was performed with the same Penetrometer configuration as
stated in steps 1–6 in the In Vivo Penetration Testing Method.
The following steps were then performed under laboratory conditions at Glide Pharma;
7 An excised sample was selected for experimentation.
8 Thaw the sample to room temperature (18–21°C) over a 4 hour period.
9 The gridded template was used to mark up 100 injection sites in close proximity to the previous
set in step 2.
10 The 100 tests were performed using the Penetrometer, in sequence from A1 through to J10,
in accordance with the Equipment Operating Procedure in Appendix D.
The in vitro testing was performed at room temperature after attempts to warm the skin to 37°C
proved problematic. The necessary support layer of expanded polystyrene (to protect the metal
probe during testing) is a very good insulator making warming through conduction impossible.
Also, the length of time required to complete the testing, approximately 90 minutes, meant
either using a water bath or convection to warm the sample would have led to the skin either
dehydrating or becoming water-logged.
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6.3.3 Data Analysis
The Penetrometer outputs a force profile that provides quantitative data during a penetration
test. An initial penetration profile into in vivo skin is shown in Figure 6.3.
The fluctuations in force in the raw data are believed to be caused by the limitations in the
displacement data resolution of the Penetrometer, but may be partly due to the heterogeneous
properties of the skin. A 5-point moving average (5PMA) has been applied to smooth out short-
term fluctuations and show the longer-term penetration event, demonstrated in Figure 5.14.
From observing the profile in Figure 6.4, the penetration event can be described as;
A An elastic deformation occurs as the skin deflects until penetration is initiated.
B The skin yields, and the probe pushes through the dermal layer.
C The penetrated skin then exerts a drag force on the probe.
D Any rise in force between C–D is due to the resistance of the underlying tissue.
There are various penetration parameters that can be measured by processing the profiles. These
are shown in Figure 6.4 and described in Table 6.1.
The peak force to penetrate, Fp, and the displacement that occurs, dp, are the most important
parameters measured within this chapter. Understanding these and describing how they vary
will ultimately inform the design of the drug delivery system. Values for σp and Wp are derived
from Fp and dp, so the significance of the findings will be transferable to the penetration stresses
and energies detected. k has not been calculated but instead was used qualitatively to compare
the skin response before penetration. Fsc and Wi have been measured for each penetration test
and their significance has been addressed in § 7.2.2 and § 7.3, respectively.
Symbol Meaning Unit
Fp Peak force to penetrate N
σp Peak stress to penetrate MPa
dp Displacement to peak penetration force mm
Wp Work done to penetrate mJ
Wi Work done to a 5.5mm injection depth mJ
Fsc Average force of sub cut after penetration N
k Skin stiffness N.mm−1
Table 6.1: Penetration parameters collected during each test, as shown in Figure 6.4.
Chapter 6. Investigations into Skin Penetration 160
02468
1
0
1
2
1
4
1
6
1
8
2
0
0
1
2
3
4
5
6
7
8
9
1
0
FORCE (N) 
D
IS
P
LA
C
EM
EN
T 
(m
m
) 
F
ig
u
re
6
.3
:
In
it
ia
l
in
vi
vo
sk
in
p
en
et
ra
ti
on
p
ro
fi
le
p
er
fo
rm
ed
on
n
ec
k
te
st
si
te
of
H
12
a
m
o
d
el
(2
5k
g
♂)
u
si
n
g
a
4
6°
w
ed
g
e-
ti
p
p
ed
p
ro
b
e
d
el
iv
er
ed
at
1m
.s
−1
.
B
o
th
ra
w
P
en
et
ro
m
et
er
d
at
a
a
n
d
5
P
M
A
(b
ol
d
li
n
e)
ar
e
p
lo
tt
ed
.
Chapter 6. Investigations into Skin Penetration 161
02468
1
0
1
2
1
4
1
6
1
8
2
0
0
1
2
3
4
5
6
7
8
9
1
0
FORCE (N) 
D
IS
P
LA
C
EM
EN
T 
(m
m
) 
A
 
B
 
C
 
D
 
k
 
W
I 
W
P
 
F
sc
 
F
p
 
σ
p
 
d
p
 
F
ig
u
re
6.
4
:
In
it
ia
l
in
vi
vo
sk
in
p
en
et
ra
ti
on
p
ro
fi
le
,
sh
ow
n
in
F
ig
u
re
6.
3,
sh
ow
in
g
m
ea
su
re
d
p
ar
am
et
er
s
d
u
ri
n
g
p
en
et
ra
ti
o
n
,
a
s
d
es
cr
ib
ed
in
T
a
b
le
6
.1
.
Chapter 6. Investigations into Skin Penetration 162
Graphical Analysis
Every penetration test results in a penetration profile. To more easily compare the data from
multiple tests (n ≤ 100), they have been expressed as the maximum, minimum and mean average
force at each displacement to provide a better general overview of the data.
Scatter plots are used to show Fp against dp indicating the ‘point of penetration’ for each test.
Range plots are used to provide a summary of the scatter plots and show the mean average Fp
against dp. The error bars indicate the range of the data.
The box and whisker plots (referred to as box plots) are used to assess and compare the central
tendency and variability of sample distributions. Box plots show the first and third quartiles, the
median (horizontal line) and the mean (3 symbol) of the data. The upper and lower whiskers
indicate the range of the data.
Statistical Analysis
To determine the effect of test site on skin penetration intra- and inter-porcine models the data
was analysed as follows;
Hypothesis tests for equality of variance (Levene’s test) were applied to compare the variability
between sample groups and/or test the validity of equal variance assumptions prior to application
of parametric testing. Outliers were not excluded unless attributed to a special cause.
Two-sample T-tests were used for pairwise comparisons of mean responses (Fp, dp) for inde-
pendent test injection site sample groups. The one way analysis of variance (ANOVA) and
post-hoc Tukey test was used for multiple comparisons of mean responses for porcine model
and test injection site sample groups (differences are considered significant where the Tukey
95% simultaneous confidence interval for the combination of means excludes zero). A paired
T-test was used to assess the difference in mean response (Fp, dp) for in vivo and in vitro sample
groups. For all tests, P ≤ 0.05 was considered significant. All data expressed as Mean ± SD. The
coefficient of variation (%CV) was calculated to allow comparison of variability across groups of
data. Differences between means have been expressed as Mean (95% CI).
Microsoft Excel (2010) and Minitab Statistical Software (v15.0) were used for the data, graphical
and statistical analysis.
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6.4 Results from an Initial Penetration Study into Skin
The initial penetration study took place on a single small porcine model, H12a (25kg, male).
This study was designed to provide initial quantitative penetration data and to understand the
amount of variation detectable in the response of in vivo and in vitro skin.
The data captured was used to compare the in vivo skin response on the left and right-hand
sides of the neck on a single model. Testing in in vitro skin has been performed to establish
how suitable the biomaterial may be as a penetration test bed for the SDI device. The skin
results captured on the H12a model have also been compared to those of for silicone rubber data
generated in § 5.6.
6.4.1 Intra-Site Variability in a Single Model
Using the in vivo penetration testing method, outlined in § 6.3.1, the left-hand side (LHS)
and then the right-hand side (RHS) of the model were injected injected 100 times with the
Penetrometer.
The penetration profiles for the LHS and RHS are shown in Figure 6.5a and 6.5b respectively.
One of the profiles into the RHS neck was removed as the data was erroneous due to operator
error whilst using the Penetrometer.
The two sets of profiles appear to have a similar general profile and distribution. Of all the
experiments within this chapter this result would have been the most expected as both test sites
should effectively mirror each other as appear on either side of the neck of the same model. For
both sites on the neck the penetration event appears to be over after a displacement of 3mm,
beyond then the probe has passed through the skin and into the subcutaneous tissue below.
The maximum and minimum lines shown in Figure 6.6a heavily overlap indicating both sites
have a reasonably similar range of forces detected. The peak forces, Fp, appear to be greater
on the RHS than the LHS and the average force at the point of penetration does also appear to
differ slightly, as shown in Figure 6.6b.
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(a) Penetration profiles from tests performed on left-hand side neck test site (n = 100)
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Figure 6.5: All penetration profiles from tests in the H12a porcine model (25kg ♂) on the (a)
left-hand side and (b) right-hand side of the in vivo neck site.
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Figure 6.6: Graphs showing the (a) maximum, minimum and mean average penetration profiles
and (b) scatter plot of Fp against dp from data collected in the H12a porcine model (25kg ♂)
on the left-hand side (n = 100) and right-hand side (n = 99) of the in vivo neck site.
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Figure 6.7: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured in vivo in the skin of a H12a porcine model
(25kg ♂) at sites located on the RHS and LHS of the neck (∗ = P ≤ 0.05, two-sample T-test).
A broad range of Fp values were observed, ranging between 7.01–11.40N for the LHS sample
group and 7.20–12.00N for the RHS sample group. The range of dp values observed was similar,
for the LHS (0.81–2.42mm) and RHS (0.81–2.44mm) side of the neck.
The variability (SD; %CV) in the force to penetrate the skin, Fp, on the LHS (0.90N; 10%)
and the RHS (0.96N; 10%) of the neck was similar (P = 0.559), as shown in Figure 6.7a. The
variability in displacement, dp, was higher for the RHS (0.33mm; 24%) of the neck compared to
the LHS (0.27mm; 22%), as shown in Figure 6.7b(P = 0.046).
The average force to penetrate the skin, Fp, on the RHS of the neck (9.46 ± 0.97N) was signi-
ficantly greater (0.71N; 95%CI 0.45, 0.97N) than that required for the LHS (8.75 ± 0.90N), as
shown in Figure 6.7a (P < 0.001). The average displacement, dp, observed for skin on the RHS
of the neck (1.37 ± 0.33mm) was significantly greater (0.13mm; 95%CI 0.05, 0.22mm) than that
observed for the LHS (1.24 ± 0.27mm), as shown in Figure 6.7b (P = 0.002).
This initial experiment performed on the H12a model has shown that the Penetrometer is capable
of measuring in vivo skin penetration parameters. The statistical significance of the difference in
results between the LHS and RHS is not of practical interest when compared to the large ranges
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captured between the Fp and dp values on both neck test sites. The penetration point can occur
between 0.81–2.42mm (dp) and between 7.01–11.40N (Fp) within a single a single subject, on
either side of the neck, indicating the extent of the intra-site variation on the porcine model.
6.4.2 Comparison of Penetration into In Vivo and In Vitro Skin
Following the in vivo work, both neck test sites were excised. The right-hand side (RHS) was
retested according to the in vitro method outlined in § 6.3.2. The RHS neck test site is shown in
vivo in Figure 6.8a. After the skin was excised, placed on expanded polystyrene and first pinned
in each corner the sample contracted in the Dorsal–Ventral axis, as shown in in Figure 6.8b,
demonstrating the effect of Langer’s lines.
When excising the in vitro skin sample it proved problematic to remove a uniform thickness
across the sample. After thawing it was apparent the underlying tissue on the RHS sample had
been closest to the cranium had shrunk back and 10 injection sites A1–10 could not be used.
Ninety repeat tests were performed elsewhere on the sample with no failures.
The resulting penetration profiles have been summarised into maximum, minimum and mean
average profiles and overlaid onto the in vivo data for the RHS of the neck as shown in Fig-
ure 6.9a. The general shape of the penetration profiles are similar up until a feature in the in
vitro data that can be observed between 3–8mm is most likely caused by the differing thickness of
the underlying tissue before the probe encounters the expanded polystyrene. Figure 6.9b shows
that there are more instances where Fp in the in vitro sample appears to be slightly higher and
occur at a smaller dp than the in vivo data.
(a) (b)
Figure 6.8: Images of the H12a model RHS neck testing site (a) in vivo and (b) in vitro pinned
onto expanded polystyrene which demonstrates well the effect of Langer’s lines caused by the
latent skin tension.
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Figure 6.9: Graphs showing the (a) maximum, minimum and mean average penetration profiles
and (b) scatter plot of Fp against dp from data collected in the H12a porcine model (25kg ♂)
RHS neck site in vivo (n = 99) and in vitro (n = 90).
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Figure 6.10: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured in the skin of a H12a porcine model (25kg ♂)
at RHS neck site in vivo and in vitro (∗ = P ≤ 0.05, two-sample T-test).
A broad range of values in force to penetrate the skin, Fp, were observed, ranging from 7.20N
to 12.00N for the in vivo sample group and 8.12N to 12.43N for the in vitro sample group.
The displacement, dp, values ranged from 0.81mm to 2.44mm for the in vivo sample group and
0.65mm to 1.78mm for the in vitro sample group, as shown in Figure 6.10b.
The variability (SD; %CV) in Fp values in the in vivo (0.96N; 10%) and the in vitro (0.93N; 11%)
was similar, as shown in Figure 6.10a (P = 0.559). The variability in dp values was higher for the
in vivo (0.30mm; 23%) compared to the in vitro skin (0.24mm; 24%), as shown in Figure 6.10b
(P = 0.005).
Pairwise comparison of the population means in Figure 6.10a shows that the average force to
penetrate the skin, Fp, on the in vitro skin (10.35 ± 0.93N) was significantly greater (0.92N;
95%CI 0.68, 1.15N) than that required for the in vivo skin (9.44 ± 0.90N) (P < 0.001).
The average displacement, dp, of 1.32 ± 0.30mm for the in vivo skin was significantly greater
(0.31mm; 95%CI 0.23, 0.38mm) than the 1.02 ± 0.24mm observed for the in vitro skin (P
< 0.001).
This experiment has shown in vitro skin to be similar in its response to penetration as in vivo
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but just as variable. Figure 6.10a shows that the range of Fp detected are similar (7.2–12.43N).
However, the dp response of the in vitro skin has been significantly compromised either through
the lack of skin tension, the effect of post-processing or by the way the material was supported
during testing. In reality, it is likely to be a combination of these factors.
Importantly it is worth noting, despite the 89 comparable tests, that this is only a single subject
and single site that has been removed (n = 1). More work would be required to preserve
mechanical properties if in vitro is to be used. In vitro skin can imitate in vivo conditions, but
as it is still subject to as much variation, it would be better to carry out device and implant
development on a synthetic material designed to behave like skin but with uniform mechanical
properties.
6.4.3 Comparison of Penetration into Skin and into Silicone Rubber
Silicone rubbers have been reported in literature as suitable in vitro test beds for mimicking
skin penetration [158,186]. The in vivo neck site results have been compared to those from the
3mm thick silicone rubber (Product no: FQ-T050 supplied by J-Flex Rubber Products Ltd.,
Retford, Notts.) originally presented in § 5.6. This comparison has been made to understand
how representative the penetration profile in a synthetic material is to that of skin.
All penetration profiles from tests in the H12a porcine model (25kg ♂) on the left and right-hand
side of the in vivo neck site combined and shown in Figure 6.11. The maximum, minimum and
mean average penetration profiles from this data has been compared with the silicone rubber in
Figure 6.12a
Figure 6.12a clearly shows distinct differences between the penetration profiles for in vivo skin
and silicone rubber. The average stiffness of the materials over the first 1mm appeared to
be similar, but the Fp and dp values were much greater for the silicone rubber, as shown in
Figure 6.12b. The scatter plot also indicated that the variation of the point of penetration of
the silicone rubber was also less variable.
Beyond the point of penetration, the in vivo skin exhibits a low coefficient of friction as the
drag forces encountered were lower. However there is a large variation within these forces, as
observed in Figure 6.11 where a difference of ≈6N between the maximum and minimum forces
measures at each displacement can be observed from 3mm onwards.
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Figure 6.12: Graphs showing the (a) maximum, minimum and mean average penetration profiles
and (b) scatter plot of Fp against dp from data collected in the H12a porcine model (25kg ♂)
in vivo neck site (n = 199) and in 3mm thick silicone rubber (FQ-T050) (n = 100).
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Figure 6.13: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured in the H12a porcine model (25kg ♂) in vivo
neck site and in 3mm thick silicone rubber (FQ-T050).
As shown in both Figure 6.13a and Figure 6.13b the peak force (Fp) and displacement (dp) for
the silicone rubber sample group was shown, in both instances, to be greater and with a smaller
variance than the in vivo skin sample group.
A T-test was not required as the mean was not of any practical significance, instead the variance
and CV were. A Levene’s test has indicated that the variances are not equal for either Fp (P
< 0.001) or dp (P = 0.044). This indicates that the synthetic material, the silicone rubber, is
significantly less variable on both accounts.
The range of force for the in vivo skin measurements was 4.99N whilst the range of silicone
rubber was much lower at 1.68N. The coefficient of variation for the Fp on the neck was 11% but
on the silicone was only 2%, making the in vivo skin measurements on the neck 5 times more
variable according to CV. Similarly the range of displacement of in vivo skin measurements on
the neck for dp was 1.63mm whilst the range of silicone rubber was 1.10mm. Comparing the CV
measured for in vivo skin (23%) against silicone rubber (10%) has again shown that the in vivo
skin measurements are much more variable according to CV, although the difference in CV for
dp are not as great as they are for Fp.
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6.4.4 Review of an Initial Penetration Study into Skin
The in vivo skin at the neck site of the H12a model was tested as this was the porcine model that
Glide had used for SDI penetration testing, a 25kg Large White male, as discussed in § 3.3.3.
The initial penetration study performed on this single model (H12a) has demonstrated the
quantitative data that can be obtained from penetration experiments on in vivo skin using
the Penetrometer. The study has shown the amount of variation in both dp and Fp, how the
penetration properties compare with in vitro skin and the potential of using a synthetic material
as an alternative penetration test bed.
The differences in the mean average between the sample groups in the LHS and RHS neck sites of
Fp 0.71N (0.45, 0.97N) and dp 0.13mm (0.05, 0.22mm) were shown to be statistically significant.
However this finding was of little practical significance when compared to the general intra-site
variability detected for the range of data. The range and %CV for Fp ≤ 4.80N (10%) and dp
≤ 1.63mm (24%) in extreme cases show how variable the penetration data is within the in vivo
skin on a single subject.
The RHS neck skin site was retested in vitro to see how the penetration parameters were
affected and whether in vitro skin was a suitable testing surface for the Glide SDI. Whilst the
Fp response of the in vitro skin was comparable, actually requiring 10% (0.92N) more force at
peak penetration than in vivo skin, the dp response of the in vitro skin was 31% (0.31mm) lower
indicating it was different to the in vivo response and less representative.
Comparing the in vivo skin data to tests performed on silicone rubber has shown the potential
of using a synthetic material as a development test bed as variation can be better controlled.
The %CV for the in vivo skin were 23% (Fp) and 10% (dp) compared to only 10% (Fp) and 2%
(dp) for the silicone rubber.
The study data has been summarised in Table 6.2 later in § 6.5.3. The findings have shown that
to use in vivo or in vitro neck skin as the only test surface to assess penetration performance,
and thus inform the system design, could be misleading as the results are prone to the inherent
variability of the skin and its response.
The data generated within this study only applied to a single subject, to understand the variation
in performance between porcine models and the influence of test site further testing was required.
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6.5 Results from a Further Penetration Study into Skin
A further penetration study has been performed with an expanded scope to include two different
sized male porcine models. Another small model was used, the H14a subject (26kg) was a
comparable size to the H12a model (26kg), and a much larger model H14a (76kg). The scope
included injecting across three test sites; the neck and inguinal sites (previously used for SDI
development) and the rump site. The data captured has shown the effect that the site and model
size has on the penetration parameters and also how truly variable the penetration parameters
are in in vivo skin. The comparison between the H12a and H14a subjects has demonstrated
intra-model variation between the two subjects. The data gathered in this study was also used
to further inform the design of a synthetic test bed in § 6.7.
6.5.1 Inter-Site and Inter-Model Variability
The experiments were performed according to the in vivo penetration testing method in § 6.3.1.
The H14a and H14b subjects were injected 100 times into the rump and neck test sites. Ten
further tests were performed in the inguinal site of H12a and 20 tests on H14a. Only a small
number of injections were performed at the inguinal site for comparison purposes only. The
inguinal site was not under consideration as a testing site due to its mobility.
Of the 430 planned tests performed 423 were recorded successfully, 7 were discarded as the Pen-
etrometer failed to capture any data. The locations of the sites tested are shown in Figure 6.14.
The resulting maximum, minimum and mean average penetration profiles can be observed for
the in vivo tests across both models into neck in Figure 6.15, rump in Figure 6.16 and inguinal
site in Figure 6.17.
Figure 6.14: Diagram showing the location of the neck, rump and inguinal test sites.
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Figure 6.15: Maximum, minimum and mean average penetration profiles from the in vivo tests
into the neck site of the H14a (n = 98) and H14b (n = 100) models.
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Figure 6.16: Maximum, minimum and mean average penetration profiles from the in vivo tests
into the rump site of the H14a (n = 95) and H14b (n = 100) models.
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Figure 6.17: Maximum, minimum and mean average penetration profiles from the in vivo tests
into the inguinal site of the H14a (n = 10) and H14b (n = 20) models.
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Figure 6.18: Scatter plot of Fp against dp for all in vivo data collected at neck, rump and inguinal
test sites in the H14a (26kg ♂) and H14b (76kg ♂) models.
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The mean average profiles show stiffness between the neck (Figure 6.15) and rump (Figure 6.16)
test sites of the H14a and H14b models to be comparable. The peak penetration force, Fp,
of each test site, between models, is not much different considering that the H14b model is
considerably heavier and older than the H14a model. In both instances of the neck and rump
test sites the H14b model does appear on average to produce a greater dp. There is a feature
on the rump penetration profiles where a second peak is present. This is absent from the neck
profiles and is possibly due to the difference in the composition of the test sites.
The rump appears to produce the highest Fp and the inguinal test site appears lowest. Fig-
ure 6.17 is comprised of only 30 tests yet demonstrates the greatest variation. The inguinal site
also shows a large amount of variation in the maximum and minimum forces encountered after
penetration, as expected considering the mobility of the site. The scatter plot of all Fp against
dp data from the study experiments is shown in Figure 6.18 and confirms observations from the
penetration profiles.
The box plot in Figure 6.19a indicates that average peak penetration force (Fp) to penetrate
the skin was greatest in model H14b at the rump site and least in model H14a at the neck site.
The one-way ANOVA test indicated that the average force, Fp, to penetrate the skin differed
between injection sites (neck, rump) and porcine model H14a (26kg ♂) and H14b (76kg ♂).
There was a significant effect of the testing sites at the 95% level of significance for the four
test sites [F (3, 389) = 61.77, P < 0.001]. Post-hoc comparisons using the Tukey test indicated
that the mean Fp value for the H14a neck site (11.72 ± 0.97N) was significantly different than
the H14a rump (12.86 ± 1.22N) and H14b rump (13.70 ± 1.25N) site. However, the H14a neck
site did not differ from H14b neck (12.06 ± 1.02N) at the 95% level of significance. All other
comparisons, including the two rump sites, were significantly different.
The box plot in Figure 6.19b indicates that average displacement to the peak force (dp) to
penetrate the skin was greatest at the neck site of model H14b and least in the rump of H14a.
The one-way ANOVA indicated that the average displacement (dp) to penetrate the skin differed
between injection sites (neck, rump) and porcine model H14a (26kg ♂) and H14b (76kg ♂) There
was a significant effect of the testing sites at the 95% level of significance for the four sites [F
(3, 389) = 18.70, P < 0.001]. Post-hoc comparisons using the Tukey test indicated that the
mean dp value for the H14a neck site (1.39 ± 0.25mm) was significantly different than the H14b
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Figure 6.19: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured in the skin of a H14a (26kg♂) and H14b porcine
model (76kg ♂) in vivo at the inguinal, neck and rump site (∗ = P ≤ 0.05, n.s. = P > 0.05,
one-way ANOVA post-hoc test).
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neck (1.67 ± 0.49mm) but not different from the H14a rump (1.34 ± 0.23mm) and H14b rump
(1.48 ± 0.31mm) sites. All other comparisons, including the two rump sites, were significantly
different.
Taken together, these dp results show that the skin sites do vary across the sites and sizes of the
models. The neck is shown to behave similarly to the rump. However, the two rump sites were
shown to be different with both inter model and inter-site variation.
The data and subsequent statistical analysis has shown in vivo skin to vary both inter-site and
inter-model for Fp and dp. The rump test site has produced the highest mean Fp and the H14b
model has produced the larger mean dp.
6.5.2 Intra-Model Variability Across Two Comparable Models
The data from the in vivo neck site of two male porcine models of comparable size (≈25kg)
in the H12a (§ 6.4.1) and H14a (§ 6.5.1) were plotted to compare penetration response, this is
shown in Figure 6.20a.
It was observed in both Figure 6.20a and 6.20b that the H14a model appeared to require more
force to penetrate. It was first thought that this difference was due to the Penetrometer test rig’s
performance varying over time between studies H12a and H14a that were performed 6 months
apart. To investigate this theory a control test was performed.
The silicone rubber data, reported in § 5.6, was produced prior to the experiment performed in
the H12a subject. Retesting this same material with the same method, outlined in § 5.6.1, at
this stage after the H14a experiment, would confirm whether the Penetrometer’s performance
had altered or alternatively such a large difference had actually been detected between the two
subjects. Fewer repeat tests were necessary (n = 20) as the synthetic material had already
proven repeatable (Fp, CV = 2%).
Figure 6.21a and 6.21b compare the distribution of data for penetration force (Fp) and displace-
ment (dp) measured in the in vivo neck site of the H12a and H14a subjects. The experiments
into silicone rubber are shown as ‘control’, performed before H12a, and ‘control (2)’, performed
post-H14a. The control experiment results, either side of the in vivo skin experiments, appeared
to indicate that the Penetrometer performance was consistent.
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Figure 6.20: Graphs showing the (a) maximum, minimum and mean average penetration profiles
and (b) scatter plot of Fp against dp from data collected in the in vivo neck site of the comparable
H12a (25kg ♂, n = 199) and H14a (26kg ♂, n = 98) porcine models.
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Figure 6.21: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured in vivo at the neck site of the H12a (25kg♂) and H14a (26kg ♂) porcine models and the 3mm thick silicone rubber (FQ-T050) control
experiments (∗ = P ≤ 0.05, n.s. = P > 0.05, two-sample T-test).
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Figure 6.21a confirmed what was observed from the graphical analysis of the penetration profiles
and scatter plot. A pairwise comparison showed that the population variances were equal for
Fp for samples from the in vivo neck sites of the H12a and H14a subjects (P = 0.984). The
two-sample T-test reported that the H14a model did require a significantly greater Fp (2.61N;
95%CI 2.37, 2.85N) than the H12a model (P < 0.001).
A comparison of the controls was performed, the population variances were equal for Fp for
the initial control sample group (n = 100) and the second control sample group (n = 20) (P =
0.566). A two-sample T-test resulted in an insignificant difference in Fp (0.04N; 95%CI -0.15,
0.23N) between the sample groups (P = 0.660). These two results indicated that the difference
detected between two subjects of comparable size was due the variation within the two test
≈25kg porcine model test subjects and not the performance of the Penetrometer.
The same set of tests was applied to the displacement values, the average dp for the in vivo neck
data was shown in the H14a subject to be significantly greater (0.09mm; 95%CI 0.02, 0.16mm)
than the H12a subject (P = 0.016). The average dp for the initial control sample group was
shown to be greater (0.16mm; 95%CI 0.04, 0.27mm) than the second control sample group (P =
0.008). Although these findings were were both statistically significant they were not of practical
importance, compared to the magnitude of difference in Fp detected.
As part of the control strategy, images of the tip of the 46° wedge-tipped metal probe were
taken before and after all 820 tests were performed across both studies, these are shown in
Figures 6.22a–d. There was a small amount of wear visible on the probe at the edges and base
of the wedge-tip which had both rounded slightly. However, as indicated by the control test
results, this wear did not effect the Penetrometer’s performance over time. The probable reason
the 46° tip was unaffected by wear was that, compared to a cutting blade or hypodermic needle,
it was not manufactured to be particularly sharp in the first instance.
(a) (b) (c) (d)
Figure 6.22: Images of 46° wedge-tipped metal probe shown (a–b) before the initial penetration
study into silicone rubber (§ 5.6) and (c–d) after the second control test.
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6.5.3 Review of a Further Penetration Study into Skin
Following on from the initial penetration study, a further study with an increased scope has
continued to show the issues of skin variation. The experiments performed across two different
sized models (26kg and 76kg) and on different test sites and has provided further evidence of how
variable in vivo skin’s response is to penetration by a 46° wedge-tipped metal probe; representing
the solid dose implant.
The effect of the 50kg size difference between the models produced a higher Fp and dp values
across all test sites. These increases and their significance is shown in Figure 6.19a and 6.19b.
The mean ± SD (%CV) results from all testing performed across both studies are summarised
in the Table 6.2.
Quantitative data confirmed what had previously only been known anecdotally, that the rump
site requires a greater force to penetrate than neck, followed by the inguinal site. This was true
for both the H14a and H14b models. The variation (%CV) in Fp across the rump and neck sites
was between 8–9%. The Fp on the inguinal site was shown to be the most variable (11–12%).
The H14b neck site had the highest average dp of 1.67 ± 0.49mm showing it was subject to
the greatest elastic deformation before penetration. The %CV for displacement data, dp, was
considerably more variable 23–29% than the Fp data, although the rump site of the H14a model
was lower at 18%. The inguinal site was disregarded at this stage.
The comparison performed between the in vivo neck site data from the H12a and H14a subjects
showed that the Penetrometer detected a 29% (2.61N) greater average peak force when penet-
rating the skin of the H14a subject. This indicated the dangers of using the in vivo skin as a
testing surface to qualitatively assess penetration performance success of the SDI. The variation
between the two subjects of comparable size was made more noteworthy considering there was
no significant difference between the H14a in vivo neck data and the 50kg heavier H14b model,
showing how inconsistent the responses were between the subjects.
In vivo pig skin, particularly at the neck site, has been shown to be unsuitable as a test bed for
exploratory work. Its inherent variability would leave any testing of SDI configurations prone to
error. The in vivo porcine model should be used for confirmatory work only and the SDI device
development should be conducted on an in vitro test bed.
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6.6 Discussion
The results from both studies have quantified penetration parameters for in vivo skin penetra-
tion; with a Penetrometer configuration designed to emulate an injection by an SDI device and
a 46° wedge-tipped solid dose implant. All of the average penetration profiles from the investig-
ations have been collated in Figure 6.23. This graph confirmed, what had previously only been
known anecdotally, that the rump site required the highest force to penetrate, Fp, followed by
the neck, then the inguinal site.
The initial study highlighted the intra-site variability within the porcine model. Glide had used
the in vivo neck site to test for penetration success and failure using the SDI device. The
variability issue extended to in vitro skin that was shown to be stiffer, with a greater mean
Fp, but as variable as it was in vivo skin. The second penetration study showed high levels of
variation detected across the neck, inguinal and rump sites across two different sized models H14a
(26kg) and H14b (76kg). The effect of the 50kg size difference between the models produced
higher average Fp and dp values and data ranges across all three test sites.
Overall the results show the dangers of using in vivo pig skin as a testing surface to assess
penetration performance success, and inform the design of the drug delivery system, is wholly
inadequate due its inherent variability. This was underlined when the Penetrometer detected
29% (2.61N) greater average peak force the Fp to penetrate the in vivo neck site of the H14a
(26kg) subject when compared to the similar sized H12a (25kg) subject. This was confirmed
to be the case after retesting the silicone rubber control. If the data from the two comparable
small porcine models were combined the point of penetration could occur on the in vivo neck
site anywhere between an Fp of 7.01–13.77N and a dp of 0.81–2.45mm, as shown in Figure 6.24
and more clearly in Figure 6.6.
These findings casts doubt on the accuracy of the results for the studies Glide Pharma performed
on the small porcine model before the clinical studies were conducted. Historically, without
control experiments in place, successfully recorded injections may actually have been attributed
to the skin being more penetrable (in certain regions, site and models) rather than improvements
in the implant or device performance. Such a range of data meant that depending on the skin
response to penetration, at a test site, an implant may be exposed to completely different stresses
through compression (Fp) or buckling (dp) forces.
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Significant mean differences and high levels of variation have been detected in all in vivo skin
penetration. This is despite the controlled manner in which the experiment has been performed.
It is worth noting the two following points;
1 The variability in penetration has been detected whilst using a 46° wedge-tipped metal probe
as the penetrator in the system. This metal probe and the Penetrometer have been shown
to be repeatable throughout the calibration (§ 5.6) and control tests (§ 6.5.2). When using
a solid dose implant as the penetrator, with the likelihood of it having a blunter or more
frangible tip, will in turn either increase the forces, displacements or energy to penetrate or
to further increase the range of all of these parameters.
2 The porcine models used in these studies were from the same supplier and bred in the same
controlled environment. It is likely that across a human patient population, accounting for
the effects of both biological and environmental influences, the variation in skin penetration
could be far greater.
From all the in vivo skin data gathered and in terms of work to penetrate, Wp, the H14a rump
site was shown to exhibit the least variable range values with respect to the mean. Wp is a
product of Fp and dp, accounting for the variation in both parameters. Table 6.3 shows that the
average energy to penetrate the site was 11.05mJ. The range of Wp at the site varied between
+62% and -44% of the mean. As the rump site is the least variable and requires a greater
average force of +1.14N (H14a) and +3.76N (H12a) than the neck sites tested it is probably a
more suitable in vivo site to test for penetration. If in vivo skin testing is to persist, penetration
success for the SDI device at the rump site is a much better indicator of the system working.
The neck and inguinal sites should only be used for their original purpose, for the established
dermal tolerability and pharmacokinetic experiments.
Although the H14a rump site has been proposed as the most suited in vivo skin test site, from the
data set available, it should only be used for the purposes of confirmatory penetration testing.
The wholesale SDI device development should be conducted on much less variable material with
foreseeable penetration characteristics. Sufficient data has been collected on the porcine model,
across the two studies, to inform the design of an in vitro synthetic test bed that has a similar
stiffness, Fp and dp response as in vivo skin, albeit with much less variation.
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6.7 Design of a Synthetic Test Bed
The findings from the work described previously in this section the findings have been used
to inform the design of a synthetic test bed. This in vitro test bed is intended to behave in
a similar way to the skin, but it is expected to have more uniform mechanical properties and
less variation, which as a consequence will allow for easier development of the implant and SDI
device. A synthetic test bed also permits more experiments to be performed and ultimately
should reduce the need for use of non-clinical models.
Approach
There are two different approaches that could be used in order to design a synthetic test bed.
One approach would be to attempt to mimic the performance of skin. This could be achieved by
selecting a synthetic membrane that penetrates at the same Fp as skin. This membrane would
require a mobile underlayer, such as a fluid-filled closed-cell foam [43]. This layer would represent
the adipose tissue and control the elastic deformation, dp, that occurs before penetration. This
composite test bed would require iteration loops to refine its response to the several different
variables within the current prototype drug delivery system; such as cassette shape, actuation
force, implant geometry, delivery speed. Whilst this may be possible, it is difficult to determine
which skin site behaviour to mimic.
There is an alternative and more practical engineering design approach to address the current
problem. Due to the extent of the variation detected, a simple single layered test bed that
can be breached at a proportionally higher force (Fp) and displacement (dp) than the current
porcine model would provide an economic solution; and a platform for the implant development
to continue whilst the optimal device configuration is still being investigated. A test bed that
can exert a higher peak penetration force Fp and at a later displacement, dp, will challenge
the device and implant under both compression and buckling, respectively. If an implant can
penetrate this simple test bed it will survive the stresses of being injected into skin.
This approach was implemented as at this stage in the understanding of solid dose injection.
Ultimately, when more knowledge is known of the porcine model or human skin then the former
method may be undertaken.
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6.7.1 Method
The test method was adapted from the initial penetration study into silicone rubber in § 5.6.
The silicone rubber sheets were placed over a 20mm thick expanded polystyrene sheet, supplied
by The Polyshop Ltd. (Worthing, W. Sussex). The expanded polystyrene provided stiffness to
the test bed and prevented any damage the metal probe after it penetrated. Silicone rubber had
been shown to have a low %CV response and the Penetrometer had proven to be repeatable in
the earlier study so only 10 repeats were required. This speeded up testing and data analysis.
Figure 6.26: Experimental equipment set up for synthetic test bed study.
The Penetrometer was configured with the 46° wedge-tipped probe and the standard cassette
shape fitted onto the front of the handset. The Penetrometer was suspended vertically in the
support stand and pressed down onto the material with ≈24N actuation force during each test,
as shown in Figure 6.26. The tests were performed in accordance to the Penetrometer equipment
operating procedure (EOP) as described in Appendix D.
Materials
Silicone rubber has already been widely used as a suitable synthetic alternative for investigating
skin penetration, as reported in § 2.5.4. A selection of 10 silicone rubber sheets with various
properties and thicknesses were sourced from two separate suppliers, these were labelled A–J
and are shown in Table 6.4. Also included in this table are the 4mm thick R31-2186 silicone
rubber test bed (K), previously used at Glide Pharma and reported in § 4.2.3, and the 3mm
thick FQ-T050 silicone rubber (Control) reported in § 6.4.3.
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6.7.2 Results
The average penetration profiles for the 12 different silicone rubber materials tested are shown
in Figure 6.27. Of all the materials tested, 9 appeared to have a similar stiffness. This was
most likely due to the underlying layer of expanded polystyrene. Although the materials have
different mechanical properties their response within the system will be altered when they are
tested over a stiffer material.
The stiffest material tested was silicone rubber D, which also exerted the highest Fp (20.20 ±
0.30N). This may be associated with the fact that D also had the greatest Shore A hardness
(80°) of materials tested. Materials A and J were the least stiff and both had the lowest Shore
A hardness value of the materials tested (10°).
Materials B and C (44.1kN.mm−1) and C (45.9kN.mm−1) had the highest reported tear strength
and were amongst the silicone rubbers that required the most force to penetrate. The Control
silicone rubber had a high Fp, although its tear strength was comparatively low (12.7kN.mm
−1),
was 1mm thicker (3mm) than materials B and C.
Thickness is a factor that is likely to affect the performance of the material. The silicone
rubbers G (1mm), I (2mm) and Control (3mm) all had the same mechanical properties but
were supplied in different thicknesses. The materials have a similar stiffness and their Fp and
dp values appeared to be proportional to their thickness. This was best shown in the range plot
in Figure 6.28. Silicone rubber G was the thinnest material tested and, although the mean dp
value was consistent with the in in vivo skin data, the Fp value was considerably lower.
The results for silicone rubber K when viewed in either the penetration profile (Figure 6.27) or
range plot (Figure 6.28) show that the material responds to penetration differently to any others
and most unlike the in vivo skin. This was likely to be because of its low Shore A hardness (20°)
value and 4mm thickness.
Silicone rubber K was previously used at Glide Pharma as a penetration test to assess the
performance of the Glide SDI. Its origin was based on qualitative methods comparing penetration
success in it to that observed in non-clinical trials; in the absence of any quantitative data able
to describe penetration. K was suspected to be unfit for purpose in § 4.2.3, when tested with a
simple test rig. This assessment with the Penetrometer has proven this conclusively.
Chapter 6. Investigations into Skin Penetration 196
02468
1
0
1
2
1
4
1
6
1
8
2
0
0
1
2
3
4
5
6
7
8
9
1
0
FORCE (N) 
D
IS
P
LA
C
EM
EN
T 
(m
m
) 
A
B
C
D
E
F
G
H
I
J
K
C
o
n
tr
o
l
F
ig
u
re
6.
27
:
T
h
e
m
ea
n
av
er
ag
e
(n
=
10
)
p
en
et
ra
ti
on
p
ro
fi
le
s,
ge
n
er
at
ed
fr
om
th
e
fo
rc
e
d
at
a
at
ea
ch
d
is
p
la
ce
m
en
t,
fo
r
a
ll
ca
n
d
id
a
te
sy
n
th
et
ic
te
st
b
ed
m
at
er
ia
ls
,
as
d
es
cr
ib
ed
in
T
ab
le
6.
4.
T
h
e
si
li
co
n
e
ru
b
b
er
(F
Q
-T
05
0)
co
n
tr
ol
is
in
cl
u
d
ed
fo
r
co
m
p
ar
is
o
n
p
u
rp
o
se
s.
Chapter 6. Investigations into Skin Penetration 197
C
o
n
tr
o
l 
H
14
aN
 
H
14
aR
 
A
 
B
 
C
 
D
 
E 
F 
G
 
H
 
I 
J 
K
 
02468
1
0
1
2
1
4
1
6
1
8
2
0
2
2
0
.0
0
.5
1
.0
1
.5
2
.0
2
.5
3
.0
3
.5
4
.0
FORCE (N) 
D
IS
P
LA
C
EM
EN
T 
(m
m
) 
F
ig
u
re
6.
28
:
R
an
ge
p
lo
t
of
th
e
m
ea
n
av
er
ag
e
F
p
ag
ai
n
st
d
p
fo
r
ea
ch
ca
n
d
id
at
e
sy
n
th
et
ic
te
st
b
ed
m
at
er
ia
l
te
st
ed
.
T
h
e
w
h
is
ke
rs
in
d
ic
a
te
th
e
ra
n
g
e
in
F
p
an
d
d
p
d
et
ec
te
d
.
T
h
e
in
vi
vo
n
ec
k
an
d
ru
m
p
te
st
si
te
s
fr
om
H
14
a
m
o
d
el
(2
6k
g
♂)
an
d
si
li
co
n
e
ru
b
b
er
(F
Q
-T
0
5
0
)
co
n
tr
o
l
a
re
in
cl
u
d
ed
fo
r
co
m
p
ar
is
on
p
u
rp
os
es
.
Chapter 6. Investigations into Skin Penetration 198
0
2
4
6
8
10
12
14
16
18
20
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
FO
R
C
E 
(N
) 
DISPLACEMENT (mm) 
H14a Rump - F avg. H14a Neck - F avg. C D F I Silicone Control
Figure 6.29: The mean average penetration profiles, generated from the force data at each
displacement, for the selected synthetic test bed materials; C (2.0mm thick, MED-4960), D
(2.0mm, MED-4980), F (1.5mm, PLAT60) and I (2.0mm, FQ-R089). The in vivo neck and
rump test sites from H14a model (26kg ♂) and silicone rubber (3.0mm, FQ-T050) control are
included for comparison purposes.
Material Thickness (mm) Sample (n) Fp (N) dp (N)
H14a Neck - 98 11.72 ± 0.97 (8%) 1.39 ± 0.25 (18%)
H14a Rump - 95 12.86 ± 1.22 (9%) 1.34 ± 0.23 (17%)
C 2.0 10 17.57 ± 0.78 (4%) 2.33 ± 0.08 (3%)
D 2.0 10 20.20 ± 0.30 (1%) 1.99 ± 0.17 (8%)
F 1.5 10 12.48 ± 0.53 (4%) 1.97 ± 0.12 (6%)
I 2.0 10 11.57 ± 0.43 (4%) 1.74 ± 0.13 (8%)
Control 3.0 100 16.32 ± 0.39 (2%) 2.23 ± 0.23 (10%)
Table 6.5: The mean average penetration data, for the selected synthetic test bed materials
shown in Figure 6.29. The in vivo neck and rump test sites from H14a model (26kg ♂) and
silicone rubber (FQ-T050) control are included for comparison purposes. Values reported in
Mean ± SD (%CV).
Chapter 6. Investigations into Skin Penetration 199
0
5
10
15
20
25
H14a H14a I F C D Control
n = 98 n = 95 n = 10 n = 10 n = 10 n = 10 n = 100
Neck Rump Silicone Rubber Sheet
FO
R
C
E 
(N
) 
Mean
(a) The peak force during penetration (Fp)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
H14a H14a I F C D Control
n = 98 n = 95 n = 10 n = 10 n = 10 n = 10 n = 100
Neck Rump Silicone Rubber Sheet
D
IS
P
LA
C
EM
EN
T 
(m
m
) 
(b) The displacement of the peak force (dp)
Figure 6.30: Box plots showing the distribution of data for the (a) peak force during penetration
and (b) displacement of the peak force measured for the candidate synthetic test bed materials,
as described in Table 6.4. The in vivo neck and rump test sites from H14a model (26kg ♂) and
silicone rubber (FQ-T050) control are included for comparison purposes.
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Figure 6.29 shows the proposed silicone rubbers to replace K as the synthetic test bed of choice.
The in vivo skin data from H14a is also shown for comparison. Of the silicone rubbers tested,
in terms of it was Fp, the material I (11.57 ± 0.43N) most closely resembled the neck (11.72 ±
0.97N) and F (12.48 ± 0.53N) resembled the rump (12.86 ± 1.22N). However the dp values were
greater for both the synthetic materials.
Although materials F and I behaved similarly to the average skin response from the H14a subject,
what was required of a test bed was a material that could exert a higher peak penetration force,
Fp, and at a later displacement, dp, to challenge the device and implant under both compression
and buckling, respectively. Material D, although higher in both Fp and dp has been shown to be
far stiffer than skin and therefore was considered unrepresentative. However, the material C and
the Control silicone were shown to have similar stiffness to skin and both had higher inclusive
Fp ranges than the in vivo skin, shown in the box plot in Figure 6.30a. The dp ranges for these
materials are at the top end, but not above, of that which has been detected in skin, as shown
in the box plot in Figure 6.30b.
All of the mean average data for the proposed candidate silicone rubbers is shown in the
Table 6.5. The coefficient of variation of the combined in vivo skin data for Fp was 8–9%
and the dp was 17–18%. This is in contrast to the low variance recorded across all the proposed
silicone rubbers. The CV values for the material C were only 4% (Fp) and 3% (dp), further
demonstrating its suitability as a repeatable test bed material.
From the materials tested either silicone rubber C (2mm, MED-4960) or the Control silicone
(3mm, FQ-T050) placed over a 20mm thickness of expanded polystyrene has been proposed as
the simple synthetic test bed. It was chance that the control silicone first used to verify the
Penetrometer performed so well in its own right as a worthy synthetic test bed.
This decision is based on the data set available that was generated at 1m.s−1. Further work would
be required to determine the rate effect on the materials. In the meantime Glide may proceed to
test penetration success of the SDI device and implant configurations on these materials knowing
they are representative of skin, but more challenging and repeatable. The in vivo rump site of
the 25kg, male porcine model should only be used to confirm what has been proven to work in
an in vitro test bed.
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6.8 Chapter Summary
The investigations within this chapter have shown that the penetration response of in vivo pig
skin exhibits intra-site, inter-site, intra-model and inter-model variation. The variability also
extended to in vitro skin, which was shown to be stiffer but as variable as in vivo skin. The
exact causes of the variable skin penetration properties will be investigated in Chapter 7.
This quantitative understanding of the porcine model has underlined the issue, first raised
in Chapter 3, of relying solely on in vivo skin as a testing surface to assess the penetration
performance of the Glide SDI device. The pre-clinical penetration test for the drug delivery
system was to inject pig skin and qualitatively record whether an implant was delivered.
The quantitative data within this chapter has shown that the large variation will bias the results.
The large ranges detected show that the key parameters measured are the peak force during
penetration, the displacement of the skin at penetration and the work required to penetrate the
skin, with variations observed of the order of 30%, 100% and 140%, respectively. The successful
deliveries recorded were thought to be due to improvements in the system. However, work in
this chapter has shown penetration success can be just as easily attributed to the skin, within
that site or model, being easier to penetrate. This was best demonstrated when the Fp sample
groups from H12a (25kg) and H14a (26kg) models were compared. The H14a model required a
29% (2.61N) greater mean peak force to penetrate than H12a.
The highest Fp value, on the H14a neck site, when converted into a penetration stress (σp)
was 24.26MPa. This is above the known compressive strength of sorbitol (≈20MPa) but less
than sordex implants (≈34MPa). This data was produced using a sharper penetrator than an
implant, therefore the true σp would be much higher. Currently only polymer-based implants
are suitable for needle-free delivery. As well as exposing the implant to buckling, the large dp
values detected also increase the work required to penetrate the skin (Wp).
From the data set available the rump site (H14a) has been proposed as the most suited in vivo
skin test site, although it should only be used for the purposes of confirmatory penetration
testing. In its place an in vitro silicone rubber test bed that is representative of skin but more
challenging and repeatable has been proposed. The test bed is to be used as a tool to better
develop the implant and SDI device design by removing the bias of the effects of skin variation.
Chapter 7
Analysis of Skin Penetration
and Variation
An analysis of skin penetration and variation data generated in Chapter 6 has been performed to
establish what may cause the inter- and intra-site variation between the different porcine models
in this chapter. The results generated have been plotted across the skin’s surface to establish
whether the variation in properties can be attributed to skin thickness, presence of underlying
features or whether Glide’s method using subjective assessment to select skin regions to test
on had any effect. The implications that variation may have on the energy requirements of
the SDI device design are discussed. An analysis of the synthetic test bed data has again
proven the Penetrometer to be accurate and repeatable. Finally, what is now known of the skin
penetration mechanism from literature and what has been learnt from performing this research
has been summarised ahead of the conclusions in Chapter 8.
7.1 Observed Intra-Site Skin Variation
Variation of the skin and its mechanical properties have been reported in the literature [41, 97,
136], although few authors have related the amount and effect the properties may have on a
penetration event. For many applications the use of a needle to pierce the skin reduces the
penetration force to an insignificant amount. However, many needle-free technologies, despite
high delivery velocities, have struggled to accommodate the effects of variation in the skin [4,86].
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The data produced in Chapter 6 has been already been presented in box plots. The large stand-
ard deviation values and ranges measured have shown how variable the skin can be. As well as
recording the magnitude of the penetration parameters the data collection method used included
the location at which each test was performed within the gridded coordinate system. This meant
not only were the tests performed equidistant from one another to capture the behaviour of the
skin across a 9cm2 area, but also that each test was traceable allowing comparison across the
tested regions.
Plotting skin data across a surface has been reported in the literature before but only for
measures of displacement by Evans et al. [122, 132, 150] who used motion capture to detect
displacements when human skin is stretched. There are no examples where penetration data
has been captured over a surface or where the distribution of the skin properties have been
measured or modelled in this way.
7.1.1 Method
The Penetrometer data collected from the data collection method outlined in § 6.3 meant that
the location of each individual test was given a coordinate to identify where on the skin site the
injection took place. The distribution of the parameters measured can be observed across the
surface of the skin.
The data collected has been gridded on the surface of the skin so that A–J runs from dorsal–
ventral and 1–10 runs from anterior–posterior, respectively, as shown in Figure 7.1. This is the
case for all the data produced at the neck and the rump test sites on the LHS of the model.
Where sites on the RHS have been used, the data has been transformed, so that it is comparable
to that of the RHS. This data was analysed and graphed using Microsoft Excel (2010).
This variation data has been presented in two different ways; in two-dimensional contour plots
and in three dimensional surface models. In total there is data available for 4 different parameters
that cover the injection phase across the 8 different tested materials.
The z-axis increments for each of the parameters has been applied not necessarily to guide
interpretation, but to convey the features that are most apparent. For the 18 of 800 tests
performed where no test data is available, either due to the condition of the skin or a fault with
the Penetrometer test rig, the surface and contour graph registers z = 0.
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Figure 7.1: Image showing orientation and coordinates for the graphical analysis. A–J runs
dorsal–ventral and 1–10 runs anterior–posterior.
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Figure 7.2: 3D surface model plot of peak force to penetrate, Fp (N), across in vivo H12a (25kg,
male, right-hand side) neck site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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7.1.2 Results
The data analysis for each parameter and each test material is shown in contour plots in Ap-
pendix F. Within these 32 different contour plots there were some that exemplify the presence
or patterns within skin variation in certain ways. From all of the graphs available, the most
noteworthy features were observed on those for the peak force to penetrate (Fp). These are
presented as three-dimensional surface models within this section.
Figure 7.2 shows the Fp as detected by the Penetrometer over the in vivo neck site of H12a
(25kg, male) model. This particular test site on the ≈25kg porcine model has been historically
used for penetration testing by Glide Pharma.
In Vivo Skin vs. Silicone Rubber
When the peak force to penetrate (Fp) the in vivo neck skin model (Figure 7.2) was compared
to that of the 3mm thick control silicone rubber (part no: FQ-T050 supplied by J-Flex Rubber
Products, Retford, Notts.), as shown in Figure 7.3, it was apparent that the variation across
the synthetic material is minimal as indicated by the relatively even Fp distribution. Assuming
the material properties are homogeneous, the marginal variation detected in Fp values may have
been caused by non-uniform behaviour of the 20mm expanded polystyrene layer underneath or
limitations of the Penetrometer’s sensitivity. Whether it was either of these or a combination,
the variation observed on the synthetic material remained far smaller than on in vivo skin.
In Vivo vs. In Vitro Skin
The peak force to penetrate (Fp) on the neck skin site has been shown to be variable in vivo.
This was also true for the skin sample when tested in vitro in Figure 7.4. No data was available
for row of data for A1–J1 as the skin was damaged when removed. The response to penetration
was shown to be variable. The peaks detected do not correspond to those observed in vivo. As
discussed in § 6.4.2, this was to be expected and could have been caused by either the post-
processing effects of freezing and thawing the sample had on the mechanical properties of the
material; or a consequence of conditions in vivo such as temperature, hydration and latent skin
tension, all of which would have been difficult to replicate.
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Figure 7.3: 3D surface model plot of peak force to penetrate, Fp (N), across 3mm thick silicone
rubber sample.
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Figure 7.4: 3D surface model plot of peak force to penetrate, Fp (N), across in vitro H12a (25kg,
male, right-hand side) neck site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
Chapter 7. Analysis of Skin Penetration and Variation 207
J
I
H
G
F
E
D
C
B
A
6
8
10
12
14
16
18
20
1
2
3
4
5
6
7
8
9
10
FO
R
C
E 
(N
) 
18-20
16-18
14-16
12-14
10-12
8-10
Figure 7.5: 3D surface model plot of peak force to penetrate, Fp (N), across in vivo H14a (26kg,
male) rump site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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Figure 7.6: 3D surface model plot of peak force to penetrate, Fp (N), across in vivo H14b (76kg,
male) rump site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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Neck vs. Rump Sites
It has been shown known in § 6.5.1 that there was a noticeable difference in in vivo penetration
properties at different test sites on the porcine model. The rump site on both the H14a (26kg,
male) and H14b (76kg, male) has been shown to require a greater peak force to penetrate (Fp)
than the corresponding neck sites. The variation on the box plots has shown that the rump may
be less variable in terms of Fp. However, when this data has been modelled in three-dimensions,
unlike the neck sites tested, the Fp distribution of the rump data appeared to show a trend.
The surface model for H14a, shown in Figure 7.5, displayed a trend where by Fp increased across
the surface from J10–A1. With the highest Fp data registering in the anterior–dorsal region of
the test site (data points A6, B9, E10, F4 and G3 have no data and should be ignored). This
observation was more intriguing when the same trend could be observed in the larger H14b rump
site too, shown in Figure 7.6. It was difficult to attribute a cause of this rise in force across the
region without more data. It may have been associated with underlying tissue or, more likely,
due to the presence of a bony structure under the skin, such as the pelvis. Either way, these
surface models have shown that it may be possible to predict the Fp required to penetrate rump
skin more easily than skin at the neck site.
Review of Observed Intra-Site Skin Variation
Observing the peak force to penetrate (Fp) data once plotted as surface models has shown value
in the data collection method outlined in § 6.3. This graphical analysis can be applied to the
other parameters and skin sites measured and plotted. The displacement to peak penetration
(dp), work done to penetrate the skin (Wp) and inject to a depth of 5.5mm (Wi) may also
show distribution patterns that suggest interrelationships between the parameters. A level of
statistical data analysis would be required to establish any correlation before any causality can
be claimed. However, of greater importance at this stage of the research was the need to establish
which properties of the skin was the major cause of penetration variation.
For completeness, the contour graphs for Fp are shown in Figures 9.10a–h, dp are shown in
Figures 9.11a–h, Wp are shown in Figures 9.12a–h and Wi are shown in Figures 9.13a–h, all
within Appendix F.
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7.2 Possible Causes of Skin Variation
Variation in skin penetration parameters has been detected in previous studies in Chapter 6 and
also observed across different skin test sites on the surface model plots in § 7.1. The causes for
this variation have been investigated to establish whether the skin thickness or underlying tissue
had an effect on penetration and also the effect of excluding regions of the neck site during in
vivo testing by the Glide Pharma operator.
7.2.1 Skin and Subcutaneous Fat Thicknesses
This experiment was designed to establish the skin and subcutaneous fat thicknesses across three
sites excised from the ≈25kg models tested in Chapter 6. These results will be compared to the
variation data and surface model plots to determine whether there were any relationships.
Method
A novel method to section and measure the thicknesses across the 9cm2 samples was devised as
they were too large for conventional equipment. This method follows on from step 6 shown in
Figure 6.2 in § 6.3.1. The following steps were performed in the laboratory at Glide Pharma;
7 The sample was selected for experimentation.
8 Whilst still frozen, the sample was sectioned in 10mm slices in line with the gridded pattern.
9 Before the sample was thawed, it was placed on a Peregrine Measuring System (Vision En-
gineering Ltd., Woking, Surrey) and the skin (epidermis and dermis) and subcutaneous fat
thickness measured, at 10mm intervals in alignment along the length.
The data was downloaded into Microsoft Excel (2010). All measurements were converted from
microns to millimetres and transformed to match the orientation shown in Figure 7.1.
Ex Vivo Skin Sectioning Method 
 
x10 
 
7 Select sample 8 Section into 10nn 
thick slices 
9 Measure thicknesses on 
vision system 
Data Analysis 
Compare to in vivo data 
Figure 7.7: Step by step diagram illustrating the method for skin thickness measurement.
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Results
Figures 7.8a and 7.8b show H12a (25kg, male) neck and H14a (26kg, male) rump skin sites,
respectively. It proved difficult to excise the skin at the neck with a uniform thickness of
underlying tissue attached. At the neck there were many different small muscles the animal uses
to manoeuvre its head. The rump site had fewer and larger muscles. The reddish markings in the
skin on the samples at regular 10mm intervals are trauma caused by the penetration testing. The
skin and subcutaneous fat is shown x50 magnification in Figure 7.8c. Distinguishing between
the epidermis and dermis was not possible due to the skin’s glassy appearance as the sample
thawed under the lights on the vision system. However, the boundaries between the skin and
fatty and muscle layers could be observed and thicknesses measured.
Muscle 
Skin 
Dermis 
Subcutaneous Tissue 
(b) 
(c) 
(a) 
Figure 7.8: Images of in vitro sectioned skin from skin thickness investigation. (a) Image showing
skin section 1A–J from H12a (25kg, male) test site, (b) Image showing skin section 1A–J from
H14a (26kg, male) rump test site, (c) x50 magnification image taken using Peregrine Vision
System showing the skin, subcutaneous and muscle layers on H14a rump section.
Site Model Sample (n) Skin (mm) Subcut Fat (mm) Total (mm)
Neck H12a 72 1.75 ±0.35 (20%) 3.32 ±1.29 (39%) 5.07 ±1.43 (28%)
Neck H14a 100 2.16 ±0.47 (22%) 3.38 ±1.29 (38%) 5.54 ±1.40 (25%)
Rump H14a 100 2.11 ±0.34 (16%) 1.76 ±0.62 (35%) 3.88 ±0.73 (19%)
Table 7.1: Average skin and subcutaneous fat thicknesses measured in vitro for sites on the H12a
(25kg, male) and H14a (26kg, male) porcine models. Values are reported in Mean ±SD (%CV).
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A lack of underlying tissue excised on the H12a neck skin meant that only 72 of the 100 test
sites were measurable. All of the test data is shown in Table 7.1.
The mean average skin thickness at the neck site of the H12a and H14a subjects was 1.75
±0.35mm and 2.16 ±0.47mm, respectively. The subjects despite being comparable (≈25kg,
male) showed a 23% (0.41mm) difference in skin thickness. Interestingly the results in § 6.5.2
found that it required a 29% (2.61N) greater average peak force to penetrate (Fp) the in vivo
neck site of the H14a (26kg) subject when compared to the H12a (25kg) subject. This indicated
that there may have been a link between skin thickness and Fp detected in the pig skin.
The mean subcutaneous fat thickness at the neck sites was equivalent for H12a (3.32 ±1.29mm)
and H14a (3.38 ±1.29mm) with only 2% difference between the mean average of each data
set. The H14a rump site was shown to be similar to the neck skin of the same subject (2.16
±0.47mm) but was considerably leaner than either of the neck sites tested.
Data Analysis
The skin thickness data is shown in a box and whisker plot in Figure 7.9. The upper and lower
whiskers represent the range of the data. This box plot confirms the similar thicknesses (and
range) measured of subcutaneous fat at the neck, whilst also showing the difference measured
in the neck skin thicknesses between the models.
Much like the graphical analysis of the skin penetration parameters, as the thickness and co-
ordinate for each test was known, it was possible to plot this data as 3D surface models to
view the distribution of the variation. The 3D surface models for the combined skin and sub-
cutaneous fat thickness for the two neck regions are shown in Figures 7.10 and 7.11. There was
little to conclude between them, except that both neck sites are shown to be highly variable.
The peaks present on the surface models indicate thicker areas of fat, these may appear over
certain features and structures under the skin such as those observed in Figure 7.8a.
Figure 7.12 shows that on the H14a rump site where there appears to be regions where the
composition was similar. The increased thickness shown towards A1 (anterior–dorsal) was also
observed on the Fp surface model for this same site in Figure 7.5, although this observation may
not be significant. For each test site the individual skin, subcutaneous and total thickness are
shown in Figures 9.16a–i in Appendix F.
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Figure 7.9: Box plots showing the skin, subcutaneous and total thickness for the RHS neck site
of the H12a (25kg, ♂) and the neck and rump of H14a (26kg, ♂) model. Box plots show the
first and third quartiles, the median (horizontal line) and the mean (3 symbol) of the data. The
upper and lower whiskers indicate the range of the data.
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Figure 7.10: 3D surface model plot of combined skin and subcutaneous fat thickness (mm) across
in vivo H12a (25kg, male, right-hand side) neck site. A–J runs dorsal–ventral and 1–10 runs
anterior–posterior.
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Figure 7.11: 3D surface model plot of combined skin and subcutaneous fat thickness (mm) across
in vivo H14a (26kg, male) neck site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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Figure 7.12: 3D surface model plot of combined skin and subcutaneous fat thickness (mm) across
in vivo H14a (26kg, male) rump site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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There were indications from the data that there may be a relationship between penetration force
and skin thickness. Few authors have investigated interactions between skin and penetration
parameters such as this (§ 2.6). The variation in the magnitude and distributions observed on
both the skin thickness and penetration parameter 3D surface models made comparing difficult.
A more direct approach was to plot the skin thicknesses values measured against the Fp data in
a scatter plot as shown in Figure 7.13a. The regression value to the linear line of best fit placed
across all the data was 17%, showing a weak relationship across the entire data set.
A Leanness Ratio (LR) was consequently introduced. This was the skin thickness divided by
the total skin and subcutaneous fat thickness. The LR was used to differentiate the leaner
regions tested independent of model or site. The regression value shown on the scatter plot in
Figure 7.13b increased to 26%, illustrating that increased leanness may be an indicator of Fp.
However, there was still 74% of variation in the data that was not accounted for.
Review
The skin and subcutaneous fat thickness investigation has shown that the neck and rump sites
are different, both in composition and the distribution patterns. It was unsurprising that the
rump site was shown to be leaner and less variable than the neck site. The skin at the rump is
situated over a single large muscle, whereas the neck site is comprised of many smaller muscles
and complex structures.
The data for the H12a neck site has been shown to be 23% thinner than the H14a model
despite being comparable in size and gender. This may have partially explained the difference
in Fp reported in § 6.5.2. This should be a concern to Glide Pharma as all porcine models for
penetration testing are only specified by size and gender. Many more control tests would be
required in future studies to ensure inter-model and inter-study comparisons can be made.
Increased skin thickness and/or leanness may indicate higher penetration force however the
relationship detected was weak and dependent on the site and model tested. Other causes
for Fp variation may be related to underlying features that had not yet been accounted for.
Experimental error cannot be ruled out and there may have been influences from the excising,
freezing, sectioning and measuring processes. To mitigate this effect, the same method was
applied to all data collected and a large sample has been used to reduce the influence of error.
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Figure 7.13: Scatter plots showing the relationship between peak force to penetrate, Fp (N), and
skin thickness of H12a (25kg, male) and H14a (26kg, male) porcine models. *Leanness Ratio is
the skin thickness divided by the total skin and subcutaneous fat thickness.
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7.2.2 Underlying Features
A possible cause for the penetration response on the skin’s surface could have been the effect
of the underlying features. Research into different imaging techniques in § 4.3 has shown the
difficulties in establishing the thicknesses and behaviours of underlying tissue without influen-
cing the data collection. Through excising the skin it has been possible to observe how skin
composition can change intra- and inter-test as shown in Figures 7.8a and 7.8b in § 7.2.1. The
difficulty using in vitro skin would be to establish the effect that the ≈24N actuation force, Fa,
applied to the surface would have on the underlying tissue behaviour when compressed in vivo.
One method of determining the effect of underlying features may have on penetration parameters
was to use all of data captured by the Penetrometer for each test. The Penetrometer measured
forces encountered over 10mm of travel at 1m.s−1. As the data was available, a mean average
of the forces beyond the point of skin penetration, typically 3–4mm to 10mm, caused by the
underlying tissue has been calculated. Some of this force, Fsc, will have been caused by drag
on the metal probe by the penetrated skin [169], although variation attributed this phenomena
was assumed to be minimal as the same penetrator and delivery depth were used for each test.
The distribution for the average post-penetration forces encountered during injection are shown
in Figures 7.14 and 7.15 for the in vivo neck test sites for the H14a (26kg, male) and H14b (26kg,
male) model, respectively. On both surface models there appeared to be a force distribution
pattern. Towards the A10 (posterior-dorsal) region there appeared to be less resistance compared
to the J1 (anterior-ventral) region. This region was closest to the cranium of the animal and
appeared more prominently on the larger H14b model, although graphically it was difficult to
draw comparisons between different parameters. The Fsc distribution pattern was in contrast
with the apparent random distributions of the peak penetration force, Fp, (§ 7.1) for the neck
of the H12a (25kg, male) and H14a models. Therefore, from graphical analysis alone, it was
unlikely that underlying tissue behaviour is the primary cause for fluctuations in Fp.
To determine the exact underlying features responsible for the Fsc distribution biopsy work may
be required, as there are limits to how much can be learnt from in vitro measurements without
the tissue being compressed by an actuation force. The parameter Fsc has shown value proving
the existence of underlying features in vivo. The neck Fsc data was more remarkable than other
materials tested, as shown in Figures 9.14a–h in Appendix F.
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Figure 7.14: 3D surface model plot of average force of subcutaneous tissue, Fsc (N), across in
vivo H14a (26kg, male) neck site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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Figure 7.15: 3D surface model plot of average force of subcutaneous tissue, Fsc (N), across in
vivo H14b (76kg, male) neck site. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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7.2.3 Glide Pharma Operator Assessment of the Porcine Model
The in vivo penetration testing method, described in § 6.3, included a prior step where the Glide
Pharma operator present would mark any regions on a 9cm2 test site that would not be typically
used. The operators would exclude regions of skin with visible damage or underlying features
before any penetration performance testing of the SDI system. This assessment is subjective
and there is no quantitative data available to suggest that the regions excluded are more or less
penetrable than the regions that are not.
An investigation into this practice has been undertaken to establish whether this skin assessment
may bias the penetration test results with the SDI through selecting regions of skin favourable
to penetration. Also, as the data analysis performed throughout Chapter 6 has accounted for
the regions that would be excluded, these findings may be inaccurate to Glide Pharma if large
differences are detected between the included and excluded regions. The operator assessment
of the skin regions has been compared to three of the main penetration parameters; the peak
penetration force (Fp), displacement to peak penetration force (dp) and the average subcutaneous
force (Fsc).
Method
As described in the method § 6.3 the operator excluded areas that would not normally be tested
prior to the study. For this analysis two neck test sites from the comparable models H12a (RHS)
and H14a (≈25kg, male) were chosen. Glide Pharma have historically performed penetration
testing on this porcine model at this site (§ 6.2). The rump site and the H14b (76kg, male)
model were assessed by the operator but have not been analysed as Glide Pharma have less
experience assessing this site and model. For comparison purposes the assessments for the other
tested sites are shown in Figure 9.15a–h in Appendix F.
All the data had already been collected throughout Chapter 6. The data analysis method was
performed in two different ways. Two-dimensional contour plots were used for graphical analysis,
to observe any similarities in the distribution patterns of the penetration parameters and the
assessment of the Glide Pharma operator. Also the data was divided into two populations and
plotted in box and whisker diagrams (referred to as box plots) that were used to assess and
compare the central tendency and variability of sample distributions. Box plots show the first
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and third quartiles, the median (horizontal line) and the mean (3 symbol) of the data. The
upper and lower whiskers indicate the range of the data. The included (white) and excluded
(red) regions are plotted as well as the combined data (grey) for comparison purposes.
Two-sample T-tests were used for pairwise comparisons of mean responses (Fp, dp, Fsc) for
independent test site sample groups shown in the box plots. P ≤ 0.05 was considered significant.
All data expressed as Mean ± SD (%CV) was calculated to allow comparison of variability across
groups of data. Microsoft Excel (2010) and Minitab Statistical Software (v15.0) were used for
the data, graphical and statistical analysis.
Data Analysis
Figures 7.16a and 7.16a show the regions that would typically be included (white) or excluded
(red) by the Glide Pharma operator for the H12a RHS and H14a on the neck test sites, respect-
ively. On the two neck test sites that have been analysed there were 99 data points for H12a (44
white, 55 red) and 98 data points for H14a (63 white, 37 red) subject. The regions that were
excluded represent the extremes at the anterior and posterior parts of the 9cm2 grid and were
closest to the skull and shoulder.
The two-dimensional contour plots show distributions of the penetration parameters Fp (Fig-
ures 7.16c and 7.16d), dp (Figures 7.16e and 7.16f) and Fsc (Figures 7.16g and 7.16h).
Using Figures 7.16a and 7.16a to identify distribution patterns within the penetration parameter
data has proven inconclusive. None of the boundaries or expanses visible on the two-dimensional
contour plots appeared to correlate with the red or white regions. Even the defined underlying
features on the H14a subject (§ 7.2.2) shown in Figure 7.16h do not appear to relate to Fp
(Figure 7.16d) or dp (Figure 7.16f). The two-dimensional contour plots were good at establishing
where there were and were not distribution patterns but have not been capable of showing
relationships between the detected patterns.
Elsewhere, an observation that can be made was the colour difference across Figure 7.16c
and 7.16d. This was a consequence of the different magnitudes required to penetrate the test
sites across the whole surface and is discussed in greater detail in § 6.5.2. The majority of the
H12a neck site required 8–10N to penetrate whilst H14a required 10–12N.
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(d) Neck H14a - Fp (N)
J
I
H
G
F
E
D
C
B
A
1 2 3 4 5 6 7 8 9 10
3.5-4
3-3.5
2.5-3
2-2.5
1.5-2
1-1.5
0.5-1
0-0.5
(e) Neck H12a - dp (mm)
J
I
H
G
F
E
D
C
B
A
1 2 3 4 5 6 7 8 9 10
3.5-4
3-3.5
2.5-3
2-2.5
1.5-2
1-1.5
0.5-1
0-0.5
(f) Neck H14a - dp (mm)
J
I
H
G
F
E
D
C
B
A
1 2 3 4 5 6 7 8 9 10
12-14
10-12
8-10
6-8
4-6
2-4
0-2
(g) Neck H12a - Fsc (N)
J
I
H
G
F
E
D
C
B
A
1 2 3 4 5 6 7 8 9 10
12-14
10-12
8-10
6-8
4-6
2-4
0-2
(h) Neck H14a - Fsc (N)
Figure 7.16: 2D contour plots for operator assessment investigation; (a-b) assessed regions for
areas that would be included (white) and excluded (red) from testing, (c–d) Fp (N) - peak
penetration force data, (e–f) dp (mm) - displacement to peak penetration force data and (g–h)
Fsc (N) - average subcutaneous force data. Contour plots are for H12a RHS (25kg ♂) and H14a
(76kg ♂), respectively. A–J runs dorsal–ventral and 1–10 runs anterior–posterior.
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The box plots proved more useful for comparing the included (white) and excluded (red) pop-
ulations of data. The variability in the force to penetrate the skin, Fp, in terms of coefficient
of variation (%CV) for samples taken in the H12a white region (9%) was marginally lower in
the red (11%) region (Figure 7.17a). The variability of Fp in the H14a white (8%) and red
(8%) regions did not differ (Figure 7.17b). The range of Fp values observed, whilst broad, was
comparable for both H12a and H14a subjects.
Pairwise comparison of the population means on H12a (Figure 7.17a) showed that the Fp of
9.54 ± 0.89N for the white region was not significantly different to the 9.40 ± 1.03N observed
for the red region (P = 0.470). Also the Fp on H14a of 11.62 ± 0.98N for the white was not
significantly different to the 11.87 ± 0.94N for the red region (P = 0.220), thus showing that Fp
appeared to be unaffected by the skin assessment performed by the Glide Pharma operator.
The displacement to penetration, dp, for the H12a white region (18%) appeared to be less
variable than the red region (25%), as shown in Figure 7.18a. The opposite was observed in the
variability in dp in the H14a model, where variation in the white region (19%) was marginally
higher than the red region (17%), as shown Figure 7.18b. The range of dp values observed were
broad with the higher values in the red H12a and white H14a regions.
The average dp observed on the white region (1.25 ± 0.22mm) was significantly lower (0.22mm;
95%CI -0.34, -0.1N) than that observed in the red region (1.47 ± 0.36mm), as shown in Fig-
ure 7.18a (P = 0.005). The dp on H14a of 1.39 ± 0.27N for the white was not significantly
different than the 1.39 ± 0.23N for the red region (P = 0.957). The dp different between the
regions was shown to be significant on H12a but not on the H14a subject.
The variability of the average subcutaneous force, Fsc, in terms of %CV for samples taken from
H12a showed both regions (11%) were comparable (Figure 7.19a). The Fsc in H14a showed the
white (12%) to be marginally more variable than the red (10%) region (Figure 7.19b). The
range of Fsc values were shown to be broadest on the red H12a and white H14a regions.
The average Fsc on the white region (5.10 ± 0.55N) was significantly lower (0.26N; 95%CI -0.48,
0.03N) than that observed in the red region (5.35 ± 0.59N), as shown in Figure 7.19a (P =
0.029). The Fsc on H14a of 6.34 ± 0.74N for the white was not significantly different than the
6.35 ± 0.61N for the red region (P = 0.220). Although the result on H12a was significant it only
accounted for a 5% (0.26N) difference between regions.
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Figure 7.17: Box plots showing the peak force during penetration (Fp) on in vivo neck test sites
of (a) H12a (25kg ♂) and (b) H14a (26kg ♂) porcine models. The included (white) and excluded
(red) regions are plotted. The combined data (grey) is provided for comparison purposes.
∗ = P ≤ 0.05, two-sample T-test.
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Figure 7.18: Box plots showing the displacement of the peak force (dp) on in vivo neck test sites
of (a) H12a (25kg ♂) and (b) H14a (26kg ♂) porcine models. The included (white) and excluded
(red) regions are plotted. The combined data (grey) is provided for comparison purposes.
∗ = P ≤ 0.05, two-sample T-test.
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Figure 7.19: Box plots showing the average subcutaneous force (Fsc) on in vivo neck test sites of
(a) H12a (25kg ♂) and (b) H14a (26kg ♂) porcine models. The included (white) and excluded
(red) regions are plotted. The combined data (grey) is provided for comparison purposes.
∗ = P ≤ 0.05, two-sample T-test.
Review
The two-dimensional contour plots proved inconclusive when investigating the effect of the Glide
Pharma operator assessment. However, on the whole the data was able to show that the regions
selected by the operator had little effect on the penetration parameters Fp, dp and Fsc, although
there were two instances in the H12a model where differences were observed. The dp was 18%
(0.22mm) lower in the included region than the excluded region and was much less variable,this
was not observed on the H14a subject. The Fsc on the H12a included region was significantly
lower by 5% (0.26N), although this result was of little practical significance.
It can be concluded from this investigation that the assessment performed by the Glide Pharma
operator had minimal effect on the penetration parameters analysed. For this reason, all the
data analysis and conclusions from Chapter 6 remain valid. As little data of practical significance
has been observed between the two populations (included and excluded) they can be combined.
The intra-test site variation observed was less than the intra-model variation observed between
the two comparable (≈25kg, male) porcine models.
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7.3 Device Design Implications
The area under the penetration profiles in the force against displacement plots used in Chapter
6 was representative of the work done. This data has been used to calculate two different energy
parameters for the 782 tests (excluding the inguinal tests) recorded; the work done to penetrate
the material (Wp), at the peak penetration force and the work done to inject to 5.5mm depth
(Wi), representative of a solid dose injection with a 4mm implant to a 1.5mm depth under the
surface of the skin. Both of these parameters are reported in millijoules and the data for each
is shown in the box plots in Figure 7.20a and 7.20b.
The H12a and H14a neck test sites have been shown to have (Mean ±SD) Wp values of 7.5mJ
±2.5 and 10.4mJ ±2.5, and Wi values of 31.0mJ ±3.0 and 39.5mJ ±3.2, respectively. Both of
these test sites were on the ≈25kg male Large White porcine model that has historically been
used by Glide Pharma for penetration testing of the drug delivery system. This penetration
data as reported in § 3.2.2 has been used to inform the development of both the device and the
implant design.
The dotted lines on the box plots show that when the H12a and H14a data sets were combined
(representing all the test data produced in vivo on the ≈25kg male Large White porcine model)
the energy required to penetrate the skin ranges between 3.2–15.5mJ (Figure 7.20a) and to
travel to a depth of 5.5mm required between 22.4–48.4mJ (Figure 7.20b).
An experiment in § 3.3.1 reported the spring-powered device to have ≈144mJ of energy available.
From the neck data reported it required up to 15.5mJ (Wp) to penetrate the skin with a wedge-
tipped metal probe at 1m.s−1. An implant with a blunter tip traveling at a higher rate would
require more energy to initiate penetration (Wp) and complete an injection (Wi). However, it
was not the magnitude of this upper value that has implications on the device, but the ranges
detected especially the lowest values of 3.2mJ (Wp) and 22.4mJ (Wi).
It was in these ‘easier to penetrate’ regions of the skin where moderate levels of penetration
success were probably observed in the non-clinical studies performed prior to the clinical trials.
During the system development this has been perceived as penetration success when actually
it was probably more of an indication of the properties of the skin at that region. In order to
overcome the skin the energy available in the device must be sufficiently above the range of skin
variation expected. Currently this is unlikely to be the case.
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Figure 7.20: Box plots showing the work done (mJ) to (a) initiate penetration and (b) inject to
a 5.5mm depth for all materials tested, as reported in Table 6.2. Box plots show the first and
third quartiles, the median (horizontal line) and the mean (3 symbol) of the data. The upper
and lower whiskers indicate the range of the data.
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7.4 Penetrometer Performance into Synthetic Materials
The findings in Chapter 6 of this thesis have shown conclusively the presence of variation in the
skin’s properties affecting the penetration parameters during solid dose injection. This work has
been based on the Penetrometer providing repeatable and reproducible data sets using the same
software settings, penetrator and velocity. In Chapter 5, this was proven to be the case when
the test rig was validated using a silicone rubber test bed as a control. Therefore the majority
of the variation detected within the penetration tests into skin can be attributed to the skin.
The penetration data produced during the synthetic test bed development in § 6.7 presented an
opportunity to further validate the Penetrometer performance. As the mechanical properties
for the silicone rubber sheets used were known from the supplier, shown in Table 6.4, it was
possible to verify the Penetrometer performance through comparing these known properties with
the Penetrometer data for Fp and dp.
The mean deflection to penetration values dp have been plotted against the Tensile strength
(MPa) and the Shore A hardness (°) and a line of best fit applied showing regression values of
37% and 61%, respectively, indicating a relationship (this data is not shown). However, when
the mechanical properties were divided by the material thickness, the regression values rose to
72% for tensile strength (Figure 7.21a) and 82% for Shore A hardness (Figure 7.21a), proving
the mechanical properties correlate with dp and are also affected by material thickness.
All of the silicone rubber tests were performed over a 20mm thickness of expanded polystyrene.
This support made the penetration profiles more representative of those in skin, though it also
meant that the results were influenced by the increased stiffness.
Other influences on the outcomes may have been the non-uniformity of the underlying layer
and subtle differences in the interactions between the Penetrometer and the different silicone
rubbers tested. These reasons may have contributed to the failure to establish any relation-
ships with peak penetration force values, Fp, or the elongation at break (%) and tear strength
(kN.mm−1) of the materials. Despite this the fact remains that as a relationship can be observed
between known mechanical properties of materials and the penetration parameters detected by
the Penetrometer, the variation detected elsewhere on skin measurements was real.
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Figure 7.21: Scatter plots showing the relationship between mean displacement to penetration,
dp (mm), and synthetic material properties proportional to their thickness. Synthetic material
properties and thicknesses were first shown in Table 6.4 and compared with dp data reported in
Figure 6.28.
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7.5 Chapter Summary
This chapter has begun to unpick the problem of skin variation and the its effect on penetration.
A novel approach using two-dimensional contour plots and three-dimensional surface models
has illustrated the distribution of the penetration parameters and the presence of intra-site
variation across the skin’s surface. Interestingly, while some of the parameters appeared to have
a distribution pattern, this often did not correspond to other known parameters, sites or models.
Investigations further analysing the data and skin samples used in Chapter 6 were undertaken
to ascertain the causes of the variation in the skin’s response to penetration. Sectioning the
neck test sites of the H12a and H14a subjects has shown their skin thicknesses to be 23%
(0.41mm) different despite both being from the same model (≈25kg, male). When plotted as
three-dimensional surface models (Figures 7.10 and 7.11) both neck sites were shown to be
extremely variable unlike the H14a rump site (Figure 7.11). The rump site’s results were more
consistent and can probably be explained by the skin being positioned over a single large muscle.
At the neck site there were many smaller muscles and complex structures under the 9cm2 area
tested.
A weak relationship has been detected between the skin thickness data and peak penetration
force (Fp). Applying a Leanness Ratio to account for the underlying subcutaneous fat showed
that only 26% of the variation detected can be explained by the leanness. The results are thought
to be site, model and method dependent and further work would be required to investigate the
effect of each of these. Other explanations such as the underlying features (4–10mm) below the
surface and the subjective test site assessment performed by a Glide Pharma operator have been
shown to have minimal effect.
The implications of intra-site variation to the device have been discussed, although it is the
impact of intra-model (H12a, H14a) variation that is the greatest cause for concern. It is
probable that skin variation has biased the development process of the Glide SDI technology. It
appears likely that penetration successes recorded in non-clinical studies could of been wrongly
attributed to design changes to the device (or implant) instead of recognising that certain regions
of skin (sites and models) that were tested on were in fact ‘easier’ to penetrate.
Further work, detailed in Chapter 8, is required to better detect, understand and account for
the skin variation before the parameters for device and implant design can be specified.
Chapter 8
Conclusions
The primary aim of this research, as explained in the introduction, was to develop a fundamental
understanding of the key parameters which affect needle-free skin penetration, and in particular
how the target itself will affect delivery. This has been achieved through a multidisciplinary
approach that has covered some, but not all, of the aspects of solid dose drug delivery.
The novelty of the drug delivery system was apparent from the literature reviewed in Chapter 2.
There are widely different reports of skin properties and penetration mechanics. Most reported
investigations are problem-specific and experimental methods, equipment and results vary.
In Chapter 3 an extensive analysis of the performance of the drug delivery system at clinical and
non-clinical trials led to the conclusion that the system specification may not be fit for purpose,
as it could not account for variation in the skin’s response to penetration with the SDI. This
design issue had been compounded by the inferior knowledge of the test bed, the inguinal and
neck regions of the porcine model used to develop the system. The path to increase penetration
success of the system required the skin, that system component that could not be controlled, to
be understood and characterised.
Initial work performed in Chapter 4 explored the mechanical properties of skin and investigated
viable imaging methods to better understand penetration. The investigations conducted with a
series of simple test rigs, and within the limitations of the Lloyd LFPlus, showed the benefit of
collecting quantitative skin data and how its response was affected by test site location on the
body, local manipulation and through modifying the cassette shape. This work established the
need for a novel test rig that could better measure penetration parameters in vivo.
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The main scientific contributions generated during this research, and reported in Chapters 5–7,
are as follows;
1. A portable novel test rig, the Penetrometer, capable of building up a body of scientific
knowledge about in vivo skin and its properties, variation and the forces required to pen-
etrate it, has been developed. As explained in Chapter 5, the Penetrometer is capable of
applying a preload to the surface of the skin (actuation force, Fa), whilst quantifying the
force (Fp) and energy (Wp) required and the deformation (dp) the skin undergoes before
it is penetrated. The penetration profiles produced, first shown in § 5.6.1, were similar
to those observed in needle and punch insertion into soft-solid materials. With software
improvements the Penetrometer would be capable of delivering different penetrators (in-
cluding implants) at different rates between 0.01–1m.s−1.
2. The Penetrometer, although designed for greater functionality, has only been used at a
single setting. All penetration tests within Chapter 6 have been performed at 1m.s−1 using
a 46° wedge-tipped metal probe to simulate a solid dose delivery. This has made it possible
to isolate the role of the skin and the impact of variation on solid dose injection. Using a
high number of repeats it has been possible to not only quantify the penetration properties
but also to demonstrate that they can vary intra-site, intra-model and inter-model, across
the 3 porcine models tested. This method, outlined in § 6.3, is more thorough than any
reported in needle-based or needle-free penetration literature to date where authors have
alluded to skin variation but never attempted to quantify it. Most notably, from the data
in § 6.5.2 it has been shown that 29% (2.6N) greater mean peak force was detected between
two porcine models of comparable size. This result indicates how challenging it may be to
reliably administer drugs through a solid dose injection across a human population whose
skin properties would be expected to be more diverse than the porcine models tested.
3. From the data set available, the rump site of a 26kg porcine model has been shown to
be the most suitable in vivo skin test site when compared to the inguinal, neck sites and
in vitro skin. Although the in vivo rump site should only be used for the purposes of
confirmatory penetration testing. For exploratory research an in vitro silicone rubber test
bed representative of skin, but more repeatable and challenging to penetrate, has been
proposed in § 6.7. The test bed is to be used as a tool to better develop the implant and
SDI device design in the absence of skin variation.
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4. The variation in penetration properties has been mapped across the two-dimensional sur-
face of the skin in Chapter 7. This work has shown that differences in penetration forces
are likely to be caused by changes in skin and subcutaneous fat thickness and the presence
of underlying features, or a combination of both. This approach was entirely novel and
there are no examples of mapping skin penetration across a surface within literature.
5. After quantifying the energies required to complete an injection (Wi), it has been shown
in § 7.3 that it can take ≤48mJ to overcome the skin and deliver to a 5.5mm depth using a
wedge-tipped metal probe. This may indicate an energy deficit within the prototype SDI
device design as, in some instances on skin, the penetration energy required for an implant
may be higher than the SDI device is capable of.
Some of these contributions, such as the test rig and methods that have been developed, are
of generic importance to the engineering understanding of skin penetration and the effect of
variation. Whilst others, such as the data sets produced, remain specific to solid dose injection.
Throughout this research more conventional penetration terminology such as energy density
(J.m−2) and fracture toughness (JIc) have been avoided. The calculations for both are highly
dependent on the properties of the penetrator, as of yet, neither the tip geometry nor formu-
lation of the implant have been defined. Therefore the exact stresses that occur as an implant
penetrates the skin have not been reported. Instead a pragmatic empirical approach has been
undertaken to establish the underlying mechanics. The maximum stresses have been calculated
using the cross sectional area as a worst case scenario if an implant tip were to fail.
As first shown in Figure 1.2 in § 1.2, the drug delivery system is comprised of three components.
The research aims within this thesis have focused on understanding skin, however it has also
been possible to consider the relationships between the key parameters that impact those from
the implant and device. These relationships are represented by the lines linking the parameters
on the evolved system model shown in Figure 8.1. The dashed lines show relationships that may
be present but have not been covered within this thesis. The grey boxes show the outstanding
business decisions that are required before all parameters can be fully specified.
Finally, it is important to note that this work has been achieved at a single velocity, actuation
force, penetrator type into silicone rubber and the porcine model. Further work is required to
establish the effect of rate, implant design and migrate this understanding to human skin.
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8.1 Discussion
This thesis has addressed an instance of designing a drug delivery system in the presence of
biological variation. Accounting for inherent variation across a human population is a generic
problem for the design of many medical devices.
In biology, differences are found between individuals of the same species in any sexually repro-
ducing population. Variations may be unremarkable in some cases and entirely obvious in others
and may affect all aspects of an organism. Typically, variations in size, appearance, mechanical
properties and biochemistry may be present. The cause of these variations is a combination of
the genetic (inherent) information and environmental influences and usually it is a combination
of the two. In humans, there are numerous inherent factors such as ethnicity, gender, age, etc.
but also many environmental influences caused by differing lifestyles such as weight, BMI, UV
exposure, etc. An example of variation that involves the environment modifying inherited char-
acteristics is height. The characteristic of being tall or short is inherited, but the availability of
food in the environment determines the actual height of the individual.
Design has found ways of accounting for some of the more obvious differences between humans,
such as the anthropometric differences in size, by implementing simple systems such discrete
clothes or shoe sizes. The same is true of many simple non-invasive medical devices. Examples
of these are splints, bandages and adjustable crutches which are all supplied or adjusted to
discrete sizes within a specified range to account for the 95th percentile of the population.
Establishing discrete increments in size is more difficult when considering invasive medical
devices. Traditionally, devices such as hearing aids, advanced wound care treatments and or-
thopaedic implants would have been supplied in standard sizes. This, although adequate, is
far from ideal. Fortunately, improvements in medical imaging and manufacturing techniques
have meant that these previously generic devices can be configured and customised to suit each
patient and account for differences in dimensions. More complex still are advanced treatments
such as in vitro fertilisation (IVF), chemotherapy or regenerative medicine. These are beyond
the relatively simple (and measurable) anthropometric differences and instead rely on a com-
bination of biological factors. The treatments may not work on everybody. Instead patients
are first screened to assess the likelihood of them responding positively to a specific treatment
before it is administered.
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The knowledge that many biological processes within the body and their interaction is almost
infinite may appear daunting [255]. However, this information is of limited practical use to
a medical device designer. Providing enough data is gathered, solutions can be found. The
examples already discussed highlight three main approaches within healthcare engineering to
account for biological variation; where commonality is present a device (or a drug) can be
supplied off-the-shelf in incremental sizes/doses, when this is not possible customised components
(or treatments) can be developed based on measurable biometric data. Finally, where the
allowable variation is outside the achievable variation, the population can be stratified instead
an approach is to stratify the population choosing only to administer a treatment (or drug
delivery system) where the technology is known to work.
The skin covers up to 2m2 of the human body and its properties across the skin’s surface have
been shown to vary [32,33]. This variation can be exacerbated by the effects of time and how the
skin is treated. Skin has evolved over millions of years and developed chemical and mechanical
barrier functions. Methods of drug delivery through the skin have typically been ‘one size fits
all’ approaches. Transdermal treatments (creams, ointments, poultices) are placed on the skin
surface with an acceptance that their perfusion will be not be 100% efficacious. A more effective
delivery is achieved through piercing the skin using a hypodermic needle, an invention much
sharper than the skin has evolved to resist. Needles, when delivered manually, are versatile and
can perform a range of tasks but they are not without their problems. When housed within an
autoinjector, various aspects of the delivery become standardised and become a ‘one size fits
all’ solution. Needle-free liquid jet injectors rely on high velocities, again, another threat that
skin has not evolved to fully counteract. These devices have been based on the ‘one size fits
all’ approach of the needle-based autoinjectors they are designed to usurp. The variation of the
skins properties has been shown to be a greater challenge when injecting without a needle.
As concluded within this thesis, the use of a spring-powered device capable of only a single
delivery profile and expected to deliver across a wide patient population will be hampered by
the presence of skin variation. The device must either be designed with a commonality identified
across all skin (such as sufficient energy or implant sharpness capable of penetrating all skin),
redesigned so that it is capable of delivering customised delivery profiles or, alternatively, the
skin types with properties that the device cannot penetrate is defined and the system is not
prescribed to this portion of the population.
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8.2 System Design Recommendations
The current Glide SDI prototype system comprises a simple spring-powered mechanical device
that pushes a sharp implant (with mechanical properties that will vary due to formulation and
manufacture) through the skin, which has been proven to be inherently variable. Analysis of the
clinical performance of the drug delivery system has shown that, from what was known at the
time, the device and implant performed as intended. Therefore it is likely that the specification
of the device was not fit for purpose and could not account for the variation in skin properties.
Currently the Glide SDI is intended to treat all patients and all types of skin. One method of
improving penetration success, as suggested in § 8.1, would be to stratify the patient population
and to attempt to control skin types the system is expected to penetrate. If this option is not to
be considered, based on the findings within this thesis, the following proposals to minimise the
effect of the skin and its variation, thus increasing the likelihood of 100% delivery into a broad
patient population, are as follows;
Increase Energy within Current Needle-Free SDI System
Data generated in Chapter 6 has shown that it can take up to 13.77N and 2.45mm to penetrate
the skin at the neck site of a 25kg porcine model (H14a). It was also shown to take up to
48mJ to inject a metal probe to a depth of 5.5mm, a comparable depth to an SDI delivery. An
experiment reported in § 3.3.1 has shown that the SDI device only has ≈144mJ available in the
rear spring. The peak penetration energy of 48mJ is likely to be much higher when factoring in
a blunter implant as a penetrator and possible rate effects of the skin at ≈6m.s−1. Increasing
the energy within the system so it can account for the allowable range is also likely to require
stronger, more robust implants to cope with these forces, although these could be lowered if an
implant formulation or manufacturing method could produce sharper tips.
Glide has not followed this approach previously and there was no quantitative data available on
the parameters required to penetrate the skin to inform the implant and device specification.
At the time of the clinical trials, polymer-based formulations had been developed but were
unsuitable to deliver the quick release profiles required for fentanyl or octreotide. Decreasing the
dissolution time of polymer implants that are 3–4 times stronger than the sordex-based implants,
as reported in § 3.3.2, would make this possible. The approach of using harder, sharper implants
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delivered faster to the skin may cause more trauma and pain during delivery which would be
considered unacceptable when used for therapeutic (multiple times daily) application.
Needle-Based Solid Dose Injection System
If the perceived value of the drug delivery system is in the solid dose either through increased
drug stability or the lack of reconstitution steps (compared to a liquid dose), it would make
practical sense to develop a variant of the device that can deliver an implant through a needle,
thus eliminating all current problems associated with skin variation. There are examples of
needle and trocar-based delivery devices that have taken this approach [68,70,71].
If the needle-based alternative is developed, the force to penetrate the skin would be much lower
(<2N), requiring less energy in the system and a significantly lower actuation force [163, 256].
The stress on an implant during delivery would be minimal as the needle tip penetrates the
skin, meaning the implant formulation can be focused on bioequivalence without compromises
for mechanical strength. The current implant diameter would require a 19Ga hypodermic needle
though the implant geometry would need to be altered to reduce the needle gauge closer to the
27–33Ga that are standard for a wide range of applications.
Intelligent Drug Delivery Device
Tests on the porcine model have shown variability across the skin’s surface. Skin within a 9cm2
area of the same site can require very different forces to overcome to achieve penetration. It is
likely that this variation will also apply to human skin. The two aforementioned options of a
more energetic delivery (that may cause trauma) or the use of a needle (forgoing the advantages
of a needle-free system) are based on a spring-powered device. An alternative approach would
be to make the power source more intelligent on the basis that a single spring setting suitable
to penetrate the skin of, or be acceptable to, an entire patient population is unlikely.
Taberner et al. [181, 182] at MIT (Boston, MA) have recently announced a needle-free drug
delivery system that uses an electromechanical power source that can be programmed to account
variation in skin behaviour during an injection and be configured to user requirements. This
technology is currently intended for delivering liquid and powdered doses. This approach should
lead to a device that can better account for variation in different skin types.
Chapter 8. Conclusions 237
8.3 Thesis Summary
The work captured in this thesis has shown first-hand the difficulties in designing, developing
and testing a novel parenteral needle-free drug delivery system.
This knowledge has been established through thorough research into the literature of needle-free
delivery technologies and the mechanisms each utilise to overcome skin. Analysing the system’s
performance and penetration data from two clinical trials in man has shown that skin, and likely
its inherent variation, was the cause of failures. As with previous needle-free technologies, the
skin required a more complete understanding before it was capable of ensuring delivery across
a patient population.
Exploratory work led to the justification, design and build of a novel skin penetration test
rig capable of simulating the delivery of a solid dose implant. This device, the Penetrometer,
required significant software development to both stabilise and validate its performance ahead of
its use on the in vivo pig skin, an established substitute for human skin. Two non-clinical studies
have been performed using the Penetrometer. Through experimental design it was possible to
produce many force profiles capturing skin penetration and provide evidence of significant levels
of variation present both intra- and inter-model (n = 3). The variation that has been detected
in the porcine model, was not known prior to the clinical trials, and is likely to be the cause of
the incomplete deliveries. Investigations into possible alternatives to in vivo skin for penetration
testing has shown silicone rubber to be more reliable than in vitro skin.
The effect of the variation of skin properties has been demonstrated where a 29% (2.6N) greater
mean peak force was detected between two porcine models of comparable size. This result
indicates how challenging it may be to reliably administer drugs through a solid dose injection
across a human population whose skin properties would be expected to be more diverse. The
peak mean stress (σp) during penetration has been shown to be 20.7MPa ±1.7 in the tougher of
the two 25kg models (at 1m.s−1 using a metal probe). This data can inform the implant design
and formulation to better ensure an implant is to survive an injection.
What has been contributed to the science of solid dose injection and the further work remaining
is summarised in Table 8.1. Prior to this thesis there was no quantitative data available, either
published or at Glide, describing the magnitude and variance of the forces and energy required
to penetrate skin with a solid dose implant.
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Area Contribution Further Work
Skin Penetration • Novel Penetrometer test rig has gen-
erated quantitative needle-free skin
penetration data in vivo.
• Force profiles comparable to those
in literature for penetration by other
means have been captured.
• Substantial amount of data cap-
tured in porcine model using
46° wedge-tipped metal probe at
1m.s−1.
• More porcine model
data is required than
n > 3.
• Require equivalent
quantitative data
for human skin
(magnitudes and
variation).
• Rate sensitive penet-
ration behaviour of
skin is unknown.
• Influence of implant
sharpness and altern-
ative designs of cas-
sette shape and ac-
tuation force on pen-
etration parameters
are unknown.
Skin Variation • Significant skin penetration vari-
ation detected in porcine model;
1 Intra-site (n ≥ 99)
2 Inter-site (n = 3)
3 Intra-model (n ≥ 203)
4 Inter-model (n = 2)
• Variation linked to skin thickness,
intra- and inter-site location and un-
derlying tissues.
SDI Device • Large ranges and coefficient of vari-
ation for both Fp (N) and dp (mm)
identified.
• The device may not have enough
energy to overcome the worst case
scenario Wi measured in porcine
model.
• Optimise design of
SDI to either lower
Fp (N) or dp (mm),
reduce variation or
supply more energy.
Synthetic Test Bed • Benefit of an in vitro synthetic test
bed demonstrated compared to us-
ing in vivo or in vitro testing.
• Silicone rubber test bed designed,
with dp representative of skin but
more challenging in Fp.
• Requires human skin
data to further in-
form design.
• Rate sensitive penet-
ration behaviour of
test bed is unknown.
Drug Delivery System • In vitro synthetic test bed proposed
as a tool to develop implant design.
• The rump site justified for future in
vivo penetration studies.
• Worst case scenario σp (MPa) cap-
tured to inform implant formulation.
• System design improvements have
been recommended.
• Implant, device and
skin interaction to be
captured in analyt-
ical model.
• System design re-
commendations may
alter business model.
Table 8.1: Summary of contributions and further work.
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8.4 Further Work
There are several options available to improve the performance of the drug delivery system, as
outlined in § 8.2. Each would require its own development path. If the SDI device was to remain
needle-free and spring-powered, Glide Pharma should only continue testing on pig skin in the
short-term, with the intention of modelling the solid dose delivery mechanism and migrating
skin understanding across to a suitable repeatable synthetic test bed.
Synthetic Test Bed
To ensure that implant design is not compromised during development by the variability shown
in the porcine model, more work is required to optimise the synthetic test bed proposed in
Chapter 6. This simple dual-layer test bed made from 3mm thick silicone rubber over expanded
polystyrene have proven to exhibit repeatable penetration properties.
No control experiments are required when using a test bed as its behaviour would be known,
unlike the variable response detected at in vivo test site. For example, if an implant can penetrate
the control silicone rubber it is capable of surviving a mean stress of at least 28.76MPa ±0.69
(2%). The test bed design would require further calibration to check for rate effects.
A 100% implant penetration success into an in vitro synthetic test bed (based on in vivo data)
would mean the implant batch would also survive delivery into the rump, neck and inguinal sites.
Any failures observed would indicate inferior implant strength or manufacturing variations. A
test bed developed from quantitative penetration data in this way would establish much better
confidence in the performance of drug delivery system ahead of a human clinical trial.
System Modelling
Testing with metal probes to simulate delivery eliminates the variability of the implant. Differ-
ent probe tip geometries should be experimented with to inform the implant manufacture and
formulation development. For example, it is known that at 1m.s−1 the porcine model (neck and
rump) would inflict a 16–24MPa peak stress on an implant during penetration. This dictates
that sorbitol-based implant formulations with compressive strengths of 20MPa ±4 are unlikely
to penetrate every time and other excipients should be used.
Chapter 8. Conclusions 240
Introducing implants, before the skin is fully understood, risks biasing the data set and would
require many more repeats to account for variation in both the implant manufacture and the
skin. The empirical data produced should be gathered and fed into an analytical model or
models. The model(s) should be able to establish the relationships that govern the penetration
parameters across multiple subjects and should eventually converge and identify the optimal
system configuration.
Further Skin Penetration Understanding
High numbers of repeats are possible at a non-clinical study. This is advantageous when trying
to capture variation across the skin’s surface. The approach of using large sample sizes, typically
n = 100, has provided statistically significant evidence of the intra-site variation present in in
vivo skin. The number of subjects, however, has remained low (n = 3). Also the knowledge gap
comparing porcine and human skin penetration properties is yet to be bridged.
To generate the same number of repeats in a human clinical trial would difficult to ethically jus-
tify. Work on in vitro skin may be possible but literature and work within this thesis has shown
that the skin behaves differently. The number of experiments required to cover all combinations
of known factors that affect human skin properties (age, weight, ethnicity, lifestyle, etc.) would
be vast. Unless a viable economic way is discovered to generate penetration data in human skin
Glide Pharma must further understand the porcine model.
Work within this thesis has proposed the rump site, pending further experiments, as the preferred
test site on the 25kg male porcine model for penetration testing. The rump takes 8.9% greater
peak force on average to penetrate and is more consistent in terms of work to penetrate.
Further understanding of the SDI inputs that affect skin penetration is required. A second
generation test rig (Penetrometer v2.0) capable of capturing force data at speeds ≤6m.s−1, the
velocity of the current prototype SDI device, should be built. Repeating the empirical approach
set out in Chapter 6, at different velocities with different cassette designs and actuation forces
would establish the optimal parameters for the SDI. Optimal would be described as lowering the
peak force of the penetration (Fp), reducing the displacement to penetration (dp) or reducing
the level of variation in either. This work would be required to be performed across multiple
subjects with suitable controls in place.
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A Technical Drawings
ITEM NO. PART NUMBER DESCRIPTION QTY.
1 10103-42T-202 Handset Cassette Holder 1
2 10103-42T-002 CAL36-025-55 FS3A, Body only 1
3 10103-42T-003 CAL36-025-55 FS3A, Rod only -
4 10103-42T-004 CAL36-025-55 FS3A, Cable only -
5 10103-42T-205 Load Cell Shim 1
6 10103-42T-014 NovaTech F251UFR0H Load Cell 1
7 10103-42T-206 Handset Rear Spring Hanger 1
8 10103-42T-204 Handset Body 1
9 10103-42T-013 Lee Spring LE026C 11S, Extension 4
10 10103-42T-012 Igus JSM-2026-06, Plain Bearing 2
11 10103-42T-203 Handset Front Spring Hanger 1
12 10103-42T-011 Igus JSM-0308-04, Plain Bearing 1
13 10103-42T-201 Handset Cassette Retainer 1
14 10103-42T-210 Handset Pin Holder Shim 1
15 10103-42T-209 Handset Pin Holder 1
16 10103-42T-212 Handset Pin Locking Sleeve 1
17 10103-42T-015 Bearing Ball, Steel, 3mm 3
18 10103-42T-211 Handset Pin 1
19 10103-42T-016 Handset Pin Release Sleeve Spring 2
20 10103-42T-213 Handset Pin Release Sleeve Retainer 1
21 10103-42T-214 Handset Pin Release Sleeve Screw 2
22 10103-42T-215 Handset Pin Release Spring Sleeve 1
23 10103-42T-217 Handset Pin Release Spring Seat Front 1
24 10103-42T-216 Handset Pin Release Spring Seat Rear 1
25 10103-42T-218 Handset Cassette Retainer Screw 1
Table 9.2: Bill of materials for Penetrometer handset, as shown in Figure 9.2.
ITEM NO. PART NUMBER DESCRIPTION QTY.
1 GEN0082 Load Cell Calibration Fixture 1
2 GEN0083 Load Cell Novatech F308 1
3 - Screw M6x1-12 1
4 - Test Spring 1
Table 9.3: Bill of materials for Calibration Test Rig, as shown in Figure 9.4.
ITEM NO. PART NUMBER DESCRIPTION QTY.
3 BK142A04K-C Small Implant Holder 1
2 BK142A03H-D Cassette Body 1
1 BK142E04P-A Single Cut Implant 1
Table 9.4: Bill of materials for cassette sub-assembly, as shown in Figure 9.3.
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Figure 9.2: Technical drawing of Penetrometer handset.
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Figure 9.3: Technical drawing of Calibration Test Rig.
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Figure 9.4: Technical drawing of standard cassette sub-assembly.
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Figure 9.5: Technical drawing of 46° wedge-tipped probe.
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B Initial Penetration Experiments
(a) 2mm thick silicone rubber with Fa = 20N.
(b) 4mm thick silicone rubber with Fa = 20N.
Figure 9.6: Penetration force displacement profiles produced using Lloyd LFPlus Mounted Pen-
etration Test Rig and a blunt (0.85mm) penetrator on silicone rubber (R31-2186) of different
thicknesses (a) 2mm and (b) 4mm, with Fa applied of 20N. Reported in § 4.2.4.
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(a) 2mm thick silicone rubber with Fa = 30N.
(b) 4mm thick silicone rubber with Fa = 30N.
Figure 9.7: Penetration force displacement profiles produced using Lloyd LFPlus Mounted Pen-
etration Test Rig and a blunt (0.85mm) penetrator on silicone rubber (R31-2186) of different
thicknesses (a) 2mm and (b) 4mm, with Fa applied of 30N. Reported in § 4.2.4.
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C LAC-1 Controller Code
Registers
The parameters for each test are inputted into the Test Schedule and pulled across into the GUI
prior to each test. Before they are entered into the LAC-1 they must be converted from the GUI
in decimal units into SMAC proprietary machine code, this is shown in Table 9.5. The buttons
on the GUI are then used to drive a Visual Basic application that uploads the test parameters
into the controller registers.
Variable Target Unit Counts Register Code
TargetPinTravel 24 mm 24000 9 AL24000, AR9
MaximumPinTravel 23 mm 23000 10 AL23000, AR10
PinStartPosition* 7.6 mm 7600 11 AL7600, AR11
PinRetractPosition* 7.6 mm 7600 12 AL7600, AR12
MaximumPinVelocity* 1000 mm.s−1 13107200 13 AL13107200, AR13
MaximumPinAcceleration 100 m.s−2 262144 14 AL262144, AR14
MaximumActuationForce 52 N 1040 15 AL1040, AR15
MinimumActuationForce 0 N 0 16 AL0, AR16
MaximumPinForce 24 N 32600 17 AL32600, AR17
RetractSpeed 300 mm.s−1 3932160 18 AL3932160, AR18
Table 9.5: Conversion of test parameters from values into the SMAC proprietary machine code.
*Indicates the parameters that are changed when test are conducted at different velocities.
PID Control Loop
In the low speed software the LAC-1 control system has a PID loop contained within it that will
always push for a constant velocity of the value requested. The current required to maintain
this velocity whilst penetrating a material is inferred into a force. In the high speed software
(>100mm.s−1), the PID loop does not establish a constant velocity, the linear actuator is ac-
celerated on a known trajectory. When the a material is penetrated it causes the actuator to
decelerate, it is this delta to the expected velocity that is converted into a force. The following
PID control loop variables are below;
Proportional Gain (SG) = 60
Integral Gain (SI) = 170
Derivative Gain (SD) = 1800
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Main Program
The following macros, MD0–20, are used within the main software control environment and
included for reference purposes. There are two different lines of code for macros MD12 depending
on whether the Penetrometer is to run in high speed mode (>100mm.s−1) or low speed mode
(≤100mm.s−1). The VB application automatically switches between these modes depending on
what value entered into Register 13.
MD0,1VM,MN,SG60,SI170,SD1800,OO0,SV131072,SA26214,SQ15000,IL8000,SE16000,DI1,GO,WA5
// Puts linear actuator in velocity mode (VM) as default, sets PID and velocity values
MD1,RW538,IB-1000,NO,MJ2,RP
MD2,DH,DI0,FI,AL0,WL1830 // Defines home, finds index
MD3,RL448,IC10,ST,MJ5,RL494,IG20000,NO,MJ4,RL1830,IG3000,NO,MJ4,RP
MD4,MF,MG”Index not found”,EP // Error report
MD5,PM,MN,GH,DH13000,MG”Homing ready”’ // Signals that programming is complete
MD6, // Blank
MD10,PM,MN,SV@13,SA@14,SQ@17,MG”10” // Moves probe to start after programming
MD11,MA@11,GO,WS,MG”11”
MD12,MA@9,GO,MG”12”,TP,RW548,TR0,MG” ,”,
// Low speed MD12 variant, puts linear actuator in position mode (PM)
MD12,QM0,sq16000,GO,MG”12”,TP,RW548,TR0,MG” ,”
// High speed MD12 variant, puts linear actuator in torque mode (QM)
MD13,RL494,IG@10,MG”E”,MJ16,TP,RW548,TR0,IG@19,MG”P2H”,MJ14,MG” ,”,RP
// RL494 Reads position (µm),RW548 Reads current (I) value
MD14,PM,RW1830,AA500,AR20
MD15,RL494,IG@10,MG”E”,MJ16,TP,RW548,TR0,RW1830,IG@20,MG”TO”,MJ16,MG” ,”,RP
// Ends test when target travel or maximum force cut-off is reached
MD16,PM,SV@18,SA@14,SQ@17,MA@12,GO // Retract after experiment
MD17,RW1830,AA500,AR20
MD18,RL494,IB@11,MG”E”,MJ19,TP,RW548,TR0,rw1830,IG@20,MG”TO”,MJ20,MG”,”,RP
MD19,MG”retracted”,EP // Error report
MD20,MG”Stalled on retract”,EP // Error report
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D Penetrometer Equipment Operating Procedure
1 Connect Penetrometer to laptop via USB cable and boot up. Load latest version of software.
2 On GUI tab click ‘program’ button to load main program into Penetrometer. Repeat until
programming status indicates 100%.
3 On the Test Schedule tab enter study name and populate with test parameters, return to GUI
and type in the first test number to automatically pull parameters from Test Schedule tab.
To override this feature click ‘manual’ button and input parameters.
4 To program the individual test parameters into the controller click on the on the ‘start’,
‘end’ and ‘set speed’ buttons. The correct stand off (start position) is automatically applied
according the speed setting, probe length/type and cassette parameters.
5 Check the correct cassette is on the hand-held unit. To replace the cassette, slide the cassette
retainer across, remove and replace the cassette and slide the retainer back across.
6 Check the correct metal probe is in the hand-held unit. To replace the probe, click ‘pin
changeover’ on the GUI tab, on the hand-held unit remove the cassette and press the probe
release collar, remove and replace the probe and release the collar.
7 To begin testing, press the hand-held unit on the surface down by to reveal the cross hairs
on the rear spring hanger (this applies the necessary actuation force simulating an injection
using the SDI).
8 On the GUI tab click ‘GO’ to start the test, maintaining actuation force throughout. If no
Results Sheet is open one will be created with the study name entered in the Test Schedule.
9 When the test is complete, the laptop will beep, lift the hand-held unit. Within 60 seconds a
plot of F/d and v/d will be displayed.
10 To continue to the next test click the ”” on the GUI and repeat stages 4–9 until the end of
the study, saving the results sheet regularly.
11 Once all tests are complete remove the cassette and probe and power down the Penetrometer,
clean probe and hand-held unit. Save and store results file and power down laptop.
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E Penetrometer Velocity Calibration Graphs
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Figure 9.8: Force vs. displacement graphs from Penetrometer velocity calibration experiment.
Data captured using Penetrometer and High Speed Camera (HSC) simultaneously. Reported in
§ 5.4.1.
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Figure 9.9: Force vs. displacement graphs from Penetrometer velocity calibration experiment.
Data captured using Penetrometer and High Speed Camera (HSC) simultaneously. Reported in
§ 5.4.1.
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F Skin Variation 2D Contour Plots
The two-dimensional contour plots have been used to show the intra- and inter-site variation
across the surface of the skin. For each plot the x and y axes run from A–J and 1–10 in the
dorsal–ventral and anterior–posterior directions, respectively. The z-axis increments for each
of the parameters have been applied not necessarily to guide interpretation, but to convey the
features that are most apparent. The relevant units are stated in the caption.
Across each contour plot, the regions of skin that remain within the same colour band are
shown to be less variable than those where boundaries between many bands are shown. The
skin regions can be compared within each test site, across test sites and across parameters to
identify distribution patterns that could indicate relationships.
Skin Penetration Paramteter 2D Contour Plots
The resulting 2D contour plots are shown for the following penetration parameters; Fp (Fig-
ure 9.10), dp (Figure 9.11), Wp (Figure 9.12), Wi (Figure 9.13) and Fsc (Figure 9.14). Each
figure shows the data across all sites tested on the H12a (25kg ♂), H14a (26kg ♂) and H14b
(76kg ♂) porcine models. The silicone rubber (FQ-T050) control is included for comparison
purposes.
Glide Operator Assessment 2D Contour Plots
The results from the Glide Pharma operator assessment for all sites tested on the H12a, H14a
and H14b porcine models are shown in Figure 9.15. The regions that would typically be included
(white) or excluded (red) from a penetration test due to visible damage or underlying features
are indicated.
Skin and Subcutaneous Fat Thickness 2D Contour Plots
The resulting 2D contour plots are shown for the skin and subcutaneous fat thickness measure-
ments for the following test sites; H12a right-hand side (Figure 9.16), H14a neck (Figure 9.17)
and H14a rump (Figure 9.18). Each figure shows the individual skin and subcutaneous fat
thicknesses and the combined thicknesses for each test site in millimetres.
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Figure 9.10: 2D contour plots showing intra- and inter-site variation of force to penetrate (Fp) in
Newtons. Data for all skin test sites across H12a (25kg ♂), H14a (26kg ♂) and H14b (76kg ♂)
porcine models. A–J runs dorsal–ventral and 1–10 runs anterior–posterior. The silicone rubber
(FQ-T050) control is included for comparison purposes. Reported in § 7.1.
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(b) Silicone Rubber.
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Figure 9.11: 2D contour plots showing intra- and inter-site variation in the displacement to
peak penetration force (dp) in millimetres. Data for all skin test sites across H12a (25kg ♂),
H14a (26kg ♂) and H14b (76kg ♂) porcine models. A–J runs dorsal–ventral and 1–10 runs
anterior–posterior. The silicone rubber (FQ-T050) control is included for comparison purposes.
Reported in § 7.1.
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(b) Silicone Rubber.
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Figure 9.12: 2D contour plots showing intra- and inter-site variation in work done to penetrate
skin (Wp) in millijoules. Data for all skin test sites across H12a (25kg ♂), H14a (26kg ♂) and
H14b (76kg ♂) porcine models. A–J runs dorsal–ventral and 1–10 runs anterior–posterior. The
silicone rubber (FQ-T050) control is included for comparison purposes. Reported in § 7.1.
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Figure 9.13: 2D contour plots showing intra- and inter-site variation of the work done to inject
skin to a depth of 5.5mm (Wi) in millijoules. Data for all skin test sites across H12a (25kg♂), H14a (26kg ♂) and H14b (76kg ♂) porcine models. A–J runs dorsal–ventral and 1–10 runs
anterior–posterior. The silicone rubber (FQ-T050) control is included for comparison purposes.
Reported in § 7.1.
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Figure 9.14: 2D contour plots showing intra- and inter-site variation in the resistance of the
subcutaneous tissue (Fsc) in Newtons. Data for all skin test sites across H12a (25kg ♂), H14a
(26kg ♂) and H14b (76kg ♂) porcine models. A–J runs dorsal–ventral and 1–10 runs anterior–
posterior. The silicone rubber (FQ-T050) control is included for comparison purposes. Reported
in § 7.2.2.
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Figure 9.15: 2D contour plots showing results from subjective skin test site assessment by a
Glide Pharma operator for skin regions that would typically be included (white) and excluded
(red) from testing. Data for all skin test sites across H12a (25kg ♂), H14a (26kg ♂) and H14b
(76kg ♂) porcine models. A–J runs dorsal–ventral and 1–10 runs anterior–posterior. Reported
in § 7.2.3.
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(a) Neck H12a (RHS) - Skin.
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(b) Neck H12a (RHS) - Subcutaneous Fat.
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Figure 9.16: 2D contour plots showing intra-site variation of skin, subcutaneous fat and combined
thicknesses (mm) across the right-hand side neck site of H12a (25kg ♂) porcine model. Reported
in § 7.2.1.
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(b) Neck H14a - Subcutaneous Fat.
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Figure 9.17: 2D contour plots showing intra-site variation of skin, subcutaneous fat and combined
thicknesses (mm) across the neck site of H14a (26kg ♂) porcine model. Reported in § 7.2.1.
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(b) Rump H14a - Subcutaneous Fat.
J
I
H
G
F
E
D
C
B
A
1 2 3 4 5 6 7 8 9 10
9-10
8-9
7-8
6-7
5-6
4-5
3-4
2-3
1-2
0-1
(c) Rump H14a - Combined.
Figure 9.18: 2D contour plots showing intra-site variation of skin, subcutaneous fat and combined
thicknesses (mm) across the rump site of H14a (26kg ♂) porcine model. Reported in § 7.2.1.
